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Within the avian influenza virus (AIV) history, H5N1 subtype is the most alarming in terms 
of its spread rate throughout the globe with its demonstrated unusual pattern of evolution. 
Persistency and constant circulation of this subtype in poultry population in a number of 
countries have resulted its establishment and declaration as enzootic. The affected countries 
are commonly characterised by high poultry populations and productions. They are also 
developing countries which have minimal funding allocated for precaution on disease 
incursion. Past observations showed that a single AIV epizootic is capable of causing 
significant economic burden throughout the world. Although epizootic, it still resulted 
sporadic cases of human infection and mortality. Therefore, H5N1 enzootic countries opt for 
vaccination strategy (usually with inactivated whole virus) to evade AIV incursions. 
However, this interferes with the AIV surveillance effort. This is due to the lack of diagnostic 
tool with the ability to differentiate AIV infected animal from vaccinated animal (DIVA). 
Following this realisation, several options are made available. Diagnostic tool development 
which is capable of DIVA requires a highly sensitive and specific target which at the same 
time is economic, and pose ease of application. In recent years, growing interest on the AIV 
matrix 2 extracellular domain (M2e) protein has propelled its exploration as the target for 
AIV serosurveillance diagnostic tool development. It has been demonstrated to be highly 
sensitive and specific in detection for AIV infection in an indirect enzyme-linked 
immunosorbent assay (ELISA) setting. The factor which made it highly interesting is its 
ability for DIVA application. M2e protein can only be found in low concentration on an AIV 
particle which is used in an inactivated vaccination strategy, while present in high 
concentration if cells are AIV infected. Therefore, this study has further explores the AIV 
M2e protein potential for AIV serosurveillance diagnostic tool development and successfully 
demonstrated an M2e-based test in a competitive ELISA format for DIVA. This particular 
ELISA format was of interest as it can be potentially used in multiple species application, as 




comparative mapping of anti-M2e antibodies from chicken, mouse and rabbit was done. 
Findings highlighted slight variations in the epitope identified for the M2e antigen by 
antibodies from different species. Mouse anti-M2e antibodies are more suitable to be used as 
the competitor antibodies against anti-M2e chicken sera in the M2e-based competitive ELISA 
test. Consequently, application of the mouse anti-M2e antibodies in the M2e-based 
competitive ELISA has demonstrated specific and sensitive indication of AIV infection in the 
H5N1 challenged chicken sera. Biotechnology developments has also introduced the single 
chain variable fragment (scFv) antibodies as specific and stable bait for antibodies detection 
against targeted pathogen’s protein (antigen). Taking advantage of this knowledge, this study 
has also successfully isolated reactive and specific anti-M2e scFv antibodies from avian 
sources. This is critical as an avian sourced antibodies to be used as bait for the targeted 
pathogen’s protein is highly relevant in the setting for AIV serosurveillance application in the 
poultry industry. These findings are significant in the effort to provide a highly sensitive and 
specific diagnostic tool, which are also cost effective, easy to apply with high throughput 
ability. Such ideal diagnostic tool for AIV serosurveillance is highly valuable, as this may 
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Highly pathogenic avian influenza (HPAIV) H5N1 is one of the most widespread and highly 
variant AIV strain with pandemic potential (Fouchier & Guan 2013). Since its major outbreak 
in 1997, HPAIV H5N1 has become established in five countries, namely People Republic of 
China, Indonesia, Bangladesh, Vietnam and Egypt (FAO 2011; Fouchier & Guan 2013). This 
is exacerbated by its concurrent circulation with other low pathogenic AIV (LPAIV), as these 
viruses evolve through recombination mechanism and the LPAIV may become the source of 
genetic pool for production of a more fit and virulent progeny (Rohm et al. 1995; Swayne 
2007). Potential emergence of a more virulent progeny through such co-circulation is the 
main reason poultry vaccination is adopted in most of these enzootic countries. This may 
reduces the rate of virus spread or even act as a barrier for a potential outbreak. Economical 
and easy to prepare, whole killed virus of heterologous or homologous strain with the field 
virus is usually used as vaccination strain (Chen, H 2009; Gutierrez et al. 2009). As protection 
against infection is associated with antigenic relatedness, homologous strain is more preferred 
to counter H5N1 infection, as its high pool of genetic variants may render heterologous strain 
vaccination ineffective (Lee & Suarez 2005; Swayne et al. 2000).  
 
The only issue surrounding this option is that the available conventional diagnostic tests are 
not capable of differentiating serologic reaction from a vaccinated animal from those of virus 
infected animal. This is because the virus used for vaccination still possess the complete 
structure of the virus, only it is not capable of replication. Hence, antibodies produced in an 
infected host is similar to those of vaccinated ones. Due to variety of factors which govern the 
outcome of vaccination such as the presence of maternal antibodies, and each bird immune 
response which may differs between species, the available AIV vaccinations are not capable 
of perfect vaccination (Bublot et al. 2006; Lee, Senne & Suarez 2004). Hence, silent spread of 
LPAIV within a vaccinated flock is still possible as vaccination may only masked virus 




population may provide enough time for the virus to evolve and surpass the protection 
provided by the vaccine strain and resulted vaccine failure (Grund et al. 2011; Lee, Senne & 
Suarez 2004; Smith, GJD et al. 2006). Thus, it is important for early live virus detection to 
halt the incursion of new virulent strains. Therefore, differentiating infected from vaccinated 
animal (DIVA) strategies have been introduced as the counter measure to this issue.  
 
DIVA strategies are aimed to enable vaccination application without compromising 
diagnostic ability to detect virus infection. Numbers of DIVA strategy options are available 
for application, namely heterologous vaccination, subunit vaccination, epitope differential of 
non-structural protein 1 (NS1), ectodomain of matrix 2 (M2e) protein, as well as the 
hemagglutinin protein 2 (HA2) (Birch-Machin et al. 1997; Boyle & Heine 1993; Capua et al. 
2002; Lambrecht et al. 2007; Suarez 2012). An ideal DIVA strategy would present to be easy 
for application, possess sensitivity and specificity for virus infection detection, and available 
for large scale screening without unnecessary economic burden.  
 
Among these DIVA strategies, the M2e protein strategy holds the most interest as a part of 
AIV surveillance. It is demonstrated as sensitive and specific test for DIVA application, 
where its high epitope density on the surface of infected cells which otherwise is low on the 
virus particle, is a useful marker for virus infection (Hemmatzadeh et al. 2013; Kim, MC et al. 
2010; Lambrecht et al. 2007). As an indirect enzyme-linked immunosorbent assay (ELISA) 
based system with recombinant M2e protein as the antigen, M2e-based ELISA is proven to be 
economical with high-throughput capacity. It holds as an ideal test for an AIV surveillance. 
However, this approach is limited by the weak immunogenicity of the M2e protein (Neirynck 
et al. 1999).  Additionally, AIV is a multispecies infectious agent (Chambers, Dubovi & 
Donis 2013). Application of an indirect M2e-based ELISA is limited to the availability of 
species-specific secondary antibodies. Hence, a more universal test format such as 





The key factor for the universality of a competitive ELISA format test lies in the availability 
of a labelled competitor antibody targeting a specific antigen that identifies dominant epitope, 
hence, similar epitope in multiple species. Successful attempts on development of competitive 
ELISA test for AIV have been done targeting the nucleoprotein (NP) (Shafer, Katz & 
Eernisse 1998; Starick et al. 2006; Zhou, EM et al. 1998). However, an NP-based competitive 
ELISA is not suitable for application in countries which adapted AIV vaccination in their 
poultry, since it is does not possess DIVA ability. In the following review, current status of 
HPAIV H5N1 in Indonesia will be explored as the background of the project development.  
 
 Thesis outline 
Chapter 1 includes a brief review on the HPAIV H5N1 status in Indonesia and the availability 
of DIVA test for surveillance purposes. These two topics are covered in details in Chapter 2 
(Avian influenza virus and DIVA strategies), which has been published as a review paper. 
This is followed by a brief literature review on antigenic mapping, competitive ELISA and 
phage display technology. This chapter is closed by a short section on the research rationale 
and aims.  
 
The following chapters are written in a publication format, where Chapter 3 has been 
published, while the remaining two chapters (Chapter 4 and 5) will be submitted for 
publication. Briefly, Chapter 3 discusses on the antigenic mapping of the M2e protein using 
different sources of anti-M2e antibodies, while Chapter 4 describes the evaluation of M2e-
based competitive ELISA using monoclonal antibodies as the competitor antibodies against a 
panel of H5N1 infected chicken sera, as well as vaccinated chicken sera. Chapter 5 describes 
the isolation of the highly reactive single-chain variable fragment (scFv) anti-M2e antibodies 
using the phage display technology. Finally, Chapter 6 is the general discussion of the thesis 





 Avian Influenza Virus (AIV): enzootic H5N1 and DIVA test in 
Indonesia  
Indonesia has been enzootic with H5N1 genotype Z viruses following its first wave of 
dissemination in 2003. Characterised by high density of poultry industry, continued 
circulation of H5N1 in Indonesia was mainly attributed to poultry trade and products 
movement within the country (Smith, GJD et al. 2006). Within the first two years of H5N1 
introduction in Indonesia, the virus has evolved rapidly that it can be distinctly grouped based 
on its geographical trait, spreading vastly across more than 3000 km, from North Sumatra to 
West Timor. This is especially intensive in the central and eastern Java, the hub of the poultry 
industry (Smith, GJD et al. 2006). It was later identified that the H5N1 which spread 
throughout the Indonesian archipelago are closely related to H5N1 originated from Hunan in 
2002 and 2003 (Wang, J et al. 2008). This transmission was assumed to have occurred 
through the route of migratory birds or poultry movement.  
 
Although culling was the primary option for H5N1 control following an outbreak, vaccination 
option has been implemented in Indonesia in 2004 once H5N1 becoming enzootic. However, 
reports of vaccine failures has been detected in mid-2005, mainly due to the emergence of 
antigenic variants of the H5N1 (Bouma et al. 2008; Swayne et al. 2011; Swayne et al. 2015). 
Study suggested that the widespread use of H5 avian influenza vaccine contributed to the 
emergence of H5 variants following drift of the virus which overcomes the vaccine-induced 
immunity (Swayne et al. 2015). This further highlights the need for AI surveillance to monitor 
the emergence of drift variant virus in the field. The only problem with this is the 
unavailability of an established method to discriminate between the virus infected sera from 
those of vaccinated sera. Therefore, strategies which enable the differentiation between 




Several DIVA options are available, as discussed in Chapter 2 of this thesis. However, further 
studies are still needed to explore several options in the effort of developing an optimal DIVA 
test which addresses the weaknesses of the currently available. Here, we look in details the 
potential of an M2e protein-based ELISA diagnostic kit development.  
 
 AIV genes, M2 and M2e protein 
Avian influenza virus is a negative-stranded RNA virus, structurally enveloped and 
segmented, and belongs to the family Orthomyxoviridae, genus Influenzavirus A (Lamb & 
Krug 2001; Nelson & Holmes 2007; Taubenberger & Kash 2010). There are eight gene 
segments of Influenza A virus (IAV), with each gene segment codes for at least one protein 
(Table 1.1, Figure 1.1). IAV is known to code for at least 13 viral proteins (Chen, W et al. 
2001; Jagger et al. 2012; Lamb & Krug 2001; Steinhauer & Skehel 2002; Wise et al. 2009; 
Wise et al. 2012; Yamada et al. 2004). Some of the segments encoded more than one protein 
through mechanisms such as an alternative reading frame (PB1-F2, PB1-N40, PA-X and M2), 
and mRNA splicing (NS1/NEP) (Chen, W et al. 2001; Jagger et al. 2012; Lamb & Choppin 
1981; Lamb & Lai 1980; Wise et al. 2009) (Table 1.1). Each of the IAV gene segments is 
characterized by 20 – 45 noncoding nucleotides at the 3ʹ end, and 23 to 61 noncoding 
nucleotides at the 5ʹ end (Steinhauer & Skehel 2002). Despite the subtypes variety and high 
mutation rate of their RNA genome, a total of 12 nucleotides and 13 nucleotides positioned at 
the 3’ and 5’ end, respectively are fully conserved in all gene segments across all strains of 
IAV.  There is a single exception on position 4 of the 3ʹ end, which displays U/C 
heterogeneity (Steinhauer & Skehel 2002).  
 
 
The M proteins possess relatively slowly evolving genes, especially the M1 gene (Ito et al. 
1991). While the M2 gene shows a much faster evolution rate than the M1 gene, it is 




immune selective pressure, as well as the overlapping reading frame between the M1 and the 
M2 proteins has been suggested to contribute to the highly conserved region of the M protein 
(De Filette et al. 2005; Ito et al. 1991).  
 
M2 protein specifically, is a small transmembrane protein of 97 amino acids, coded by an 
overlapping reading frame (ORF +1) of segment 7 of AIV (Lamb & Choppin 1981; Lamb, 
Lai & Choppin 1981). It shares a common start codon with the M1 protein, a collinear 
transcript product of segment 7, up until the ninth aa, while the remaining 88 aa of the M2 
continues at the second (+1) ORF (Lamb, Lai & Choppin 1981; Lamb, Zabedee & Richardson 
1985) (Figure 1.2). It is a type III integral membrane protein which forms a homotetramer to 
be functional. It consists of three main parts; a 55 amino acid (aa) cytoplasmic C-terminal, a 
19 aa transmembrane protein, and a 24 amino acid (aa) external domain (M2e), exposed on 















Figure 1.1 An illustration of the avian influenza virus virion.  It is  generally round in shape, 
covered with three types of surface proteins, namely, hemagglutinin (HA), neuraminidase 
(NA), and matrix protein 2 (M2).  The rounded structure of the virion is maintained by the 
matrix 1 (M1) protein which encapsulate eight ribonucleoproteins. Each ribonucleoprotein is 
responsible for at least one AIV protein, and it is structurally made of nucleoproteins bound 
together by the virus genomic RNA to make a twisted, self-coil strand. At the opposite end of 
the loop structure, the strand is associated with the RNA polymerase complex formed by the 
polymerase-acidic (PA), polymerase basic type 1 (PB1) and polymerase basic type 2 (PB2) 




Figure 1.2 An illustration of the M1 and M2 protein mRNA with their coding regions (box) 
and the number of amino acid for each protein. Non-coding regions are represented with the 
















1 PB2 2,341 759 30-60 Component of RNA polymerase, cap recognition 
2 
PB1 2,341 757 30-60 Component of RNA polymerase, endonuclease activity, elongation 
PB1-F2  87c  Pro-apoptotic activityc 
PB1-N40  718  Modulate polymerase function d 
3 
PA 2,233 716 30-60 
Component of RNA polymerase, cap-bindinge, endonuclease activitye, viral RNA 
binding and replicatione 
PA-X  61e  Repress cellular gene expression, modulate host response to infectionf 
4 HA 1,778 550 500 Surface glycoprotein, receptor binding, fusion activity, major antigen 
5 NP 1,565 498 1,000 RNA binding, RNA synthesis, RNA nuclear import, antigen 
6 NA 1,413 454 100 Surface glycoprotein, virion release, antigen  
7 
M1 1,027 252 3,000 
Matrix protein, interaction with vRNPs and surface glycoproteins, nuclear export, 
budding, antigen 
M2 366 97 20-60 Membrane protein, ion channel activity, virus entry and assemblyg 
8 
NS1 890 230  
Inhibit host mRNA polyadenylationh, inhibit nuclear exporti, inhibit pre-mRNA 
splicingj, regulate viral RNA polymerase activityk, stimulate translation of specific 
viral mRNAsl, interaction with host cell proteinsm, viral IFN antagonistn antigen 
NS2 / NEP 418 121 130-200 Nuclear export of vRNPs 
a Palese and Shaw (2007), b Lamb and Krug (2001), c Chen, W et al. (2001), d Vater (2011)e Hara et al. (2006), f (Hu, J et al. 2015; Jagger et al. 2012), g (Beale et al. 2014; 
Wise et al. 2012), h (Nemeroff et al. 1998), i (Fortes, Beloso & Ortin 1994), (Qiu & Krug 1994); j (Lu, Qian & Krug 1994); k (Shimizu et al. 1994), (Marion et al. 1997); l 






 M2 protein 
M2 proteins function as ion channels during virion uncoating at the beginning of cell 
infection, and regulate the pH of the Golgi apparatus which is essential for HA glycoprotein 
maturation (Sugrue & Hay 1991). M2 protein is also responsible for the acidification of the 
viral interior that weakens protein-protein interactions, thus enabling the release of RNP into 
the cellular cytoplasm, prior to entry into the nucleus (Lamb, Zabedee & Richardson 1985; 
McCown & Pekosz 2005). Findings also suggested that M2 protein is responsible for 
preventing premature conformational rearrangement of the HA proteins during their transport 
in the Golgi lumen to the cell surface for virion formation (Sugrue et al. 1990; Sugrue & Hay 
1991), and plays a role in subverting autophagy and thus, contributed to the maintenance of 
virion stability (Beale et al. 2014).  
 
1.4.1.1 M2 cytoplasmic domain and transmembrane domain 
The cytoplasmic C-terminal of M2 protein is amphipathic helix oriented, comprising 
approximately 54 to 55 amino acids (Hull, Gilmore & Lamb 1988; Schnell & Chou 2008). 
The C-terminal shows significant diversity at the last 10-21 amino acids (Khurana et al. 
2009). It has been suggested that the M2 cytoplasmic tail is responsible for efficiency in 
genome packaging into the virus particles and virus assembly; and participates in 
morphogenesis of virions (Chen, BJ et al. 2008; Grantham et al. 2010; Iwatsuki-Horimoto et 
al. 2006; McCown & Pekosz 2005). It is also crucial for stabilization of the tetramer 
formation of M2 protein (Salom et al. 2000; Schnell & Chou 2008). 
 
The M2 transmembrane is an α-helix composed of 19 amino acids, which is a part of the ion 
channel construct (Lamb, Zabedee & Richardson 1985). As mentioned before, the ion channel 
functions to regulate the pH of proton channel upon virus entry into the host cells, uncoating 




formation (Hay et al. 1985; Lamb, Zabedee & Richardson 1985; Pinto, Holsinger & Lamb 
1992; Sugrue et al. 1990; Sugrue & Hay 1991). 
 
1.4.1.2 M2 extracellular (M2e) domain 
Out of 97 amino acids, approximately 18 to 23 N-terminal amino acids are exposed on the 
virion surface, nine of which are reported to be highly conserved in all IAV strains (Ito et al. 
1991; Khurana et al. 2009; Lamb, Zabedee & Richardson 1985; Liu, Li & Chen 2003; 
Zabedee & Lamb 1988). The M2 protein can be easily detected due to its abundance on the 
infected cells (Fang et al. 1981), but only a small amount of this protein has been found on 
mature virion (14 to 68 M2 molecules per virion) (Zabedee & Lamb 1988). Its small size and 
low abundance on the virion surface membrane in comparison to the other two membrane 
proteins (HA and NA), has made it only capable of eliciting a low immune response (Black et 
al. 1993). Low copy number of the M2e protein on the virion surface membrane is suggested 
to be related to its pH regulating function (Park et al. 1998). It is suggested that the 
overabundance of the protein might cause an early disruption of the M1-RNP complex due to 
rapid and over-acidification in the virus endosome during virus entry to host cell (Martin & 
Helenius 1991). The low copy number of the M2 protein per virion in turn allows the M2e 
protein to escape immune selection pressure, thus contributing to the conservation of this 
region (Black et al. 1993; De Filette et al. 2005; Fiers et al. 2009; Gerhard, Mozdzanowska & 
Zharikova 2006). It also shares a coding region with the matrix protein, thus limiting its 
possibility to undergo major changes (De Filette et al. 2005).  
 
 M2e as potential universal vaccine 
The M2 protein has long been the target for the development of influenza universal vaccine 
due to its highly conserved sequence and its proven ability to significantly reduce morbidity 
and mortality in various animal models (Fiers et al. 2004; Neirynck et al. 1999; Zharikova et 




for vaccination. Among others were the uses of M2 protein in passive transfer vaccination 
(Liu, Zou & Chen 2004; Treanor et al. 1990), vaccination with conjugated M2 protein (Fan et 
al. 2004; Neirynck et al. 1999), vaccination with a complete M2 protein (Ilyinskii et al. 2008), 
or only with the extracellular domain of the M2 protein  (Denis et al. 2008; Frace et al. 1999; 
Hashemi et al. 2012; Lambrecht et al. 2007; Leung et al. 2015; Liu, Li & Chen 2003). Mostly, 
these studies demonstrated the ability of anti-M2 antibodies in conferring protection to the 
non-natural host (mouse) against homologous and heterologous lethal virus challenge, with 
reduction in the virus titer (Fan et al. 2004; Fiers et al. 2009; Fiers et al. 2004; Mozdzanowska 
et al. 1999; Neirynck et al. 1999; Slepushkin et al. 1995). Immunization with recombinant 
virus expressing M2 protein in chicken however, showed no indication of M2 being 
immunogenic or protective  (Nayak et al. 2010). Nevertheless, another study which 
immunized chicken using recombinant M2 protein and M2e peptide found significant anti-M2 
antibodies, but lack the ability to bind the M2 protein on the virus surface or virus infected 
cells (Swinkels et al. 2013). This means that both M2 protein and M2e peptide were 
immunogenic, however was likely not protective. Although the currently available M2e 
vaccine may be applicable in other species, it may not be an optimal vaccine for the poultry 
industry.    
 
 M2e as DIVA marker 
M2e protein has also been targeted as a DIVA marker due to its epitope differential 
characteristic (Hadifar et al. 2014; Hemmatzadeh et al. 2013; Kim, MC et al. 2010; 
Lambrecht et al. 2007). Despite being low in number on a mature virion, the M2e protein 
exist in a vast amount on an infected cells (Fang et al. 1981; Zabedee & Lamb 1988). A 
number of studies on M2e-ELISA application using synthetic peptide have indicated that this 
protein is an effective means of differentiating animals infected with HPAIV strains from 




Lambrecht et al. 2007; Nemchinov & Natilla 2007). However, the use of synthetic peptide for 
a routine surveillance is costly, since the peptide needs to be synthesized in vitro.  
 
Alternatively, the use of recombinant protein offers a much lower cost for higher output, with 
continuous access for a large scale screening (Hemmatzadeh et al. 2013). Apart from being 
more affordable, a recombinant protein M2e-based ELISA developed for DIVA testing has 
shown a comparable performance to the synthetic M2e peptide-based ELISA (Hemmatzadeh 
et al. 2013). It clearly differentiates between chickens which are challenged with live virus or 
infected, with those which are vaccinated with the whole-killed virus. However, this system 
tends to generate non-specific reactions when tested with serum from older chickens, and 
haemolysed serum. It was also noted that monomer form of M2e used in ELISA demonstrated 
limited antigenicity and this consequently resulted poor diagnostic capability (Hemmatzadeh 
et al. 2013). Further attempt on presenting M2e in a multimeric form significantly increased 
efficiency of anti-M2e antibody detection in ELISA (Hadifar et al. 2014; Tarigan et al. 2015). 
Most importantly, these H5N1 M2e-based ELISA was able to detect positive sera from other 
AIV strains, namely H5N2, H9N2, H7N7 and H11N6 (Hemmatzadeh et al. 2013). These 
findings further support M2e applicability in AIV field surveillance with its DIVA ability 
which is not restricted to H5N1, but also other AIV strains.    
 
 Antigenic mapping 
Antigenic or epitope mapping is the identification process of antigen-antibodies binding site 
on the protein surface (Wang, LF & Yu 2004). It is an important technique developed to 
understand the correlation of function and structure of protein-protein interactions, such as the 
elucidation of antigen neutralizing sites (Bannister et al. 2011; Morris 1996). An epitope-
based mapping approach is advantageous due to the specificity of immune response produced, 
while providing a valid and robust basis for potent drug design and vaccine development as a 





 Antibody and Antigenic determinants  
In an operational basis, epitopes are classified into two types, either continuous or 
discontinuous (Regenmortel 1996; Smith, GP & Petrenko 1997; Wang, LF & Yu 2004) 
(Figure 1.7). Continuous epitope or also known as linear or sequential epitopes corresponds to 
short amino acid residues which can bind to antibodies raised against the target protein. 
Sequence resemblance as minimum as three amino acid residues can be observed between the 
continuous epitope with the antigen sequence (Bottger & Bottger 2009; Smith, GP & 
Petrenko 1997).  
 
Meanwhile, discontinuous epitope are made of nonlinear amino acid which are distant from 
each other and brought together through protein conformation or protein folding (Smith, GP 
& Petrenko 1997; Wang, LF & Yu 2004) (Figure 1.3). No sequence resemblance can be 
observed when discontinuous epitope are aligned with the antigen sequence. This is because 
the epitope structure depends on the conformation of the native protein, where amino acid 
which are locally apart from each other are brought together (Bottger & Bottger 2009; 








Figure 1.3 Schematic presentation of antibodies interaction with antigen. Epitope is the amino 
acid residues interacting with the antibodies, where (A) represents the continuous epitope, 
while (B) represents the discontinuous epitope. Adapted from Hjelm (2011).  
 
 
Structurally, an epitope (either continuous or non-continuous) are usually located in the 
protruding regions of proteins or accessible surface regions (Novotny et al. 1986; Thornton et 
al. 1986). Previous study noted that an epitope is likely to be located at the highest point of 
hydrophilicity, if not next to it (Hopp & Woods 1981), and are likely to be characterized by 
moderately conserved residues which are crucial for the stability and protein-protein 
associations (Keskin, Ma & Nussinov 2005).  
 
Identification of a dominant epitope will provide specific target for vaccine design which may 
has the potential for pathogen neutralization (Li et al. 2013; Shi et al. 2015). Knowledge on 
dominant epitope of a target antigen may also be used as basis for diagnostic tool 
development in an epidemiological surveillance. Therefore, this thesis explores antigenic 
mapping to identify the dominant M2e antigenic determinant to solidify its choice as the 





 M2e antigenic determinants 
The first discussion on M2e protein in regards of its protein sequence was due to the anti-M2e 
monoclonal antibody (14C2) ability to restrict growth of AIV in plaque assay (Zabedee & 
Lamb 1988). Continuous interest on M2e protein as a universal vaccine drives deeper 
explorations of its protein sequence, which eventually lead to description of M2e epitopes 
(Table 1.2). It was described that the N-terminal of M2e (amino acid 1-9), which is highly 
conserved across AIV strains, is capable of inhibiting AIV replication (Fu et al. 2009; Liu, Li 
& Chen 2003). Others revealed that aa 6-13 of M2e is responsible for the demonstrated 
protective immunity in their findings, together with other variations of M2e epitope of aa 4-16 
and aa 7-12 (Liu, Zou & Chen 2004; Zhang et al. 2006; Zou, Liu & Chen 2005). Further 
analyses on M2e protein antigenicity using different types of immunogen (e.g fusion protein, 
live virus and peptide) and different antibody sources (i.e rabbit, mice, human) revealed a 
range of identified M2e epitopes encompassing aa 2-16 in general (Grandea III et al. 2010; 
Pejoski et al. 2010; Wang, R et al. 2008). Other also showed that the N-terminal of M2, aa 2-
10 contain immunogenic epitope but not sufficiently protective (De Filette et al. 2011), which 
contradicted the previously reported findings. It is noted that different species may differ in 
their germline gene repertoires, antibody generating mechanism and affinity maturing of their 
antibody molecules (reviewed in Finlay and Almagro (2012). Therefore, different level of 
M2e antigenicity and slight variations in the described M2e epitopes might have been 
influenced by the host species. It is the interest of this thesis to further identify any difference 







Table 1.2 Summary of epitopes recognized on influenza A virus M2e protein by different antibodies. Adapted from Hasan et al (2016).  




(AS1, AS2, AS3, AS4) 
Rabbit Fusion-M2e (BSA) 2SLLTEVETPIR12 11 (Liu, Li & Chen 2003) 
Monoclonal 
(8C6, 1B12) 




(Liu, Zou & Chen 
2004; Zharikova et al. 
2005; Zou, Liu & Chen 
2005) 
Monoclonal Mice Live virus & synthetic peptide    4LTEVETPIRNEWG16 13 (Zhang et al. 2006) 
Monoclonal 
(L66, N547, Z3G1, C40G1, 
14C2) 
Human 
(λ HAC or KM™ 
mice) 
Fusion-M2e (BSA) 2SLLTEVETPIRNEWG16 (L66) 
   3LLTEVETPIRNEWG16 (N547) 
   3LLTEVETPIR12 (Z3G1) 
                          9TPIRNE14 (C40G1) 






(Wang, R et al. 2008; 
Zabedee & Lamb 
1988) 
Monoclonal Mice Fusion-M2e (BSA) 2SLLTEVET9 (M2e8-7) 
   3LLTEVETPIR12 (Z3G1) 
8 
10 
(Wang, Y et al. 2009) 
Monoclonal Mice Fusion-M2e (BSA)       4LTEVETPIRN12 (L18) 
2SLLTEVET9 (O19) 
2SLLTEVETPIRNEWGCRNDSSD24 (P6) 




(Fu et al. 2009) 
Polyclonal Mice  2SLLTEVETPIRNEWG16 15 (Pejoski et al. 2010) 
Monoclonal Human  2SLLTE6 (TCN-031, TCN-032) 5 (Grandea III et al. 
2010) 
 Mice Fusion-M2e (KLH) 2SLLTEVETP10 9 (De Filette et al. 2011) 
Difference at residue I11T between the current and previous studies corresponded to the human and swine specific M2e sequence in the former (I11) and avian specific M2e 






 Enzyme-linked immunosorbent assay (ELISA) for AIV surveillance 
and DIVA 
Highly specific and effective conventional serologic diagnostic tests are available for AIV 
detection, such as the hemagglutination inhibition (HI) and agar gel precipitation (AGP) tests. 
Although these tests are simple in principle and cost effective, they are also hard on time and 
impractical (Jenson 2014; Pedersen 2014). Recent developments of diagnostic tests witnessed 
the increased application and development of enzyme-linked immunosorbent assay (ELISA)-
based tool as platform (Aydin 2015; Chen, HW, Wang & Cheng 2011; Ding et al. 2014; He et 
al. 2013). This is highly likely due to its simple and easy application, yet sensitive and 
specific enough to detect the targeted antigen.  
 
 ELISA principles, components and types 
ELISA (direct ELISA) is first introduced as a quantitative assay for detecting antibodies, and 
is originally based on radioimmunoassay (RIA) principle (Engvall, Jonsson & Perlmann 
1971; Van Weemen & Schuurs 1971). Both ELISA and RIA differs in that antigen/antibody 
in the former is conjugated with enzymes instead of radioactive iodine 125 in the latter. 
ELISA harbours the same sensitivity as the RIA, yet is simpler and more affordable (Engvall 
2010).   
Briefly, ELISA is a method which utilises the antigen-antibody specific binding capability to 
quantitate the presence of antigen or antibody in a fluid sample. Quantification is done 
through the measurement of colorimetric reading mediated by an enzyme which is conjugated 
to the secondary antibody. Three main components of this assay are (i) the capture system, 
which is immobilized on a solid support; (ii) the analyte, which is the substance to be 
measured, and (iii) the detection system, a chromogenic substrate that changes its colour 
intensity according to the strength of the immune reaction (Butler 2000; Paulie, Perlmann & 
Perlmann 2005; Porstmann & Kiessig 1992). Thus, in principle, ELISA uses an enzymatic 
indicator system for antigen-antibody reactions, with either qualitative or quantitative results 
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(Butler 2000). Four general types of ELISA are available, namely, direct ELISA, indirect 
ELISA, sandwich ELISA and competitive ELISA (reviewed in Aydin (2015)).  
 
Both direct and indirect ELISA involve the attachment of antigen to a solid surface. However, 
direct ELISA only requires one antibody (primary) which is enzyme-conjugated to quantify 
the amount of antigen or antibody (Figure 1.4 (a)). In indirect ELISA, an additional 
(secondary) antibody tagged with enzyme is used to detect the primary-antibody-antigen 
complex (Lindstrom & Wager 1978) (Figure 1.4 (b)). It is noted to be more specific in 
comparison to direct ELISA due to the additional secondary-antibody. Meanwhile, sandwich 
ELISA is different than the previous two ELISA. Instead of the antigen, sandwich ELISA 
utilises a capture antibody (binder) to be attached to a solid surface (Kato et al. 1977) (Figure 
1.4 (c)). Then, sample containing antigen to be tested is added to the attached antibodies 
before the addition of a second set of antibody (enzyme-conjugated) specific to the antigen. 
The targeted antigen are captured in between the capture- and the enzyme-conjugated-
antibody used for quantification, hence, sandwich ELISA. This ELISA is also highly specific 
due to two sets of antigen-specific antibodies used. All three ELISA show high colorimetric 
intensity upon substrate development if the targeted antigen/antibodies are present.  
 
Finally, competitive ELISA utilises either antigen-specific antibody or antibody-specific 
antigen to be immobilised on a solid surface (Yorde et al. 1976) (Figure 1.4 (d)). Sample to be 
tested and enzyme-conjugated antigen/antibody are added simultaneously to the immobilised 
antibody/antigen. If samples contain antibodies/antigen specific to the binder, it will compete 
with the positive antigen/antibody to bind to the immobilised antibody/antigen, hence 
competitive ELISA. Different from the previous ELISA, upon substrate development, 
presence of specific antibodies/antigen is indicated by low colorimetric intensity as only some 
binders are occupied by the enzyme-conjugated antigen/antibody. Meanwhile, high 
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colorimetric intensity indicates absence of specific antibodies/antigen, because all binders are 
occupied by enzyme-conjugated antigen/antibodies.  
 
Selection between different types of ELISA is generally based on the availability of 
antigen/antibody-specific antibodies/antigen. This is especially for the secondary antibodies 
required in both indirect and sandwich ELISA, as well as the competitor antibodies for 
competitive ELISA. Although both direct and indirect ELISA are simple enough to perform, 
direct ELISA is prone to false positive with known low sensitivity. Indirect ELISA requires 
different types of secondary antibodies for testing samples from different species. Both 
sandwich ELISA and competitive ELISA possess the highest specificity for antigen/antibody 
detection. However, the setback for sandwich ELISA lies in the availability of a paired 
antibodies (Jordan 2004), while competitor antibodies needs to be universal yet sensitive 
enough for it to be applicable across species. Monoclonal antibodies are highly specific for 
such purposes while peptide can be rapidly available to be used instead of antibodies in recent 
years. However, both are not feasible options for a large-scale and long-term application, such 
as in pathogen surveillance. Nevertheless, competitive ELISA in particular is applicable with 
a large amount of samples and the use of recombinant antigen/antibody is possible (Yang, M 





Figure 1.4 Illustrations of different types of ELISA in which arrows represent the wash and 
rinse step. (a) Direct ELISA, (i) Samples to be tested are immobilised on the solid surface, (ii) 
enzyme-conjugated antibody are added, before substrate development, (iii) High colorimetric 
density indicates presence of targeted IgG. (b) Indirect ELISA: (i) Sample containing the 
targeted IgG added to wells with immobilised antigen, (ii) Specific IgG bind to the antigen, 
(iii) Addition of enzyme conjugated antibodies to identify the antibody-antigen-complex, (iv) 
High colorimetric density indicates presence of targeted IgG. (c) Sandwich ELISA: (i) The 
22 
 
first antibody of the target-specific IgG is immobilize on the solid surface, (ii) Addition of 
samples containing the potential target IgG, (iii) Addition of the second antibody which is 
target IgG-specific, (iv) High colorimetric density indicator of target IgG presence. (d) (i-iii) 
Competitive ELISA (cELISA) with the presence of positive antibodies (test sample), where it 
competes for the antigen with the enzyme-labelled competitor antibodies, thus reduces the 
color saturation indicating a positive competition; (d) (iv-vi) cELISA with the presence of 
negative antibodies (test sample) where it gives no competition to the enzyme-labelled 
competitor antibodies resulting high color saturation indicating a negative competition. 
Adapted from Gan and Patel (2013). 
 
 
 AIV and ELISA 
In the context of AIV, comparison studies between conventional test hemagglutination 
inhibition (HI), agar gel precipitation (AGP), serum neutralization and ELISA for AIV 
detection found that ELISA demonstrated the most sensitive, specific and accurate results 
among the tests (Faraz et al. 2010), although precaution is required when monitoring AIV in 
its early stage of infection (Shiraishi et al. 2012). A number of ELISA targeting the AIV 
protein such as the hemagglutinin, neuraminidase and nucleoprotein have been developed 
(Jensen et al. 2013; Jin et al. 2004; Wu, R et al. 2007). Some ELISA kit are also commercially 
available for rapid screening of AIV infection, such as the ID-Vet IDScreen® (Idvet, 
Montpellier, France), IDEXX FlockChek™ AI MultiS-Screen Ab Test Kit Idexx, Westbrook, 
ME), Synbiotics FluDETECT™BE (Synbiotics, Kansas City, MO), and BioCheck AIMSp 
(BioChek, Reeuwijk, The Netherlands). However, it was reported that these ELISA are not 
applicable for AIV screening in wild birds due to the nature of AIV in wild birds and different 
level of pathogenicity demonstrated by AIV strains in different species (Alexander, Parsons & 
Manvell 1986; Claes et al. 2012; Forman, Parsonson & Doughty 1986). Nevertheless, 
considerations on the simplicity and easy implementation of ELISA ensures continuous 
efforts in developing alternative ELISA for AIV screening is still progressing.  
 
In the past, nucleoprotein-based competitive ELISA has demonstrated its reliability and 
applicability for surveillance use in multispecies (Shafer, Katz & Eernisse 1998; Starick et al. 
2006; Zhou, EM et al. 1998). However, these available ELISA are not applicable in countries 
where vaccination using killed whole virus are used (Chen, H 2009; Marangon, Cecchinato & 
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Capua 2008). The reason being the targeted antigen are not capable of DIVA application 
(reviewed in Pantin-Jackwood and Suarez (2013)). Hence, this thesis incorporates an attempt 
to develop a competitive ELISA based on the isolated anti-M2e-antibody which has been 
demonstrated as reliable for AIV infection detection and DIVA application.  
 
 Phage display technology  
Phage display technology is a method which enable the selection of foreign protein, expressed 
alongside the bacteriophage protein. This involves the insertion of the gene of interest in a 
vector either a phage or a phagemid; a plasmid which modified to have the ability to amplify 
in a bacteria and a bacteriophage (Smith, GP 1985, 1993; Smith, GP & Petrenko 1997). 
Highlight of this technology are the physically linked phenotype and genotype of the phage, 
and the ability to select the protein of interest through biopanning – a process of affinity 
selection to the desired antigen.  
 
Generally, there are three stages of a phage display experiment, namely (i) the construction of 
a protein or antibody library, (ii) the selection of targeted protein or antibody through affinity 
selection, and (iii) the verification of the isolated protein or antibody using biological assay or 
analyses (Huang, Bishop-Hurley & Cooper 2012) (Figure 1.5). Construction of the desired 
antibody library requires initial considerations in the phage display properties selection, such 
as the antibodies gene sources, bacteriophage to be used, recombinant antibody format, vector 
for phage display and its coat protein selection. Once all of these options has been sorted out 
and the construction has successfully produced the desired phage library, selection of 
antibodies with the targeted specificities is done through ‘biopanning’. Briefly, biopanning 
involves the repetition of the following steps; (a) binding of bacteriophages displayed 
antibodies against the targeted antigen to capture specific binders, (b) washing to remove the 
non-specific binders or low affinity binders, and (c) elution of bacteriophages displayed 
antibodies for further amplification. Additional rounds of biopanning can be done to increase 
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specificity of the isolated antibodies, with modification in the capture antigen concentration 
(lower the concentration to target highly specific antibodies), and number of washes which 
may varies from 10 to 30 cycles (increase wash to target antibodies with high specificity). 
Finally, the specificity of the isolated antibodies can be verified using bioassays such as 
ELISA and western blotting.  
 
Due to the ability of phage display technology to isolate specific antibodies to the targeted 
antigen, it has been mainly used to study protein-protein interaction, especially for health and 
medical purposes (reviewed in Bazan, Calkosinski and Gamian (2012)), such as producing 
proteins to be used as therapeutic agents for autoimmune diseases (Farilla et al. 2002; Kim, Y 
et al. 2011; Klotz, Meuth & Wiendl 2012) and tumour targeting (Cyranka-Czaja et al. 2012; 
Lin et al. 2012; Yang, J et al. 2011).  
 
 
Figure 1.5 Phage display technology involves (a) the insertion of gene of interest into a vector 
(such as phagemid) and infect it with the helper phage to produce recombinant bacteriophage 
library which expresses the antibodies of interest. (b) Affinity selection is done to select the 
bacteriophages with the highly reactive antibody using plate coated with the specific antigen. 
(c) Unbound bacteriophages are washed away and only bacteriophages expressing the specific 
antibodies are captured by the antigen. (d) Specifically bound bacteriophages are eluted and 
amplified. (e) Amplified bacteriophages are checked for positive gene insertion and 
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expression using (f) PCR, ELISA and SDS-PAGE. Adapted from (Hoogenboom & Chames 
2000). 
 
 Naïve and immunized library as a source of phage library 
The immune system variable gene (V-gene) repertoire is the key source of diversity for a 
phage display library. The V-gene can be obtained from either an immune donor (Clackson et 
al. 1991; Okamoto et al. 2004) or naïve (non-immune) donor (Marks et al. 1991; Sommavilla 
et al. 2010) (reviewed in Griffiths and Duncan (1998)). An immune donor would provide a V-
gene repertoire which are highly biased towards the antibodies against the immunogen. 
Therefore, a relatively small library (approximately 105 clones) are sufficient to represent the 
possible antibodies diversity. Also, an immune phage library provides affinity matured 
antibodies, which enable the selection of antibodies with high affinity. However, an immune 
donor source may not always possess the antibodies with the desired properties, as immune 
response may varied from one host to another. Besides, targeted antigen may be toxic and 
fatal for the potential donor. Tolerance mechanism is a probable issue if antibodies against 
self-antigen, which is highly valuable as therapeutic agents, is desired.  
 
Meanwhile, a non-immune donor will not require any immunisation, and its non-specific and 
diverse pool of antibodies library may open up possibilities of retrieving antibodies against a 
diverse set of antigen (Pansri et al. 2009; Schwimmer et al. 2013). Isolation of antibodies 
against self-antigen is possible, and a shorter time (less than two weeks) is required for 
antibodies generation. Nevertheless, such naïve donor will require a large library clones to 
ensure isolation of high affinity antibodies, and the nature of naïve V-gene repertoire is highly 
unknown and unpredictable. Therefore, selection of V-gene repertoire is highly dependent on 




 Filamentous bacteriophage for phage display 
Various types of bacteriophage are available for protein or antibody display application, such 
as the T4, T7 and lambda phage display system (Beghetto & Gargano 2011; Gamkrelidze & 
Dabrowska 2014; Talwar et al. 2015). However, the widely used bacteriophage for phage 
display is the filamentous bacteriophages (f1, fd, M13) for it will not lyse the cell it infected 
while producing its progeny (Bazan, Calkosinski & Gamian 2012). Generally, a filamentous 
phage is about 900 nm in length with diameter of 6-10 nm, and infects Escherichia coli with F 
pili (Berkowitz & Day 1980; Newman, Swinney & Day 1977). It is composed of a single-
strand DNA which encoded nine genes, which are clustered into three main groups, namely 
genes for replication (g2/g10 and g5), virion structure (g7, g9, g8, g3 and g6), and 
assembly/secretion (g1/g11, and g4) (reviewed in Rakonjac (2012) and Rasched and Oberer 
(1986)). Its DNA is encapsulated in a cylindrical capsid made of five types of coat proteins, 
with p8 coating the whole filamentous phage body; p3 and p6 at one end of the phage, while 
p7 and p9 at the other end (Endemann & Model 1995; Grant et al. 1981; Henry & Pratt 1969) 
(Figure 1.6).  
 
 
Figure 1.6 An illustration of a filamentous bacteriophages. Structurally, it has a single-
stranded DNA encapsulated in a cylindrical capsid, which made of the major coat protein p8 
(pVIII); with p9 (pIX) and p7 (pVII) at one end, and p6 (pVI) and p3 (pIII) at the other end. 




Majority of phage display used protein fusion with either p3 or p8, dependant on the aims of 
the target display. If affinity selection is desired, p3 is a better option because it is a 
monovalent display system which allows identification of high affinity binders. However, p8 
is a polyvalent display system, and avidity effect is more dominant than its affinity which 
usually lead to low affinity ligands (reviewed in Bratkovic (2010) and Huang, Bishop-Hurley 
and Cooper (2012)). 
 
 Recombinant antibody display format  
Different recombinant antibody display format is also available for selection, including the 
antigen-binding fragment (Fab), single chain variable fragment (scFv) and its modifications 
(Carlsson et al. 2012; Shen et al. 2007; Wen et al. 2012). Generally, antibody is a protein with 
a Y-shaped structure produces by a host to bind foreign or non-self-molecule as a part of the 
immune defence system (Tizard 2013). The arms structure of the antibody that make up the 
tip of the Y’s (V-shape) determine the versatility and specificity of the host immune responses 
to an antigen, while the stem structure govern the biological activity that define its response, 
such as complement-mediated lysis, enhanced phagocytosis or allergy.  
 
An antibody consists of two main fragments, namely the constant fragment (fragment 
crystallisable, Fc), and the antigen-binding fragment (Fab) (Figure 1.7). The Fab is further 
characterised by a pair of each of the following: constant heavy fragment (CH), constant light 
fragment (CL), variable heavy fragment (VH) and variable light fragment (VL). The H chain is 
usually 60 kDa in weight, while the L chain is 23 kDa (Bird & Walker 1991; Tizard 2013). 
Variable region of an antibody is characterised by two features, namely the hypervariable 
domains and the framework regions (Tizard 2013). The hypervariable regions are the three 
regions where the sequences are highly variable, while the framework regions are the 
relatively constant regions in between these hypervariable domains. These hypervariable 
regions are also known as the complementarity-determining regions (CDRs) (Wu, TT & 
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Figure 1.7 Schematic presentation of the immunoglobulin gene, composes of the constant 
region (Fc) and the variable region (the heavy chain, VH and the light chain, VL, each with 
complimentarity determinant regions, CDRs). Single chain fragment variable (scFv) is 
composes of the variable chain of heavy and light, connected with a linker, usually 
(Gly4Ser)3. Adapted from Tizard (2013).  
 
Fab consists of VH, CH1, VL and CL, and such association is stabilized through heterodimer 
formation between VH/CH1 and VL/CL interfaces (Rothlisberger, Honegger & Pluckthun 
2005). Meanwhile, scFv is made of VH and VL domains, tethers by a flexible peptide linker 
such as the glycine-serine (Gly4Ser)3 linker (Bird et al. 1988; Chen, W et al. 2014; Freund et 
al. 1993; Glockshuber et al. 1990; Holliger & Hudson 2005). Comparative evaluation of both 
Fab and scFv showed that Fab is a more functionally stable recombinant antibody format 
(Quintero-Hernandez et al. 2007; Rothlisberger, Honegger & Pluckthun 2005). Nevertheless, 
more interest was on scFv due to its small size (30 kDa) in comparison to Fab (50 kDa), and 
presence of a single polypeptide chain which eases fusion protein construction (Nimmagadda 
29 
 
et al. 2012; Rothlisberger, Honegger & Pluckthun 2005; Weber et al. 2014). ScFv design, 
construction and expression in E. coli enable the demonstration of the gene structure-function 
relationship in terms of antigen-antibody interactions. Exhibition of its high affinity and 
stability make the scFv a useful tool for both clinical and medical applications (Chen, W et al. 
2014; Min et al. 2011; Singh et al. 2010). Among the successful application of scFv were in 
hepatitis A antigen quantification for vaccine preparation (Nimmagadda et al. 2012), 
diagnosis of mycotoxins in field and stored grain or in food (Hu, ZQ et al. 2013), production 
of antibody for use in treatment against influenza virus (Pissawong et al. 2013), and for use in 
immunodetection of staphylococcal enterotoxins A, a prevalent causes of foodborne diseases 
(Chen, W et al. 2014).  
 
 Phagemid as phage display vector 
Two different types of vectors are available for protein display, namely the phage vector and 
the phagemid – a plasmid-based vector. Both vectors are structurally based on the natural Ff-
phage sequence, with phagemid vector is only equipped with fusion protein gene, but lacks 
other phage genes (reviewed in Russel, Lowman and Clackson (2004)). Phagemid is also 
modified to carry the plasmid replication origin which allows its replication in E. coli. 
Basically, a phagemid contains replication origin of a plasmid, a selective marker, the 
intergenic region (IG), a phage coat protein gene, restriction enzyme recognition sites, a 
promoter, a DNA segment encoding signal peptide, and a molecular tag (Figure 1.8) (Qi et al. 
2012). Phagemid is also often modified to have an amber stop codon (TAG) between the 
displayed sequence and gene III. This allows expression of soluble protein when the vector is 
transferred into a non-supE suppressor strain E. coli such as HB2151 (reviewed in Azzazy 
and Highsmith Jr (2002)). While a phage vector is fully capable to replicate and produce 
phage displaying the desired protein once it is introduced into E. coli, phagemid is converted 
into a filamentous phage after its co-infection with helper phage such as M13KO7, VCSM13, 
hyperphage (Rondot et al. 2001) and their derivatives (Baek et al. 2002; Kramer et al. 2003; 
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Soltes et al. 2003). In terms of its display, phage vector displays protein polyvalently 
(heterologous protein), while phagemid vector allows monovalent protein display (reviewed 
in Qi et al. (2012).  
 
Phagemid is more widely used as vectors in phage display due to the following factors; (i) its 
large capacity in accommodating foreign DNA fragment, (ii) efficient transformation which 
results in high diversity of phage library, (iii) various selection of restriction enzyme 
recognition site are available for convenient gene manipulation, (iv) fusion protein expression 
level can be modulated with ease, and (v) genetically more stable after multiple propagations 
(Bass, Greene & Wells 1990; Breitling et al. 1991; Qi et al. 2012). As noted in previous 
section, coat protein III and VIII are the most common coat protein used for expression (Qi et 
al. 2012). It is also noted that phagemid with coat protein III has a bigger insert size capacity 
for foreign proteins in comparison to phagemid with coat protein VIII (Smith, GP 1993). 
However, coat protein III may only be used to express up to five copies of the fusion proteins, 
while coat protein VIII is capable of expressing up to thousand copies (Veronese et al. 1994).  
 





Considering the options available for isolation of anti-M2e antibodies for DIVA and AIV 
surveillance purposes, this thesis has employed the following selections: H5N1 immunized 
library from chicken, the natural AIV host, to specifically increase the possibilities of V-gene 
repertoire harbouring high affinity anti-M2e antibodies; and filamentous bacteriophage which 
displays an scFv antibody format through coat protein III, while using phagemid to fully 
exploit the advantages it has to offer to isolate the antibody of interest, for application in an 
ELISA-based system.  
 
 Research Rationale and Aims 
AIV M2e protein has been demonstrated to be capable of DIVA application, which is a 
critical feature for AIV surveillance in H5N1 enzootic countries. The major issue concerning 
this protein is that it is a weak immunogen by nature. However, its differential epitope density 
between virus infected cell and on the virion itself (which used in whole-killed virus 
vaccination) made it valuable and worthy to explore for DIVA application. It is noted that the 
first virus challenge experiment after vaccination in chicken may only evoke a low amount of 
anti-M2e antibodies due to the protective threshold build by killed virus vaccination (Heinen, 
de Boer-Luijtze & Bianchi 2001). Therefore, a highly sensitive and highly specific detection 
tool is required to ensure that the detectability of M2e protein is not impaired due to such 
interference.  
 
M2e-based competitive ELISA will be a highly optimal diagnostic tool for AIV surveillance 
as it is simple, easy and has a high throughput. Apart from capable of DIVA, an M2e-based 
competitive ELISA has the potential to be used with more than just one species, as AIV is a 
multiple host pathogen (Chambers, Dubovi & Donis 2013). However, a competitive ELISA is 
only applicable if the protein (competitive antibodies) recognizes the same antigenic 
determinant – the dominant epitope, across species. No known comparison of M2e epitope 
has been done previously among different species. Therefore, it is the interest of this thesis to 
32 
 
characterize the antigenic determinant of M2e protein from different anti-M2e antibodies 
sources.  
 
Findings from the M2e mapping are to provide a basic information on the suitability of the 
available anti-M2e antibodies to be used as the competitor antibodies in a competitive ELISA 
setting. Therefore, it is also the aim of this thesis to develop a potential M2e-based 
competitive ELISA using the generated anti-M2e antibodies.  
 
It is noted that scFv antibodies displayed on phage are mostly stable and demonstrated high 
affinity to the targeted antigen (Chen, W et al. 2014; Min et al. 2011). Therefore, this thesis 
aims to isolate reactive anti-M2e antibodies using the phage display technology from H5N1 
exposed birds for the development of M2e-based competitive ELISA. Presumably, 
construction of anti-M2e phage displayed antibodies library will enable the selection of the 
most reactive antibodies to the targeted protein.  
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Vaccination is becoming a more acceptable option in the effort to eradicate avian influenza 
viruses (AIV) from commercial poultry, especially in countries where AIV is ‘endemic’. The 
main concern surrounding this option has been the inability of the conventional serological 
tests to differentiate antibodies produced due to vaccination from antibodies produced in 
response to virus infection. In attempts to address this issue, at least six strategies have been 
formulated, aiming to differentiate infected from vaccinated animals (DIVA), namely (i) 
sentinel birds, (ii) subunit vaccine, (iii) heterologous neuraminidase (NA), (iv) non-structural 
1 (NS1) protein, (v) matrix 2 ectodomain (M2e) protein, and (vi) haemagglutinin subunit 2 
(HA2) glycoprotein. This short review will briefly discusses the strengths and limitations of 
these DIVA strategies, together with the feasibility and practicality of the options as a part of 
the surveillance program directed towards the eventual eradication of AIV from poultry in 
countries where highly pathogenic avian influenza is ‘endemic’. 
 
Keywords: avian influenza virus, vaccination, DIVA strategies 
 
 Avian influenza virus (AIV) 
 Gene segments and proteins 
Avian influenza viruses are enveloped, segmented, negative-stranded RNA viruses, belonging 
to the family Orthomyxoviridae, genus Influenzavirus A (Lamb & Krug 2001; Taubenberger 
& Kash 2010). Influenza A virus (IAV) is composed of eight gene segments, and each gene 
segment codes for at least one protein. To date, IAV is known to code for 13 viral proteins 
(Jagger et al. 2012; Wise et al. 2012). Some of the segments encoded more than one protein 
through mechanisms such as alternative reading frame (PB1-F2, PB1-N40, PA-X and M2), 
and mRNA splicing (NS1/NEP) (Chen et al. 2001; Jagger et al. 2012; Lamb & Choppin 1981; 




AIV is classified based on the antigenic variation displayed by the virus surface protein – 
haemagglutinin (HA) and neuraminidase (NA) (Assaad et al. 1980). A total of 144 possible 
subtype combinations have been identified for AIV based on the 16 HA subtypes and 9 NA 
subtypes (Fouchier et al. 2005) found  circulating in the aquatic bird population identified as 
the AIV natural reservoir, predominantly the Anseriformes (particularly ducks, geese, and 
swans) and Charadriiformes (particularly gulls, terns, and waders) (Munster et al. 2007; 
Webster et al. 1992). Two new HA subtypes (H17, H18) and NA subtypes (N10, N11) have 
recently been identified circulating in bats from Central America (Guatemala) and South 
America (Peru) (Tong et al. 2012; Tong et al. 2013).  
 
 AIV transmissibility  
Observations indicated that movement of AIV from wild to domestic birds occurs relatively 
frequently due to shared ecosystem, where prolong and repeated exposure of domestic birds 
to the virus facilitate adaptation of virus to a new host (Swayne 2007). However, virus 
adaptations for a new host is a complex and a rare event as majority of these transmissions 
will only cause transient virus infections with limited spread as observed in AIV poultry 
surveillance (Alexander 2007; Suarez 2010). However, it is important to note that some 
species such as domestic ducks and geese, turkeys as well as the Japanese quails are more 
susceptible to AIV infections and may have been the bridging species of wild birds AIV into 
the chickens and other gallinaceous poultry (Swayne & Slemons 2008).  
 
 AIV evolution  
Continuous outbreaks of AIV infection are driven by two main evolutionary mechanisms used 
by the virus to evade host immune systems: antigenic drift and antigenic shift (Nelson & 
Holmes 2007). Antigenic drift occurs in response to the host immune pressure when 
mutations accumulate in the surface glycoproteins HA and NA, causing minor changes to the 
antigenic structure of the virus (Nelson and Holmes, 2007). Antigenic shift results from 
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reassortment of infecting virus subtypes that lead  to introduction of strains with completely 
novel gene combination and often with improvements in the capacity for the production of 
more viable and fit virus progeny (Holmes et al. 2005).  
 
 AIV pathogenicity 
AIV is classified into low and highly pathogenic avian influenza virus (LPAIV and HPAIV, 
respectively) based on its lethality in chickens (Gallus gallus domesticus) (Swayne 2007; 
Swayne & Suarez 2000). In domestic poultry, LPAIV generally causes subclinical infection 
with virus shedding in infected birds, if not mild respiratory disease. In contrast the HPAIV, 
also formerly known as the fowl plague, causes multiorgan systemic disease, with high 
percentage of morbidity and mortality in both domestic and wild birds (Alexander 2000; 
Swayne & Suarez 2000). 
 
The AIV pathogenicity generally relies on the cleavability of the HA0 subunit to HA1 and 
HA2 by the host cellular proteases (Klenk et al. 1975; Lazarowitz & Choppin 1975; Rott et al. 
1980), and HPAIV is characterised by the presence of polybasic amino acids at the HA0 
cleavage site instead of a monobasic motif observed for LPAIV (Bosch et al. 1981; Horimoto 
& Kawaoka 1994; Senne et al. 1996). The monobasic structure of the HA0 cleavage site is 
only cleavable by the trypsin-like enzymes which are present at limited sites in the host, hence 
LPAIV infections are confined to respiratory or gastrointestinal tract (Klenk & Garten 1994; 
Lazarowitz, Compans & Choppin 1973; Rott 1992). In contrast, the polybasic motif found in 
the HPAIV HA0 is cleaved by ubiquitous proteases present within cells of multiple organs 
throughout the body, such as furin and subtilisin-related proteases (proprotein convertase 6 – 




 LPAIV and HPAIV in poultry 
Any of the 16 HA subtypes circulating in wild birds reservoirs are considered as LPAIV, 
while all HPAIV are of H5 and H7 subtypes, although not all of these subtypes are HPAIV 
(Alexander & Brown 2009; Swayne & Suarez 2000). Apart from the HPAIV H5N3 outbreak 
in common terns (Sterna hirundo) in South Africa in 1961 (Becker 1966) and HPAIV H5N1 
outbreak in wild waterfowl in two parks in Hong Kong in 2002  and bar-headed geese (Anser 
indicus) in western China in 2005 (Chen et al. 2005), HPAIV has been rarely isolated from 
wild bird populations (Swayne & Suarez 2000). Due to the complex pathobiology of AIV, 
viruses which are highly pathogenic (HP) in domestic birds, generally do not necessarily 
cause diseases in Anseriformes birds (ducks and geese) in experimental condition (Alexander, 
Parsons & Manvell 1986; Forman, Parsonson & Doughty 1986). It is important to note that 
HPAIV usually occurs in domestic gallinaceous poultry (chickens, turkeys, quails and guinea 
fowls) after exposure to and adaptation of LPAIV from wild birds (Rohm et al. 1995; Swayne 
2007). This is usually a unidirectional infection, where the domestic bird-adapted AIV rarely 
re-infects wild bird’s population (Swayne 2007), with the exception of the Asian lineage 
H5N1 HPAI virus (Chen et al. 2005; Liu et al. 2005).  
 
 Virulence shift of LPAIV to HPAIV 
The LPAIV H5 and H7 subtypes can acquire virulence factors and become HPAIV through 
several mechanisms focused on the HA protein, which are (i) the substitution and insertion of 
basic amino acids (aa) in the HA cleavage site (Horimoto et al. 1995; Swayne 1997), (ii) loss 
of carbohydrate which covers the HA cleavage site through residue mutations (Kawaoka, 
Naeve & Webster 1984), (iii) recombination of HA with other AIV viral gene such as 
nucleoprotein (NP) gene (Suarez et al. 2004), or the matrix (M) protein gene (Pasick et al. 
2005), or with the 28S ribosomal RNA (Khatchikian, Orlich & Rott 1989), and (iv) 
polymerase slippage which caused sequence duplication, thus insertion in the HA gene 
(Garcia et al. 1996; Perdue et al. 1997). Nevertheless, it was suggested that a hidden virulence 
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potential was readily embedded within the LPAIV strains capable of transformation to a HP 
strain, where the acquisition of polybasic cleavage site is the key activator for the virulence 
shift (Bogs et al. 2010; Stech et al. 2009). This assumption is based on observations where 
alterations in other AIV viral proteins such as deletion of matrix 2 (M2) protein or NP 
cleavage site reduced AIV pathogenicity (Zhirnov & Klenk 2009); while point mutation 
accumulation in the NA protein (Deshpande, Naeve & Webster 1985), amino acid deletion in 
the NA stalk (Munier et al. 2010) and amino acid substitution in the non-structural protein 1 
(NS1) (Jiao et al. 2008) and polymerase proteins (basic polymerase 2,PB2 and acidic 
polymerase, PA) (de Wit et al. 2010; Hatta et al. 2001) promotes virulence of AIV.  
 
 Evolutionary pattern of H5N1 
Within the AIV history, the pandemic potential of Asian lineage H5N1 virus is by far the 
most alarming due to the rate of its spread and the unusual evolutionary pattern showed by 
this particular subtype (Fouchier & Guan 2013; Watanabe et al. 2011). Unlike the emergence 
of other HPAIV which occurs in chickens, the initial outbreak of H5N1 was recorded in 
domestic geese in Guangdong Province, China in 1996, which then became the primary 
precursor virus for the major outbreak in chicken farms in Hong Kong in 1997 (HK-97) 
(Shortridge et al. 1998; Xu et al. 1999). Although the HK-97 genotype had been eliminated 
through mass poultry depopulation in 1997, the genetic variants of the primary precursor virus 
(Goose/Gd-like) have continued to circulate exclusively in aquatic poultry until late 2000 
(Cauthen et al. 2000; Webster et al. 2002), where the host range expanded to include 
terrestrial poultry in the following year, providing a larger pool of genetic material for 
reassortment (Chen et al. 2004; Guan et al. 2002).  
 
The rapid rate of H5N1 evolution was later validated with the identification of six H5N1 
reassortants in Hong Kong and mainland China in early 2001, immediately before the 
outbreak in Hong Kong, mid-May the same year (Guan et al. 2002; Li et al. 2004; Sims et al. 
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2003). It was identified that this reassortant virus possessed a HA gene that originated from a 
Goose/GD/96-like virus, while the other seven internal genes were a result of reassortment 
from other non-H5 avian influenza viruses (Webster et al. 2002). Although no infection with 
H5N1 was detected from July 2001 onwards, Hong Kong experienced an outbreak caused by 
the HPAIV H5N1 again in February 2002 (Li et al. 2004; Sims et al. 2003). Eight new H5N1 
genotypes were isolated including genotype ‘Z’, which later become dominant in southern 
China (Li et al. 2004). Characterized with the deletions of 20 aa in the NA stalk and 5 aa in 
the NS protein (Guan et al. 2002), genotype ‘Z’ has been responsible for the emergence of the 
2003 and 2004 H5N1 outbreaks, marking the first dissemination wave of H5N1 into eight 
countries in East and South East Asia, leading to establishment of ‘endemicity’ in Vietnam 
and Indonesia (Fouchier & Guan 2013; Wang, Vijaykrishna, et al. 2008). 
 
Although the Asian lineage H5N1 virus was ‘endemic’ in poultry since 1997, it had later 
spread and persisted in the wild bird population, evidenced by  the H5N1 outbreak in the 
migratory waterfowl, the bar-headed geese (Anser indicus) at Qinghai Lake in western China 
in 2005 (Chen et al. 2005; Liu et al. 2005). Subsequently, the virus spread rapidly across Asia, 
Europe, the Middle East, and Africa, marking the second wave of H5N1 dissemination, 
affecting wild migratory birds and poultry (Gilbert et al. 2006; Wang, Vijaykrishna, et al. 
2008). The third wave of H5N1 dissemination to South East Asian countries followed 
immediately in late 2005. It was characterized by the emergence and predominance of the 
H5N1 Fujian-like viruses, replacing the multiple H5N1 sublineages in China which were 
responsible for the previous disseminations (Smith et al. 2006). This event led to the 
panzootic  of H5N1 in poultry, especially in the Asian continent where intermittent outbreaks 
have been reported, particularly in countries where H5N1 is ‘endemic’ (China, Vietnam, 





 AIV and vaccination 
Following the identification of wild birds as the agent of long distance virus transmission 
(Artois et al. 2009; Olsen et al. 2006; Tian et al. 2015), and the possible transmission of the 
virus through domestic animals (Verhagen et al. 2014), culling of the infected birds and the 
flocks of birds with suspected exposure to the virus have been used as the primary control 
measures, especially in countries where disease has been recently introduced (Suarez 2005, 
2012). However, in countries where infection was already widespread and ‘endemic’, and 
other methods were not likely to eradicate the infection, vaccination was chosen as the 
primary control tool (Domenech et al. 2009; Suarez 2012; Swayne et al. 2011).  
 
To date, AIV vaccination using the inactivated vaccines, and to a smaller portion using the 
live recombinant vaccine (NDV-H5) has only been exercised as a control or a preventive 
measure to eradicate HPAI viruses in poultry, either in the event of epidemics, such as seen in 
Mexico (H5N2, 1994-1995, 1995-2001) (Villareal 2009), Italy (H7N1, 1999-2000; H7N3 and 
H5N2, 2003-2006) , Hong Kong (H5N1, 2002-2003) (Capua, Mutinelli, et al. 2002; 
Marangon, Cecchinato & Capua 2008; Sims et al. 2003; Villareal 2009) and others ; or in 
countries where HPAIV are ‘endemic’, as is the case for HPAI H5N1 in China, Indonesia, 
Vietnam and Egypt (Chen 2009; FAO 2011; Marangon, Cecchinato & Capua 2008; 
Marinova-Petkova et al. 2014).  
 
Vaccination helps to control the spread of infection as vaccinated birds will acquire an 
elevated level of resistance to infection, thus lower shedding and environmental 
contamination by virus (Capua et al. 2009; Swayne et al. 2011). Nevertheless, to achieve 
disease eradication, it is important for a vaccination programme to be implemented in 
conjunction with adequate biosecurity enforcement and continuous surveillance of infection 
in vaccinated bird population (Capua et al. 2009). Although vaccination is highly 
recommended as a control and preventive tool for AIV, silent spread of infection in 
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vaccinated populations is a major concern, especially where AIV is ‘endemic’. This is due to 
inability of the available inactivated AIV vaccines to provide complete protection to a virulent 
field challenge, allowing for a small number of birds to become infected and excrete the virus 
without apparent clinical manifestation of infection. Long term circulation and establishment 
of AIV in vaccinated population have been reported to cause changes in the genetic and 
antigenic properties of the virus, producing escape mutants as reported in Mexico (Lee, Senne 
& Suarez 2004a), China (Smith et al. 2006), and Egypt (Grund et al. 2011). Due to the 
inability of the available standard serological tests used in disease surveillance to differentiate 
antibodies produced by vaccination from those that arise by field virus infection, strategies 
have been developed to differentiate infected from vaccinated animals (DIVA).  
 
 Current understanding of DIVA strategies for AIV 
Vaccine development work with the aim to enable DIVA application was first published by 
Van Oirschot et al. (1986) for Aujeszky’s disease virus in pigs; and this investigator later 
coined the acronym DIVA (Van Oirschot 1999). In parallel growth with the use of vaccine 
against AIV, advances of DIVA strategies were focused on vaccine developments which are 
capable of DIVA while permitting the use of the available standard serological tests (DIVA-
vaccine approach). Alternatively, DIVA-antigen approach focused more on the serological 
tests development while allowing the use of conventional vaccines (killed virus).  
 
In this section, six DIVA strategies were discussed in terms of the vaccine format and the 
available complementary companion diagnostic tests: (i) sentinel birds, (ii) subunit vaccine, 
(iii) heterologous NA, (iv) non-structural 1 (NS1) protein, (v) matrix 2 ectodomain (M2e) 
protein, and (iv) hemagglutinin subunit 2 (HA2) glycopolyprotein (gp) (Birch-Machin et al. 
1997; Boyle & Heine 1993; Capua, Terregino, et al. 2002; Hemmatzadeh et al. 2013; 
Lambrecht et al. 2007; Suarez 2012). Summary of these strategies can be seen in Table 2.1.  
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 Sentinel birds 
The most basic strategy used for detection of live virus infection in a vaccinated flock is the 
employment of sentinel birds, where approximately 1% of the birds in the monitored farm are 
left unvaccinated and routinely tested serologically to detect flock exposure to live virus 
(Suarez 2005, 2012). This strategy offers a sensitive measure of any rising infection within 
the vaccinated flocks, and monitoring can be done using the available diagnostic tests such as 
the haemagglutination inhibition (HI) test and the ELISA test detecting NP or HA antibodies. 
This strategy was successfully employed alongside the heterologous NA emergency 
vaccination during the HPAI H7N1 outbreak in Italy in 2000 to monitor the field situation 
(Capua et al. 2009).  
 
 Recombinant subunit vaccines 
As described earlier, HA gene encodes a structural virus protein with important functions for 
immunity and is one of the key determinants of AIV antigenic properties  (Klenk et al. 1975; 
Lazarowitz & Choppin 1975). Although optimum protection is achieved through the use of 
vaccination with whole inactivated virus homologous to the circulating strain, studies have 
indicated that the presence of HA alone in vaccine elicits protective immune response against 
viral infection (Robinson, Hunt & Webster 1993; Webster et al. 1994). In the subunit vaccine 
strategy, the AIV HA gene is expressed in bacteria, viruses or yeast system before being 
purified and prepared for use as a vaccine (Crawford et al. 1999; Davis et al. 1983; Saelens et 
al. 1999). A variety of different AIV viral vectors have been studied, where protective 
immunity was demonstrated upon experimental challenges (Table 2.2).  
 
Apart from being efficacious and safe for application, the recombinant subunit vectored-virus 
vaccines offer immunity through a single vaccination, with the option of vaccination against 
multiple diseases and the availability of mass vaccine administration (Li et al. 2011; Swayne 
et al. 2003). Works on recombinant subunit vaccines have expanded significantly following 
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the advances of reverse genetic technology (Neumann & Kawaoka 2001), where it allows 
rapid regeneration of reassortant viruses, thus reduces vaccine production time by 
approximately 2-months (Hoffmann et al. 2002). However, most importantly, the subunit 
vaccines allow a clear distinction between antibodies produced by vaccination or wild type 
AIV infection, which is crucial for DIVA surveillance purposes using the standard diagnostic 
tools. In theory, the vaccinated birds will only produce antibody against the expressed HA 
protein, but none for internal proteins such as NP and M proteins. Since the vaccinated birds 
will remain naïve to the internal proteins, infected birds can be identified if antibodies against 
these proteins are present (Li et al. 2011). Standard diagnostics test available are the agar gel 
immunodiffusion (AGID) which detects the anti-NP and anti-M antibodies (OIE 2014); and 
the commercially available enzyme-linked immunosorbent assay (ELISA) kit such the AIV 
FlockChek ELISA kit (IDEXX labs) (Li et al. 2011), specifically designed for detecting anti-
NP antibodies. To date, the recombinant fowlpox-influenza H5 vaccine is licensed and 
available in El Salvador, Guatemala, Mexico, China and USA (Swayne & Kapczynski 2008), 
while recombinant herpesvirus turkey (rHVT) is licensed in Egypt and USA, with 
recombinant duck enteritis virus (rDEV) being licensed in China (OIE 2014; Swayne & 
Spackman 2013).  
 
 Heterologous NA vaccine 
The heterologous NA vaccine strategy employs an inactivated AIV containing similar HA 
subtype but different NA subtype to the outbreak strain (Capua, Terregino, et al. 2002). 
Vaccinated birds are protected against live virus infection by development of anti-HA 
antibodies, and can be differentiated from infected birds through detection of antibodies 
against the NA subtype. This strategy allows the use of the standard killed vaccines and 
screening can be done against anti-NA antibodies using an indirect immunofluorescence 
assay (Capua, Terregino, et al. 2002), in place of the conventional neuraminidase inhibition 




Only three known applications of the heterologous NA vaccine in the field are known. It was 
first introduced as a measure to differentiate between vaccinated and infected birds during the 
1999-2000 H7N1 HPAIV outbreak in Italy (Capua, Mutinelli, et al. 2002). The vaccine was 
prepared using inactivated H7N3 virus, and infected birds were detected by an indirect 
immunofluorescent antibody test (iIFAT) specifically developed for anti-N1 antibody (Capua, 
Terregino, et al. 2002). Similar strategy was implemented during the outbreak of LPAI H7N3 
in Italy in 2002-2003, where inactivated H7N1 was used for vaccination, and during the 
outbreak of HPAI H5N1 in Hong Kong in 2002, inactivated H5N2 virus was used for 
vaccination (Capua & Alexander 2004).  
 
 AIV nonstructural 1 (NS1) protein: Differential immune response 
The NS1 protein is a multifunctional protein which among its purpose is to regulate viral 
RNA polymerase activities and viral mRNA translation (Enami et al. 1994; Lamb & Choppin 
1979; Shimizu et al. 1994). It is a non-structural protein which is only detectable in infected 
cells, but not in packaged virions (Skehel 1972). Based on this observation, a DIVA-antigen 
approach has been suggested which allows the use of conventional whole-killed virus for 
vaccination (Ozaki et al. 2001).  A diagnostic ELISA that targets NS1 antibodies is a simple 
screening test, as had been previously recognised for foot and mouth disease virus (Neitzert et 
al. 1991). The first successful demonstration of this strategy for AIV was reported for the 
equine influenza A virus (Birch-Machin et al. 1997), where NS1 antibodies were identified 
only in infected ponies but not in the vaccinated ones. Most works on the development of 
NS1 protein as antigen for DIVA have expressed recombinant NS1 protein in vectors such as 





 Matrix 2 ectodomain (M2e) protein: Highly conserved protein 
M2e protein is the external part of a homotetrameric transmembrane protein encoded by 
segment 7 of the IAV through an alternative reading frame (+1) mechanism (Holsinger & 
Lamb 1991; Lamb, Lai & Choppin 1981). This protein forms ion channels on the AIV surface 
that are crucial for the release of viral genome into the host cell cytoplasm during virus entry 
(Lamb, Zabedee & Richardson 1985; McCown & Pekosz 2005), and serves as a pH regulator 
for the Golgi apparatus which is essential for HA glycoprotein maturation (Sugrue & Hay 
1991). Two factors have led to the recommendation of M2e protein as DIVA antigen: (i) the 
relatively invariable nature of M2e protein across AIV strains (Ito et al. 1991; Khurana et al. 
2009), where its small size and low abundance in comparison to the other two surface 
glycoproteins (HA and NA) have allowed M2e protein to escape immune selection pressure 
and antigenic drift  (Fiers et al. 2009); and (ii) the abundance of the M2e protein on the 
surface of infected cells despite being low in copy number in a mature virion (~3% of the 
surface glycoprotein population) (Black et al. 1993; Zabedee, Richardson & Lamb 1985). 
Both of these characteristics have suggested that M2e protein could be a sensitive, specific as 
well as a universal DIVA antigen. The earliest report on the application of M2e as DIVA 
antigen in poultry has demonstrated a sensitive M2e peptide-based ELISA for detection of 
M2e antibodies following infection with HPAIV strains H5 and H7 (Lambrecht et al. 2007). 
Similar sensitivity of M2e protein as DIVA antigen has also been demonstrated in a challenge 
study using LPAIV H9N2 (Kim et al. 2010), as well as against multiple AIV reference 
antisera (Hemmatzadeh et al. 2013).  
 
 Haemagglutinin subunit 2 (HA2) glycoprotein (gp): Highly conserved epitope 
HA2 glycoprotein (gp) is the C-terminal fragment of the cleaved form HA protein (Skehel & 
Waterfield 1975; Wilson, Skehel & Wiley 1981). It is considerably the more conserved region 
out of the two HA cleavage products (HA1 and HA2), especially at its N-terminal end, known 
as the fusion peptide (first 11 residues) which is involved in the fusion activity of IAV (Daniels 
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et al. 1985; Skehel & Waterfield 1975). The HA2 gp has been suggested as another potential 
target for DIVA tool based on two key criteria. Firstly, HA2 is highly conserved throughout the 
16 HA subtypes of IAV (Fouchier et al. 2005; Nobusawa et al. 1991; Okuno et al. 1993), with 
only two known epitope variants corresponding to the classical phylogenetic grouping of AIV 
HA protein (Sui et al. 2009). Four antigenic sites have been identified from HA2, namely site I 
(aa 1-38, the N-terminal), sites II and IV (aa 125-175) which exhibit different reactivity among 
IAV subtypes, and site III (aa 38-112) (Vareckova, Mucha & Kostolansky 2013). As observed 
with the M2e protein approach, detection of antibodies against the highly conserved HA2 gp 
would theoretically enable a universal detection of all IAV subtypes. Secondly, this conserved 
region is only accessible to immune recognition following virus infection. It has long been 
noted that HA0 cleavability is essential for IAV infectivity (Klenk et al. 1975; Lazarowitz & 
Choppin 1975), where the cleavage of HA0 to form HA1 and HA2 subunits is a prerequisite 
for membrane binding and virus entry to the host cell (Maeda & Ohnishi 1980; Skehel et al. 
1982). HA2 gp is not accessible in the HA0 native form as it is buried in the pocket formed by 
the stalk of the HA stem trimer (Skehel & Wiley 2000; Vareckova, Mucha & Kostolansky 
2013). However, once the HA0 is cleaved, the HA2 gp will be exposed and inserted into the 
target membrane to allow the conformational change which will lead to membrane fusion and 
virus entry (Bullough et al. 1994; Chen et al. 1998). Considering these findings, it is reasonable 
to assume that the presence of antibodies against discrete epitopes on HA2 gp would also be 




Table 2.1 List of available strategies for differentiating infected animals from vaccinated animals (DIVA), with some of their advantages and 
limitations in general. 
Strategy Sentinel bird Recombinant subunit vaccines Heterologous NA 
Differential immune response 





 Naïve unvaccinated bird are 
marked and randomly spread in 
a vaccinated flock 
 Sentinel birds are routinely 
tested for influenza virus 
exposure 
 Vaccine using a vector 
expressing HA and NA proteins 
 
 Example: Fowlpox-vectored 
recombinant vaccine for the H5 
subtype 
 Vaccines containing the same HA 
subtype as the field strain, but a 
different NA subtype.  
 
 Example: If the field virus is H7N2, 
the vaccine is H7N3 
 Vaccination using whole-killed 
virus 
 Observation of the differential 
immune responses to the targeted 





 Hemagglutinin Inhibition (HI) 
test 
 Agar gel immunodiffusion 
(AGID) 
 Type A-specific ELISA (detect 
anti-NP) 
 Agar gel precipitin (AGP),  
 ELISA targeting antibodies to 
the matrix (M) protein or the 
nucleoprotein (NP) 
 Fluorescence microsphere 
immunoassay (FMIA) 
 Neuraminidase Inhibition (NI) test 
 Indirect immunofluorescence assay 
(iIFAT) 
 FMIA 
 Modified NI test 
 ELISA-based targeting the 
antibodies to specified proteins 
Advantages  Low cost 
 Readily applicable 
 Sensitive procedure for 
monitoring in vaccinated flock 
 
 Efficacious in providing 
protection 
 Commercially available 
 Mass administration 
 The standard diagnostic tests 
are applicable 
 
 Efficacious in providing protection 
 Rapidly available through reverse 
genetics technology  
 
 Conventional inactivated virus can 
be used for vaccination 
 Only a single diagnostic test 
needed 
Limitations  Labor intensive 
 Time consuming 
 Naïve birds can potentially act 
as virus amplifiers and be the 
source of infection 
 
 Test sensitivity is yet to be 
determined 
 Prior knowledge on circulating strain 
 Possible introduction of the same NA 
subtype field strain with the NA 
subtype used for vaccination 
 Undetermined sensitivity of 
serologic testing 
 Low throughput screening capacity  
 iIFAT – time consuming, laborious 
and the result interpretation is 
subjective 
 Risk of false-positive due to the 
presence of protein contaminant 
from non-purified vaccine i. e NS1 
protein 
 Risk of false-negative in 
surinfected host due to the inability 
of host to seroconvert  






 DIVA strategies applicability and developments  
An ideal surveillance tool is required to be (i) cost effective, (ii) rapid and easily manageable, 
and (iii) to possess a high sensitivity and specificity in discriminating between naïve-infected 
host from a vaccinated-only host, as well as a vaccinated-infected host.  
 
Although the sentinel bird strategy is simple to employ, there are concerns that the naïve birds 
may increase the infection risk for the vaccinated flock following repeated and lengthy 
exposure to the high load shedding of the virus by the sentinels (Suarez 2012). Acquiring a 
new infection is still possible in the vaccinated flock due to the continuously evolving nature 
of AIV, as well as technical vaccination issues, such as ineffective application or insufficient 
coverage, with poor antigenic match of the vaccine with the field strains (Lee, Senne & 
Suarez 2004a).  Furthermore, this strategy is only capable of detecting virus infection in a 
naïve host placed in a vaccinated flock, with no direct indication of live virus infection in the 
vaccinated host itself. This has decisively dismisses it from being an option for a long term 
application for surveillance purposes. 
 
 DIVA vaccine-based strategies: recombinant subunit and heterologous NA  
For DIVA vaccines approach, multiple studies have demonstrated the effectiveness of 
recombinant vaccine strategies in providing the necessary protection against clinical signs, as 
well as fulfilling its role for DIVA purposes (Table 2.2). However, the fowlpox-HA (H7) 
vaccine was found to show a reduced protection in chickens which have been previously 
vaccinated or infected with fowlpox virus (Bublot et al. 2006). Host range restriction may also 
apply for a particular virus vector such as observed for the infectious laryngotracheitis virus 
(ILTV) as it replicates poorly in turkeys (OIE 2014). Nevertheless, mass administration and 
multiple diseases vaccination options offered by the recombinant vaccines highlight the 
feasible application of recombinant vaccines, as evidenced by the continuous development 




Following the introduction of heterologous NA vaccination application in Italy (Capua, 
Terregino, et al. 2002), various combinations of HA and NA proteins have been tested and 
recommended, including the use of rare NA subtypes for vaccine development such as N5 
and N8   (Table 2.2) (Beato et al. 2007; Capua et al. 2009). Introduction of the eight-plasmid 
reverse genetics system which allows rapid de novo generation of reassortant live virus has 
made it possible for the rapid availability of a heterologous vaccine once the NA subtype of 
the wild type circulating virus is known (Beato et al. 2007; Lee, Senne & Suarez 2004b). 
Nevertheless, a collection of vaccine with various combinations is necessary to ensure swift 
implementation in case of outbreak where multiple virus subtypes are present in a single host 
or population (Swayne et al. 2011).  
 
Since the conventional diagnostic tests are not applicable for the heterologous NA approach, 
companion tests specific for this strategy, iIFAT have been developed (Capua, Terregino, et 
al. 2002). Although the test is highly specific and sensitive for application (Cattoli et al. 
2006), the iIFAT is also time-consuming and labour intensive assay, as it is with the classical 
NI test (Aymard-Henry et al. 1973; Capua, Terregino, et al. 2002). It has been suggested that 
these NA based tests be replaced with a faster, simpler and higher throughput ELISA-based 
screening system, such as the N2-specific ELISA-based test (Kwon et al. 2009) and 
truncated-N1-specific ELISA (Wu et al. 2009). Alternatively, a modified version of the NI 
test is made available where MUN (2ʹ-[4-methylumbelliferyl]-α-D-N-acetylneuraminic acid 
sodium salt hydrate) was used as the NA substrate in place of the traditional fetuin-based NI 
test, providing a more rapid analysis and quantitative results where the antibody responses can 
be measured over time (Avellaneda, Sylte, et al. 2010). Recent developments have revealed a 
range of refinements on the available known tests (NI and ELISA) (Avellaneda, Sylte, et al. 
2010; Wang et al. 2011). However, due to the need for the production of both vaccine and its 
tailor-made companion test for an optimized performance, limited availability of facilities and 
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resources are the major drawbacks for this particular strategy. Most importantly, in dealing 
with H5N1 ‘endemic’ countries, homologous strain is a much preferred option for vaccination 
as heterologous NA is not an ideal strategy to apply given the diverse genetic variants of 
H5N1 (Chen 2009; Grund et al. 2011; Gutierrez et al. 2009). 
 
 DIVA test-based strategies: NS1, M2e and HA2 proteins 
 DIVA tests based on NS1, M2e and HA2 proteins are viewed more favourably in terms of 
their practicality (Table 2.1). These strategies offer a more straightforward approach in 
comparison to the subunit and the heterologous NA vaccination strategies, where the DIVA 
test strategy complements the conventional homologous inactivated vaccine administration. 
Although studies have shown that the presence of HA protein in a vaccine is enough to 
provide a good protection against live virus infection, in most cases it only reduces the 
clinical signs, and AIV is still sheds in the faeces of infected birds (Swayne et al. 2001; 
Swayne et al. 2000). Virus shedding could be in low amount, but the silent spread 
(asymptomatic) of viral infection is still possible due to the generation of escape mutants in 
response to vaccination pressure (Lee, Senne & Suarez 2004a). Taken together, homologous 
strain vaccination is still by far provides the most optimum protection against virus infection, 
as antigenic relatedness is a significant factor in determining the level of protection induced 
by vaccination (Lee & Suarez 2005; Swayne et al. 2000).  
 
NS1 protein is highly conserved among AIV subtypes, which is a highly favourable 
diagnostic property (Tumpey et al. 2005; Wang et al. 2011; Zhao et al. 2005). However, 
several studies have identified that the NS1 protein also exists in truncated forms in nature 
(Dundon et al. 2006; Long et al. 2008; Suarez & Perdue 1998), giving rise to concerns that 
this could affect the overall accuracy of NS1 DIVA test. Also, different level of species 
susceptibility to AIV infection should be taken into consideration before NS1 DIVA test is 
adopted for routine use. A study in turkey showed that the NS1 antibodies were only present 
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for a short time following infection (10 days post-challenged).  AIV with a low replication 
capability in a specific host, either due to low virus adaptability or due to host vaccinal 
immunity will not be able to produce detectable level of NS1 antibodies despite infection 
(Avellaneda, Mundt, et al. 2010; Dundon et al. 2007; Soleimani et al. 2012; Takeyama et al. 
2011). Similar observation can also be resulted due to the poor immunogenicity of NS1 
protein as reported in a challenge study in chickens (Avellaneda, Mundt, et al. 2010).  
 
This strategy also suffers from decreasing specificity with increasing number of vaccination. 
Low amount of NS1 antibodies were detected in chicken after three times of vaccination with 
the killed virus contributing to non-specific reactions in the tests, thought to be due to 
antibody response against leftover NS1 proteins present in the unpurified vaccine (Soleimani 
et al. 2012; Tumpey et al. 2005; Zhao et al. 2005). This shortcoming however, suggested to be 
eliminated through the use of vaccination virus with truncated NS1, which remove the 
possibility of NS1 antibodies detection in vaccinated hosts (Talon et al. 2000; Tumpey et al. 
2005). Studies on the truncated NS1 protein (10 nucleotides deletion in the middle of the NS1 
protein-coding sequence) demonstrated its capability of providing protective host immunity 
after influenza virus challenge in mouse, pig and horse models (Quinlivan et al. 2005; Richt et 
al. 2006; Wang, Suarez, et al. 2008). This has raised the possibility of developing live 
attenuated virus as vaccine while retaining the capacity of NS1 protein as DIVA marker, 
although the reversion of the live-attenuated virus to virulent virus is a concern (Wang, 
Suarez, et al. 2008). This was later vindicated by a study on live mutant NS1 AIV showing its 
reversion to virulence after five back passages in chicken, thus suggests that a killed vaccine 
made from a mutant virus with shorter NS1 gene is much safer as well as being practical for 
DIVA application (Brahmakshatriya, Lupiani & Reddy 2010). Following the occasional 
detection of NS1 protein antibodies in vaccinated chickens, the NS1-ELISA was suggested to 
be more suitable for flock monitoring rather than individual birds diagnosis (Takeyama et al. 




M2e DIVA strategy on the other hand has issues on its specificity and immunogenicity of the 
M2e antigen. Non-specificity in the recombinant M2e-ELISA was identified to be caused by 
test serum reactions against the carrier protein used in the M2e expression system 
(Hemmatzadeh et al. 2013). Although this was not observed in the ELISA system employing 
synthetic M2e-peptide, the use of recombinant-M2e protein is much preferred as the latter 
offers a much lower cost for higher output, with continuous access for use in large scale 
screening (Hemmatzadeh et al. 2013).  
 
Concerns have also been raised where undetectable levels of seroconversion in infected 
animals may lead to false negative results in M2e-based ELISA. Previous findings indicated 
that M2e is a weak immunogen (Neirynck et al. 1999), where AIV infections (H1N1 and 
H3N2, respectively) in mice and humans have engendered poor M2e-specific antibody 
responses  (Feng et al. 2006). A low M2e-antibody response was also observed after a 
primary infection in pigs with H3N2 or H1N1, but it was increased significantly following 
challenge infection using H1N1 (Heinen, de Boer-Luijtze & Bianchi 2001). This is 
hypothesized to be contributed by the small size of the M2e antigenic determinant which 
limits the number of M2e-reactive B cells for antibody secretion. This is further exacerbated 
by the antigenic competition posed by the much higher population of HA and NA proteins on 
the virus surface particle (Feng et al. 2006).  
 
However, in a challenged duck study by Lambrecht et al. (2007), a decreasing trend of M2e 
antibodies level was reported with the increasing number of vaccination. Increased immunity 
established by vaccination was assumed to reduce efficient virus replication, hence 
influencing development of M2e antibody which in turn affected test sensitivity. False 
negative results have been observed by Kim et al. (2010) where low level  of M2e-antibodies 




Nevertheless, attempts to address these issues have been demonstrated through the 
improvement in the M2e-ELISA detection efficiency by incorporation of multiple repeats of 
the M2e protein in the recombinant-M2e-ELISA system (Hadifar et al. 2014; Tarigan et al. 
2015) . Otherwise, DIVA application based on M2e protein is proven to have a wide range of 
reactivity against other IAV subtypes in chickens (Hemmatzadeh et al. 2013).  
 
HA2 peptides were first demonstrated as antigen for H5N1 serodiagnosis using  ELISA by 
Khurana et al. (2011) following identification of one immunodominant epitope through a 
complete antibody repertoire characterization of H5N1 infection in human (Khurana et al. 
2009). Although HA2-specific antibodies have been reported in natural infection in both 
humans and mice, HA2 is a weak natural immunogen (Stanekova et al. 2012). As observed 
for the M2e protein DIVA strategy, this factor may also lead to false negative results for the 
HA2 gp-based antibody detection due to low seroconversion in infected host. However, this 
approach warrants further study to validate this assumption and to overcome this limitation, as 




Table 2.2 List of selected studies on the development of DIVA strategies for Influenza A virus and the summary of their findings within the last decade. Key: 
‘+’ indicates presence of protection by the vaccines or the strategy successfully demonstrated DIVA ability; ‘-‘indicates negative protection by vaccines or 










DIVA test tool 




t vaccine  
 Newcastle Disease 
(NDV) virus expressing 
HA protein (H5) 
 Herpesvirus of turkey 
(HVT) expressing HA 
(H7) 
 Virus-like particle (VLP) 
expressing HA and M1 
(H9) 
 Fowlpox (FP) 
recombinant expressing 
HA (H7 and H5) 
 Infectious 
laryngotracheitis (ILT) 
virus expressing HA (H7) 
 H5N1/PR8-519 (S2 
glycoprotein of murine 
hepatitis virus-MHV 






















ME) +/- + 
 Reduced protection 
shown by FP-HA (H7) 
in chicken which 
previously vaccinated or 
infected with fowlpox 
 
 
(Bublot et al. 2006; Ge 
et al. 2007; Kim et al. 
2014; Lee et al. 2011; Li 
et al. 2008; Li et al. 
2011; Lozano-
Dubernard et al. 2010; 
Swayne et al. 2001; 
Swayne et al. 2000; 
Veits et al. 2003; Veits 
























Inactivated wild type: 
 H7N3 


































N2 or N3 
protein; 
 
ii. Micro-NI test 
with N1, N2 




with N2, N8 





 Micro-NI test is time 
consuming 
 
 Modified version of the 
micro-NI test  provide a 
more rapid option 
 
 ELISA-based test offers a 
relatively easier and rapid 
application overall 
(Avellaneda, 
Sylte, et al. 
2010; Capua, 
Terregino, et al. 
2002; Cattoli et 
al. 2006; Cattoli 
et al. 2003; 
Kwon et al. 























DIVA test:  
Recombina
nt NS1 
Inactivated wild type: 
 H3N2 
 H3N8 










 H5N9  
















 Non-specific reactions in 
NS1-ELISA reported is 
speculated due to the non-
purified vaccine used 
 
 Incorporation of truncated 
NS1 in vaccine strain is 
recommended to address 
NS1 protein contamination 
issue 
 
 Differences in NS1 immune 
response between strains and 
species have been 
demonstrated i.e. in turkeys 
and chickens 
(Dundon et al. 
2007; Ozaki et 
al. 2001; 
Soleimani et al. 
2012; Tumpey 
et al. 2005; 























DIVA test:  
Truncated 
NS1 




















 Low seroconversion in 
vaccinated-and-challenged 
turkeys  
o limited replication site by 
LPAIV lead to low titer 
of AIV despite infection 
(in comparison to HPAIV 
infection) 
o could vary between bird 
species 
(Wang et al. 
2011; Wang, 





Inactivated wild type: 
 H5N9  




















 Recombinant M2e-ELISA is 




 Development of tetramer-
M2e as antigen has increased 
the sensitivity of this 
strategy, compared with the 
monomer-M2e based ELISA 
systems 
(Hadifar et al. 
2014; 
Hemmatzade
h et al. 2013; 










 Recommendations for DIVA programs 
For AIV successful monitoring program, DIVA vaccine needs to be (i) effective, (ii) readily 
distinguishable from the wild type virus, (iii) rapidly available, (iv) cost effective, and ideally 
(v) applicable by mass administration (by spraying or drinking water); along with companion 
diagnostic tests or DIVA test which are (i) simple and rapid, (ii) suitable for mass screening, 
(iii) highly sensitive and specific, and (iv) low cost.  
 
In general, DIVA vaccines (subunit, recombinant and heterologous vaccines) which have 
been described in the previous section showed high efficiency in providing the optimal 
protection against AIV infection and capable of DIVA application. Factors affecting vaccine 
effectiveness such as vaccine strain and target species have to be critically considered to 
ensure maximum vaccine coverage. Close monitoring of field virus is vital especially where 
AIV is ‘endemic’ as continuous infection and circulation of virus promotes immune pressure, 
thus drifting off the field virus from vaccine seed virus (Swayne & Kapczynski 2008). 
Availability of vaccine supply particularly in AIV ‘endemic’ countries should be well 
managed and maintained as vaccine production is a time consuming process despite its 
relatively short shelf life (about two years) (Marangon, Cecchinato & Capua 2008). AIV 
‘endemic’ countries usually possess high poultry density, thus cost effectiveness is a critical 
factor in decision making, which is why advanced vaccines with mass applicability are highly 
favourable features.  
 
By far, ELISA–based diagnostic test is highly recommended for surveillance and monitoring 
purposes. However, to ensure the robustness of a DIVA test, field trials using both LPAIV 
and HPAIV challenge strains still need to be explored in various poultry species model since 
previous findings have demonstrated that test sensitivity varies between challenge strain and 
bird species used. Epitope mapping of the DIVA antigens will be an interesting venue to 
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A common approach for developing diagnostic tests for influenza virus detection is the use of 
mouse or rabbit monoclonal and/or polyclonal antibodies against a target antigen of the virus.  
However, comparative mapping of the target antigen using antibodies from different animal 
sources has not been evaluated before. This is important because identification of antigenic 
determinants of the target antigen in different species plays a central role to ensure the 
efficiency of a diagnostic test, such as competitive ELISA or immunohistochemistry-based 
tests. Interest in the matrix 2 ectodomain (M2e) protein of avian influenza virus (AIV) as a 
candidate for a universal vaccine and also as a marker for detection of virus infection in 
vaccinated animals (DIVA) is the rationale for the selection of this protein for comparative 
mapping evaluation. This study aimed to map the epitopes of the M2e protein of avian 
influenza virus H5N1 using chicken, mouse and rabbit monoclonal or monospecific 
antibodies. Our findings revealed that rabbit antibodies (rAbs) recognized epitope 
6EVETPTRN13 of the M2e, located at the N-terminal of the protein, while mouse (mAb) and 
chicken antibodies (cAbs) recognized epitope 10PTRNEWECK18, located at the centre region 
of the protein. The findings highlighted the difference between the M2e antigenic 
determinants recognized by different species that emphasized the importance of comparative 
mapping of antibody reactivity from different animals to the same antigen, especially in the 
case of multi-host infectious agents such as influenza. The findings are of importance for 
antigenic mapping, as well as diagnostic test and vaccine development. 
 






Matrix protein 2 (M2) of avian influenza virus (AIV) is a 97 amino acids (aa) protein encoded 
by RNA segment 7 of the influenza A virus (IAV) (Lamb, Lai & Choppin 1981). It is 
translated from spliced mRNA and shares a common start codon with the matrix 1 (M1) 
protein and the first nine aa, while the remaining 88 aa continues at the second (+1) open 
reading frame (Lamb, Lai & Choppin 1981; Lamb, Zabedee & Richardson 1985). In its native 
state, M2 is a homotetrameric type III integral membrane protein composed of three domains; 
namely, a 54 aa cytoplasmic domain located in the viral envelope or cytoplasmic membrane 
of infected cells, a 19 aa transmembrane domain, and an N-terminal 24 aa ectodomain (M2e) 
which is exposed on the surface of the virus infected cells and  on the viral particles 
(Holsinger & Lamb 1991; Lamb & Choppin 1981; Lamb, Lai & Choppin 1981; Sugrue & 
Hay 1991). In the infected cell the M2 protein forms an ion channel which is vital for viral 
genome delivery into the host cell during virus entry (Lamb & Choppin 1981; Lamb, Zabedee 
& Richardson 1985; McCown & Pekosz 2005; Pinto, Holsinger & Lamb 1992; Sugrue et al. 
1990; Sugrue & Hay 1991). Briefly, M2 ion channel activity is activated by acidification of 
virus-containing endosomes after internalization of the virus particle into the host cell via 
clathrin-dependant and –independent mechanisms (Lamb & Krug 2001; Whittaker & 
Helenius 1998). 
 
Amino acids 1-9 of the M2e protein are highly conserved across AIV strains, while minimal 
aa  variation is observed for residues 10 to 24, making it an attractive target for AIV universal 
vaccine development  (Black et al. 1993; De Filette et al. 2005; Fiers et al. 2009; Gerhard, 
Mozdzanowska & Zharikova 2006; Ito et al. 1991; Khurana et al. 2009; Lamb, Zabedee & 
Richardson 1985; Liu, Li & Chen 2003; Neirynck et al. 1999; Pejoski et al. 2010; Zabedee & 
Lamb 1988). The M2e protein is low in copy number on the virus particle, but it is abundantly 
expressed on the surface of an infected cells (Lamb & Choppin 1981; Park et al. 1998). This 
differential epitope density between infected cells (high) and a mature virion (low) (Black et 
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al. 1993; Zabedee, Richardson & Lamb 1985) is the key feature for its recommendation as a 
marker for differentiating infected animals in vaccinated population (DIVA), a strategy used 
in AIV surveillance (Kim et al. 2010; Lambrecht et al. 2007). 
 
The sensitivity and specificity of M2e-based DIVA have been demonstrated in our previous 
works (Hadifar et al. 2014; Hemmatzadeh et al. 2013; Tarigan et al. 2015). This raised our 
interest towards the potential use of M2e in a competitive enzyme-linked immunosorbent 
assay (ELISA) format as a surveillance tool for AIV infection. The principle of competitive 
ELISA lies in the ability of the test subject antibody (e.g. chicken) to inhibit competitor 
antibodies, usually produced in rabbit or mouse, from binding to the target antigen. Hence, it 
is important for the competitor antibodies to react with the same viral epitopes as the 
antibodies produced by the test species. Such an ELISA format has been successfully 
demonstrated for the nucleoprotein of AIV, which has been proven to be reliable and 
applicable for multispecies surveillance (Shafer, Katz & Eernisse 1998; Starick et al. 2006; 
Zhou et al. 1998). However, M2e-based competitive ELISA is a better alternative DIVA test 
for an AIV surveillance tool, especially in the highly pathogenic AIV H5N1 ‘endemic’ 
countries, where poultry vaccination using inactivated AIV is practiced.  
 
It is accepted that due to differences in the germline gene repertoire in different species, 
accompanied by distinct mechanisms for generation and affinity maturation of antibodies, 
antigenic determinants recognized by a host can vary from one species to another (Darnule et 
al. 1980; Finlay & Almagro 2012; Rotter et al. 1983). Earlier studies on M2e protein for 
vaccine development have reported several antigenic determinants identified by anti-M2e 
antibodies isolated from rabbit, mouse and human (Grandea III et al. 2010; Pejoski et al. 
2010; Wang et al. 2009). In most cases, the M2e epitopes recognized were located in the 
region that span from the N-terminal to the middle region of M2e, and vary in length from 5 
residues (2SLLTE6) (Grandea III et al. 2010), up to 15 residues 2SLLTEVETPIRNEWG16 
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(Pejoski et al. 2010; Wang et al. 2009). Here, we describe epitope mapping using anti-M2e 
antibodies from chicken, mouse and rabbit to identify the M2e antigenic determinants for 
each antibody group, and to assess the most suitable animal source of anti-M2e antibodies in 
M2e-based competitive ELISA as an advanced DIVA test for H5N1 infections in poultry.  
 
 Material & Methods 
 Peptides for mouse and rabbit immunization and antigenic mapping 
Peptide immunization for mouse and rabbit was done using the 17 amino acid (aa) M2e 
peptide (M2e2-18), corresponding to residues 2 to 18 of HPAIV H5N1 Indonesian strain 
A/Chicken/West Java/PWT-WIJ/2006, ( 2SLLTEVETPTRNEWECK18) (Hadifar et al. 2014; 
Hemmatzadeh et al. 2013; Tarigan et al. 2015). It was conjugated with Keyhole Limpet 
Hemocyanin (M2e-KLH) at the C-terminal end for the anti-M2e antibodies production in 
mice (Abmart, Shanghai, China) and rabbits (Peptide 2, Chantilly, Virginia, USA).  
 
M2e-mapping was done using two sets of overlapping short peptides spanning M2e2-24. Set 1 
included eight peptides of 9-10 aa length (WatsonBio, Houston, Texas) with two aa offsets 
each; while set 2  included  three peptides of 14 aa length (Abmart, Shanghai, China) with 
three aa offsets each (Table 3.1). M2e2-18 was used for anti-M2e antibodies screening in 
indirect ELISA, as well as the positive antigen control in mapping ELISA, instead of  M2e2-24, 
as both showed similar reactivity in previous study (Hemmatzadeh et al. 2013). All peptides 








Table 3.1 Overlapping peptides covering the full length H5N1 M2e protein (M2e2-24), 
designed with 10 amino acid (aa) with 2 offsets, and 14 aa with 3 offsets each. Peptide M2e2-

















 Antibodies (sera) 
Three different sources of anti-M2e antibodies were used in this study, namely chicken 
polyclonal antibodies (cAbs), mouse monoclonal antibodies (mAbs), and rabbit polyclonal 
antibodies (rAbs) (Table 3.2). CAbs were produced as described previously (Hadifar et al. 
2014; Tarigan et al. 2015). In brief, commercial layer chicks were inoculated with inactivated 
H5N1 AI vaccine (Medivac-AI, PT Medion, Bandung, Indonesia), once (16 weeks of age), 
twice (12 and 16 weeks of age) or three times (8, 12 and 16 weeks of age). All chicks were 
challenged with live H5N1 strain (either A/Ck/West Java/PWT-WIJ/2006, or A/Ck/West 
Java/Sbg-29/2007) two weeks after the last vaccination. All challenge experiments were 
conducted in the Biosecurity level 3 (BSL3) facilities at the Indonesian Research Centre for 







        4LTEVETPTRN13 
M2e 6-15 
                6EVETPTRNEW15 
M2e 8-17 
                        8ETPTRNEWEC17 
M2e 10-19 
                             10PTRNEWECKC19 
M2e 12-21 
                                    12RNEWECKCSD21 
M2e 14-23 
                                             14EWECKCSDSS23 
M2e 16-24 
                                                       
16ECKCSDSSD24 
M2e 5-18 
           5TEVETPTRNEWECK18 
14 aa M2e 8-21 
                       8ETPTRNEWECKCSD21 
M2e 11-24 
                                
11TRNEWECKCSDSSD24 
M2e 2-18 
2SLLTEVETPTRNEWECK18 17 aa 
101 
 
Veterinary Science, Bogor, Indonesia. Collected sera were tested for M2e reactivity using 
indirect M2e ELISA (Hadifar et al. 2014; Hemmatzadeh et al. 2013). Reference H5N1 sera 
(A/Chicken/Scotland/59) was obtained from the Veterinary Laboratory Agency (New Haw, 
Addlestone, UK) as described previously (Hemmatzadeh et al. 2013).  
 
Hybridoma cells producing anti-M2e mAbs were produced by Abmart (Shanghai, China) 
following immunization of mice with M2e(2-19)-KLH peptide. Briefly, six female BALB/c 
mice were injected subcutaneously at multiple sites with an emulsion contained 0.05 mg 
KLH-M2e peptide mixed with complete Freund’s adjuvant (CFA). Immunization was done 
four times 14 days apart. Booster injections were given 14 days after last immunization with 
0.05 mg KLH-M2e peptide in incomplete Freund’s adjuvant (IFA). Serum sampling was done 
seven days after the third and fourth immunization and sera tested for anti-M2e antibodies 
using indirect M2e-ELISA. Fusion of myeloma cells and spleen cells was followed by another 
indirect M2e-ELISA screening. Selected clones of hybridoma cells were expanded and grown 
in Dulbecco’s modified Eagles medium (DMEM) high glucose with L-glutamine (HyClone, 
GE Healthcare) with 15% foetal bovine serum (HyClone, GE Healthcare) and 1% (v/v) 
penicillin and streptomycin (Gibco, Thermofisher Scientific). MAb supernatants from cell 
culture were column purified using Pierce Recombinant Protein A Agarose (Thermofisher 
Scientific). No significant difference was observed between the column purified and 
precipitated mAb in indirect ELISA. Thus, for the experiments described here, the mAb 
supernatants were precipitated using 50% saturated solution of ammonium sulphate and the 
protein pelleted was resuspended in sterile phosphate saline buffer (PBS) and stored at -20°C 
until required.  
 
Eight New Zealand White rabbits with the average age of 6 months were chosen to obtain 
hyperimmune serum against the M2e peptide.  Rabbits were inoculated at five subcutaneous 
sites with an emulsion that contained 0.1 mg of KLH-M2e peptide mixed with CFA.  The 
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rabbits received booster injections containing 0.1 mg KLH-M2e peptide in IFA at day 14 and 
28. Blood was collected two weeks after the final immunization and antisera tested using 
indirect M2e-ELISA.  
 
Table 3.2 Antibody types and animals used for the generation of antibodies either by H5N1 









































 Indirect M2e-ELISA and antigenic mapping 
All peptides were dissolved in diethylpyrocarbonate (DEPC)-treated water (Bioline) to a final 
concentration of 1 mg/ml. Peptides were diluted with 0.1 M carbonate-bicarbonate buffer, pH 
9.6 (0.1 M Na2CO3, 0.1 M NaHCO3) to the final concentration of 10 µg/ml, and 100 µl was 
added to each well of a 96-well flat bottom microtiter plate (Maxisorp, NUNC) and incubated 
at 4°C overnight. The coated plates were washed five times with PBS containing 0.05% 
Tween 20 (PBS-T) and blocked with 2% BSA in PBS (200 µl/ well) for 2 hrs at room 
temperature (RT). The chicken test sera were diluted with the high salt dilution buffer (HS-
DB: 0.1 M Tris pH 7.4, 0.5 M NaCl, 1 mM Na2EDTA, 2% w/v BSA, 3% w/v Triton X-100, 
3% w/v Tween 20) (Hadifar et al. 2014; Hemmatzadeh et al. 2013), and mouse and rabbit sera 
were diluted in PBS containing 1% BSA and 0.05% Tween 20 (PBS-BSA-T) with the 
dilution of 1:100 for all sera. The blocked plates were washed for five times with PBS-T 
before the diluted serum was added into wells containing each peptide (100 µl/well). After 1 
hr of incubation at RT, the plates were subjected to another five rounds of washing. Species-
specific antibodies conjugated with horseradish peroxidase (HRP) enzymes were prepared by 
dilution of anti-chicken HRP with HS-DB, and anti-mouse HRP (Sigma) and anti-rabbit HRP 
were diluted with PBS-BSA-T. Diluted secondary antibodies were added to each well (100 
µl/well), followed by 1 hr incubation at RT. After washing, the substrate solution [100 µg/ml 
of tetramethylbenzidine substrate (TMB) (Sigma, St Louis, MO, USA)] in citrate buffer (pH 
8) containing hydrogen peroxide (100 µl of 0.6% H2O2) was added (100 µl/ well) and 
incubated at RT for 5 – 20 minutes before the reaction development was stopped with stop 
buffer (1 M sulphuric acid) (50 µl/ well). The optical density (OD) of each well was 
determined at OD 450 nm using the BioRad Benchmark Plus Microplate Reader (BioRad, 




 Statistical and bioinformatics analyses 
Each antigenic peptide was tested in three dilutions with two replicas each. A range of 
univariate and multivariate analyses were employed in this study as previously described 
(Ebrahimi et al. 2014), using MINITAB 17 statistical package (Minitab 17 Statistical 
Software  2010). The mean OD450 values for the antigen negative wells were subtracted from 
the mean OD450 values of antigen positive wells to get the corrected OD450 values. One-way 
ANOVA and pair-wise mean comparison by Tukey test was used to compare the corrected 
ELISA values of different antigenic peptides within each type of antibody (chicken, mouse, 
and rabbit). Antibody reactivity to the M2e peptides was considered as strong (>1.00), 
medium (0.50-1.00), weak (0.25-0.50) and negative (<0.20) in reference to its OD450 value.  
 
Clustering based on Average Linkage algorithm was used to illustrate the 
similarities/differences between different peptides in reaction with each type of antibody. The 
same method was used to cluster antibodies against antigenic peptides. Principle Component 
Analysis (PCA) was used to find the groups of antibody response against antigenic peptides. 
Also, PCA analysis is a powerful multivariate test which is able to find the differentiating 
factors in biological characteristics (features) (Mahdi et al. 2014; Zinati et al. 2014). This test 
was used to identify the antigens that showed discriminating reactivity between mouse, 
chicken, and rabbit antibodies. Hydrophobicity plot of M2e protein (aa 2-24) was constructed 
using the BioEdit software (North Carolina State University) and CLC Genomics (QIAGEN) 
(Hall 1999). 
 
 Ethics statement 
Animal work carried out at the Indonesian Research Centre for Veterinary Science, Bogor, 
Indonesia was approved by the Research Committee of Indonesian Research Centre for 
Veterinary Science. The experimental chickens were handled by an expert veterinarian in 
animal studies based on the guidelines of the National Health and Medical Research Council of 
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Australia. The animals were checked daily for clinical signs, morbidity, and mortality. All 




 Chicken, mouse and rabbit antibodies selection using indirect-M2e ELISA 
Positive anti-M2e cAbs were selected based on findings from previous reports (Hadifar et al. 
2014; Hemmatzadeh et al. 2013), where end-point HI antibody titers for all cAbs were 
approximately 1:512 dilutions (data not shown). Meanwhile, positive anti-M2e mAbs and 
rAbs showed ELISA titers between 1:1600 to 1:3200, and 1:800 to 1:1600, respectively. As 
expected, comparison of mean OD450 readings for chicken, mouse and most rabbit antibodies 
showed strong (OD450 >1.0) reactivity to the M2e2-18 (Table 3.3). All results for statistical 
analysis can be found in the supplementary data.  
 
 Chicken sera recognized at least 2 different epitopes spanning M2e residue 5-18 
and 10-17 
M2e mapping ELISA results revealed a distinctive reactivity pattern between the chicken sera 
exposed to the A/Ck/West Java/Sbg-29/2007 (Sbg-29/2007) (n = 4) and A/Ck/West 
Java/PWT-WIJ/2006 (PWT/2006) (n = 2). Anti-M2e sera from chickens exposed to Sbg-
29/2007 (2A17, 2B2, 2B47 and 2D10) showed a range of medium to strong reactivity to 
M2e8-21, strong reactivity to M2e5-18 and weak to strong reactivity to M2e8-17 (Table 3.3). With 
the exception of cAb 2B47, Sbg-29/2007 antisera also showed a range of weak to strong 
reactivity to M2e10-19. Non-reactivity of cAb 2B47 to M2e10-19 was not fully understood, but 
this particular cAb was only reactive to peptides which included residues E8 and T9 (Figure 
3.1 and 3.2). Collectively, Sbg-29/2007 antisera showed reactivity to peptides which shared a 




While Sbg-29/2007 antisera were reactive to peptides with 10 residues (M2e8-17 and M2e10-19), 
as well as 14 residues (M2e5-18 and M2e8-21), chicken antisera to PWT/2006 (PL64 and PL80) 
were only reactive to the 14 residues M2e5-18 (Table 3.3). Despite M2e5-18 sharing residues 
with the whole M2e6-15 and M2e8-17, and most residues in M2e4-13 and M2e10-19, neither of the 
PWT/2006 antisera reacted to any of these shorter peptides. This suggested that these 10-
residue peptides were inadequate to represent the PWT/2006-strain epitope which elicited 
antibody responses in the chickens.   
 
Although the reference H5N1 serum (produced against A/chick/Scotland/59 strain) was 
commercially generated based on its hemagglutinin inhibition titer, it showed strong reactivity 
to peptide M2e2-18 (mean OD450 2.02) (Table 3.3). However, no reactivity was observed 
between the reference sera and any of the mapping peptides. Alignment of the peptides 
recognized by the chicken sera showed that at least two epitopes, in addition to the 
immunogen, were recognized, namely M2e5-18 (
5TEVETPTRNEWECK18) and M2e10-18 
(10PTRNEWECK18) (Table 3.3, Figure 3.3). Both epitopes contained residues M2e 10-17, 
which are recognised by all cAbs and which correspond to the most hydrophilic part of the 




Table 3.3 Mean OD450 readings for chicken (
a, b, c), mouse (d) and rabbit (e) antibodies reactivity to the M2e peptide.  
Antibody 
OD450 on Peptide 
M2e 2-18 M2e11-24 M2e8-21 M2e5-18 M2e16-24 M2e14-23 M2e12-21 M2e10-19 M2e8-17 M2e6-15 M2e4-13 M2e2-11 
2A17a 2.11  0.02 - 0.92  1.66  0.04 - 0.05 - 0.04 - 0.81  0.87  0.17 - 0.03 - 0.06 - 
2B2a 2.07  0.01 - 0.58  1.51  0.02 - 0.04 - 0.05 - 0.26  0.35  0.20 - -0.01 - -0.01 - 
2B47a 1.85  -0.22 - 1.20  1.32  -0.08 - -0.27 - -0.12 - -0.20 - 1.13  -0.11 - -0.21 - -0.13 - 
2D10a 2.33  0.04 - 2.14  2.14  0.10 - 0.10 - 0.14 - 2.02  2.24  0.17 - 0.09 - 0.05 - 
PL64b 2.29  0.04 - 0.01 - 0.76  0.08 - 0.08 - 0.14 - 0.02 - 0.10 - 0.10 - 0.07 - 0.10 - 
PL80b 2.34  0.10 - -0.05 - 1.13  0.16 - 0.02 - 0.07 - -0.02 - 0.08 - 0.13 - 0.01 - 0.04 - 
Reference H5N1c 2.02  -0.05 - -0.01 - -0.03 - 0.03 - 0.03 - 0.00 - 0.00 - 0.02 - 0.01 - 0.01 - 0.04 - 
1N5d 2.63  0.01 - 0.02 - 0.01 - 0.00 - 0.01 - 0.02 - 0.03 - 0.03 - 0.01 - 0.00 - 0.00 - 
2D16d 3.30  0.02 - 0.01 - 0.01 - 0.00 - 0.02 - 0.03 - 0.01 - 0.03 - 0.00 - -0.01 - -0.01 - 
2E14d 2.62  0.35  0.13 - 0.02 - 0.00 - 0.00 - 0.10 - 0.54  0.01 - 0.01 - 0.00 - 0.00 - 
2G14d 2.26  0.01 - 0.00 - 0.05 - 0.00 - 0.00 - 0.00 - 0.01 - 0.01 - 0.03 - 0.00 - 0.03 - 
3D23d 1.69  0.04 - 0.02 - 0.09 - 0.02 - 0.02 - 0.03 - 0.02 - 0.08 - 0.06 - 0.01 - 0.01 - 
3H4d 2.58  0.01 - 0.01 - 0.02 - 0.00 - 0.01 - 0.02 - 0.01 - 0.02 - 0.03 - 0.00 - -0.01 - 
Rab-1e 1.86  -0.10 - 0.08 - 1.82  -0.13 - -0.19 - -0.14 - -0.13 - 0.13 - 1.46  1.31  -0.04 - 
Rab-2e 0.49  -0.48 - -0.34 - 0.38  -0.53 - -0.53 - -0.52 - -0.52 - -0.45 - 0.42  0.24  -0.40 - 









OD450 on Peptide 
M2e 2-18 M2e11-24 M2e8-21 M2e5-18 M2e16-24 M2e14-23 M2e12-21 M2e10-19 M2e8-17 M2e6-15 M2e4-13 M2e2-11 
Rab-4e 0.68  -0.43 - -0.28 - 0.55  -0.46 - -0.46 - -0.45 - -0.45 - -0.35 - 0.60  0.39  -0.34 - 
Rab-5e 1.26  -0.20 - -0.04 - 1.45  -0.22 - -0.22 - -0.20 - -0.20 - -0.02 - 1.14  1.01  -0.14 - 
Rab-6e 1.41  -0.26 - -0.01 - 1.76  -0.30 - -0.30 - -0.28 - -0.28 - -0.13 - 0.94  1.44  -0.12 - 
Rab-7e 1.46  -0.27 - -0.03 - 1.25  -0.31 - -0.30 - -0.29 - -0.29 - -0.14 - 1.34  1.01  -0.13 - 
Rab-8e 0.68  -0.43 - -0.28 - 0.55  -0.46 - -0.46 - -0.45 - -0.45 - -0.35 - 0.60  0.39  -0.34 - 
For statistical analysis, please refer to Supplementary (Appendix). 
aChickens exposed to A/Ck/West Java/Sbg-29/2007 
bChickens exposed to A/Ck/West Java/Sbg-29/2007 
cChickens exposed to A/chick/Scotland/59 
dMice immunised with KLH-M2e2-19 









Figure 3.1 Hydrophobicity plot of M2e protein sequence (residue 2 to 24) based on Kyte & 
Doolittle scale mean of hydrophobicity profile in BioEdit. 
 
 
Figure 3.2 Clustering based on average linkage algorithm illustrates the similarity of chicken 
antibodies reactivity to the M2e peptides as indicated on the nodes of each group. Left to 
right: Cluster 1 (red box) chicken sera which reacted with M2e5-18 and M2e2-18; Cluster 2 (blue 
box) chicken sera which reacted with M2e8-17, 10-19, 5-18, 8-21 and M2e2-18; and 2D10 chicken 
serum which reacted with M2e8-17, 10-19, 5-18, 8-21 and M2e2-18.  
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 Chicken sera reactivity pattern is highly influenced by its immunogen as well as 
individual chicken immune response  
Clustering analysis of chicken antisera based on their reactivity with M2e peptides revealed 
two major clusters broadly related to the antigen used to immunise the donor chickens (Figure 
3.3). Cluster 1 grouped Sbg-29/2007 antisera together, particularly 2B2, 2A17 and 2B47, 
based on their reactivity to M2e8-17, 10-19, 5-18, 8-21 and M2e2-18; while cluster 2 grouped  
PWT/2006 antisera (PL64 and PL80), based on their reactivity to M2e5-18 and M2e2-18, along 
with the reference H5N1 sera (produced against A/chick/Scotland/59) which only reacted to 
peptide M2e2-18.  
 
Although cAb2D produced against the Sbg-29/2007 strain shared a similar reactivity pattern 
with cAbs 2B2 and 2A17 (M2e8-17, 10-19, 5-18, 8-21 and M2e2-18), clustering analysis recognized 
cAb 2D10 sera as the least similar to the other sera. Observation of its OD450 readings showed 
that cAb 2D10 reacted strongly with all five peptides (OD450 2.02 – 2.33) (Table 3.3) which 
was not observed with the other sera. And uniquely this sera also had high anti-M2e 
antibodies titre (1:10,240).  
  
 Mouse monoclonal antibodies recognized epitopes M2e2-18 and M2e11-18 while 
rabbit polyclonal antibodies recognized epitope M2e6-13 
M2e comparative mapping by mAbs showed minimal variability in their reactivity patterns. 
While all six mAbs strongly reacted with peptide M2e2-18 (OD450 1.69 – 3.30), only mAb 
2E14 showed a weak and medium reactivity to M2e10-19 and M2e11-24, respectively (Table 
3.3). Together, mAbs recognized an M2e epitope containing a minimum of eight residues 
(11TRNEWECK18) to 17 residues (2SLLTEVETPTRNEWECK18), in which the epitopes 
mostly overlapped with the epitope recognized by cAbs described above (Figure 3.3).  
 
Apart from the similar strong reactivity observed for peptide M2e2-18 (OD450 1.73), rAbs also 
demonstrated strong reactivity to M2e4-13, M2e6-15 and M2e5-18 (Table 3.3), a combination 
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which was not demonstrated in the previous two groups of antibodies. All these peptides 
shared residues 6EVETPTRN13 which indicated that the epitope recognized by rabbit was 
different from the chicken and mouse antibodies.  
 
Comparison of the M2e epitopes recognized for all three groups of antibodies clearly showed 
that the chicken, mouse and rabbit sera recognized five epitopes, namely M2e residues 2-18 
for all antibodies, with specifically M2e residues 5-18 and 10-17 recognized by the cAbs, 
M2e residues 11-18 recognized by one mAb, and M2e residues 6-13 by the rAbs (Figure 3.3). 
The shorter epitopes represented by the different antibodies group was recognized on two 
different sites of the M2e protein.  cAbs and mAbs antibodies recognized epitopes located at 
the central region of the M2e protein (10PTRNEWECK18), while the rAb antibodies 






Figure 3.3 The antigenic determinants of M2e protein recognized by chicken, mouse and rabbit antibodies highlighted with the red boxes. In the order from 
top to bottom, chicken antibodies to Sbg-29/2007 strain that recognized peptides containing residues 10PTRNEWEC17; chicken antibodies to PWT/2006 
strain recognized peptides with residues 5TEVETPTRNEWECK18; mouse monoclonal antibodies recognized peptides with residues 11TRNEWECK18 and 
rabbit antibodies recognized peptides with residues 6EVETPTRN13. Tested antibodies are listed on the left, while the peptides corresponding to the residues 
recognized by each group are indicated on the right.  
cAb: chicken antibodies 
mAb: mouse antibodies 






 Discussion  
Based on our previous success in demonstrating the effective use of M2e protein as a target 
for DIVA strategy, we attempted to develop a competitive ELISA test targeting the M2e 
protein. This test was anticipated to possess a broad host species applicability which is 
capable of DIVA for a simple yet effective AIV surveillance tool in domestic poultry. We 
have here described the comparative mapping of anti-M2e antibodies from chickens, mice and 
rabbits. Our findings revealed the occurrence of two separate epitopes on the M2e protein, 
where one epitope was exclusively recognized by the rAbs antibodies, while the other was 
recognized by both mAb and cAbs. It is important to note that for development of a 
competitive ELISA, the test and competitor antibodies need to cross-react with the same, or at 
least similar epitope, within the same antigen. Such is the case where cAbs are the test 
antibodies, while mAbs but not rAbs are the potential competitors. 
 
Despite the difference in the immunogen used for anti-M2e antibody production in mice and 
rabbits (KLH-conjugated peptide) versus chickens (H5N1 live virus), our findings that the  
five M2e epitopes within the sequence 2SLLTEVETPTRNEWECK18 recognised by cAbs, 
mAbs and rAbs were similar to those of others (De Filette et al. 2011; Fu et al. 2009; Grandea 
III et al. 2010; Liu, Li & Chen 2003; Liu, Zou & Chen 2004; Pejoski et al. 2010; Wang et al. 
2008; Wang et al. 2009; Zabedee & Lamb 1988; Zhang et al. 2006; Zharikova et al. 2005; 
Zou, Liu & Chen 2005) (Table 3.4). The high frequency of epitope 6EVETPTRN13 occurrence 
in the previous studies suggests that it is likely to be a dominant epitope for M2e protein. 
Additionally, epitope 6EVETPTRN13 is potentially a major epitope for rAbs, whereas a 
previous study on immunization of rabbits and mice using M2e2-10 
2SLLTEVETP10 
conjugated with KLH (SP1-KLH) showed to be more immunogenic in  rabbits than it was in 




Minimal variation observed for mAbs was likely due to the double selection using M2e2-19-
KLH-based ELISA for hybridoma production and final selection. This limited the mAbs 
reactivity only to the immunogen with low cross reactivity to the other peptides used in the 
study. Nevertheless, one mAb recognized two other peptides which contain residues M2e 11-
18 (Figure 3.3) that overlapped with M2e epitopes recognized for cAbs. Hence, mAb was 
suggested to be a better competitor in a cELISA-based test for cAbs in contrast to rAbs, as the 
latter showed fewer overlapping residues (Figure 3.3).  
 
However, it was notable that one mAb and the majority of cAbs showed slight variation in 
peptide recognition. Although the antigenic determinants recognized by the mAb and cAbs in 
the current study overlapped with the epitopes found previously (residues 5 to 16 of M2e) 
(Pejoski et al. 2010; Wang et al. 2008; Zabedee & Lamb 1988; Zhang et al. 2006; Zharikova 
et al. 2005), they differed in that two of the recognized epitopes (10PTRNEWEC17 for cAbs, 
11TRNEWECK18 for mAb) extended further from the mid-region into the C-terminal end of 
the M2e protein (Table 3.4). Both were shorter epitopes (8 aa in length) and independent of 
the N-terminal peptide (M2e2-9), with one or two more residues at the epitope C-terminal 
(C17 and K18) than previously reported epitopes recognized in humans and mice. This 
suggests that residues 2SLL4 is a less important antigenic determinant in chickens and rabbits 
than it is in humans (Grandea III et al. 2010). Conversely, C17 and K18 may possibly be 
important residues for cAbs epitope recognition. Importance of K18 for mAb epitope 
recognition was also suggested by the reported loss of anti-M2e antibody responses following 
immunization with truncated M2e2-16 in a vaccine study in mice (Pejoski et al. 2010). 
Difference by two to three residues between the M2e epitopes recognized by mAbs has also 
been described previously (Zhang et al. 2006). Zhang et al. (2006) suggested that such 
observations could be due to either a true existence of species-related variation in epitope 
recognition, or difference in assay sensitivity used for epitope recognition, or both (Zhang et 
al. 2006). Epitope variation was observed in a separate M2e-unrelated study in rabbits using 
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10 human proteins, where although the epitopes recognized for a single protein were similar, 
they were not identical (Hjelm et al. 2012). The epitopes recognized by mAbs in the current 
study represent another species-related variation of the existing recognized M2e epitopes, 
while this is the first known M2e epitope reported in chickens. Nevertheless, M2e residue 
C17 and K18 may be of contributing to the antigenic characteristics of M2e. 
 
M2e protein residues S2, T5, E6, P10, I11, E14 and W15 have been identified as critical for 
antibody interactions (Cho et al. 2015; Grandea III et al. 2010; Huleatt et al. 2008; Tompkins 
et al. 2007; Wang et al. 2009; Zharikova et al. 2005). Epitope studies have suggested that 
charged residues (E, K an D), and polar residues (R, N, Q, P and T) are preferred in highly 
antigenic epitopes (Sun et al. 2011; Tsai et al. 1997), where the hydrophilic amino acids (R, 
K, N, P, H, D and E) are more prominent (Raghunathan et al. 2011). A recent analysis of the 
M2e crystal structure complexed with monoclonal antibody has recognized that residues T5, 
E6, V7, P10, R12 and N13 assist M2e hydrophilic interactions, which contributes to epitope 
accessibility in antigen-antibody binding (Cho et al. 2015). Amino acid variation at residues 
P10, E14 and E16 resulted in predicted M2e structural differences between two H5N1 strains, 
Vietnam/1194/04 and Hong Kong/156/97 (Leung et al. 2015). The latter H5N1 strain showed 
a folded hairpin structure that limits antigen recognition in comparison to a relatively more 
accessible structure observed in the former. M2e protein sequence is not available for 
PWT/2006 strain used in current study. The M2e amino acid sequence of A/chick/Scotland/59 
(EMBL accession number CY015082) and A/Ck/West Java/Sbg-29/2007 (H5N1) (GenBank 
accession number AKI82362.1) only differs by residue E14G for Scotland/59, and K18C for 
both from the M2e A/Vietnam/1194/04, hence a similar ‘open’ structure is likely for the Sbg-
29/2007 M2e protein.  
 
It is noted that antibodies from chickens exposed to two different strains of H5N1 in current 
study recognized two dominant but overlapping epitopes on the M2e protein. Differences 
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observed may be related to the M2e membrane-bound protein conformation of these two 
H5N1 strains. Factors such as degree of protein protrusion from membrane surface (Thornton 
et al. 1986), as well as its accessibility for binding activities (Novotny et al. 1986) highly 
influence the whole presentation of the protein to the birds immune system. Reactivity with 
only the 14 aa mapping peptide (M2e5-18, 
5TEVETPTRNEWECK18) observed for sera 
PWT/2006 may be related to the structural element formed by the protein on the virus 
particle. Previous study on the human tryptophanyl-tRNA synthetase epitopes using 10 aa and 
15 aa peptides has demonstrated similar observations (Hjelm et al. 2010). It was suggested 
that the 10 aa peptides (M2e4-13, 6-15, 8-17 and 10-19) were not sufficient to imitate the functional 
structure of the epitope since it is located in a loop structure partially characterized by an α-
helix. In the case of the M2e protein, its three-dimensional structure showed a compact U-
shaped conformation, where a β-turn structure is adopted by residues T5 to E8, and 310 helix 
from residues I11 to W15 (Cho et al. 2015). Hence, it was likely that although the two 
epitopes residues overlap, the PWT/2006 sera were only reactive to the 14 aa peptide M2e5-18 
due to the lack of complete residue for a functional epitope formed by the 10 aa peptides.  
 
Difference in length of recognized epitopes in anti-M2e cAbs may be related to the different 
degree of virus virulence between the H5N1 strains and individual chicken immune 
responses. Strong reactivity to the M2e peptides observed for the 2D chick sera in current 
study was reasoned to be due to the double boosts vaccination using killed virus, followed by 
a live virus challenge. Current findings revealed that the Sbg-29/2007 antisera were capable 
of recognising shorter epitopes in comparison to the PWT/2006 strain. Slight differences in 
signal intensity for each identified peptide for Sbg-29/2007 antisera were also noted in 
relation to the number of vaccinations for each individual birds. Previous study on epitope 
patterns in rabbit’s parallel immunizations with a single antigen showed that polyclonal 
response in individual animal may differs in their affinities (Hjelm et al. 2012). Also, the 
difference in the immunogen used was implicated in the lack of response to the mapping 
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peptides observed for the reference H5N1 sera. Temporal and spatial distant origin of the 
strain used for immunisation (Scotland/59) from the strain used as the basis for the mapping 




Table 3.4 Summary of epitopes recognized on influenza A virus M2e protein by different antibodies.  




(AS1, AS2, AS3, AS4) 








(Liu, Zou & 
Chen 2004; 
Zharikova et 
al. 2005; Zou, 
Liu & Chen 
2005) 
Monoclonal Mice Live virus & synthetic peptide    4LTEVETPIRNEWG16 13 (Zhang et al. 
2006) 
Monoclonal 
(L66, N547, Z3G1, C40G1, 14C2) 
Human 
(λ HAC or KM™ mice) 
Fusion-M2e (BSA) 2SLLTEVETPIRNEWG16 (L66) 
   3LLTEVETPIRNEWG16 (N547) 
   3LLTEVETPIR12 (Z3G1) 
                          9TPIRNE14 (C40G1) 










Monoclonal Mice Fusion-M2e (BSA) 2SLLTEVET9 (M2e8-7) 
   3LLTEVETPIR12 (Z3G1) 
8 
10 
(Wang et al. 
2009) 
Monoclonal Mice Fusion-M2e (BSA)       4LTEVETPIRN12 (L18) 
2SLLTEVET9 (O19) 
2SLLTEVETPIRNEWGCRNDSSD24 (P6) 




(Fu et al. 
2009) 
Polyclonal Mice  2SLLTEVETPIRNEWG16 15 (Pejoski et al. 
2010) 
Monoclonal Human  2SLLTE6 (TCN-031, TCN-032) 5 (Grandea III 
et al. 2010) 
 Mice Fusion-M2e (KLH) 2SLLTEVETP10 9 (De Filette et 
al. 2011) 
Polyclonal & monoclonal Chicken, mice, rabbit Live virus & fusion-M2e (KLH)            5TEVETPTRNEWECK18 (cAbs)  
                            10PTRNEWEC17 (cAbs) 
2SLLTEVETPTRNEWECK18 (cAbs, mAbs, rAbs) 
                                11TRNEWECK18 (mAb) 







Difference at residue I11T between the current and previous studies corresponded to the human and swine specific M2e sequence in the former 







Although the relatively limited number of serum samples available for testing in the current 
study do not represent the complexity of antibody response to M2e protein, nevertheless, the 
results presented provided information on differences of M2e epitope recognition by mouse, 
rabbit and chicken antibodies. Identification of antigenic determinants or epitopes of the 
target protein will enable us to formulate the most suitable source of anti-M2e antibodies for 
further development. 
 
In summary, we have identified five epitopes spanning residue 2 to 18 of M2e protein for 
mouse, chicken and rabbit sera with variations in length (8 to 17 aa) from two localities on the 
M2e protein (N-terminal and mid-region). We also concluded that mouse anti-M2e antibodies 
are more suitable to be used as a competitor antibodies than the rabbit anti-M2e antibodies for 
further work on M2e-based competitive ELISA diagnostic test. This was highly suggestive by 
the overlapping epitopes (11TRNEWEC17) demonstrated by both chicken antibodies and one 
of the mouse antibodies.  
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A rapid and sensitive serodiagnostic tool which effectively discriminates vaccinated from 
virus infected animals (DIVA) will simplify surveillance of H5N1 in poultry in vaccinating 
countries. The reliability of an M2e-based indirect ELISA for DIVA application suggested its 
potential for use in a competitive based ELISA (cELISA) application. Following our recent 
findings on similar epitope identified by both mouse and chicken anti-M2e antibodies, we 
investigated the potential use of mouse anti-M2e monoclonal antibodies (mAbs) in an M2e-
based cELISA for H5N1 surveillance in poultry. Field sera from 15 known positive 
(challenged, infected) and 339 negative (145 vaccinated-non-challenged and 194 non-
vaccinated-non-challenged) chickens were used to test four mAbs. Results indicated that the 
use of mAb 3H4 as competitor antibody significantly differentiated between the H5N1 
positive (62%-98% inhibition) and negative sera (5.8%-53.0% inhibition) in chicken. Here, 
we successfully demonstrated the potential use of mouse mAb in an M2e-based cELISA 
format as an improvement of the available M2e-based indirect ELISA where it removes the 
needs for species-specific secondary antibodies. Hence, it can be widely used in species other 
than chicken for H5N1 surveillance in enzootic countries.  
 
Keywords: highly pathogenic avian influenza virus, M2e protein, competitive ELISA, M2e 
antibodies, mouse monoclonal antibodies, DIVA 
 
 Introductions 
Highly pathogenic avian influenza virus (HPAIV) H5N1 is one of the most widespread AIV 
subtypes, largely due to its rapid rate of evolution which consequently becoming enzootic in 
several countries (Guan et al. 2002; Hasan et al. 2016; Watanabe et al. 2011). Vaccination is 
used as a control measure to mitigate further outbreaks in these countries, but emergence of 
virus variants is of concern due to drift of the field virus from the seed strain used for vaccine 




surveillance tool is required to ensure early and rapid detection of active AIV infection in 
poultry populations (Ahmed et al. 2012; Fouchier & Guan 2013; Grund et al. 2011; Wang et 
al. 2008).  
 
Conventional serologic tests for AIV detection, such as the hemagglutination inhibition (HI) 
and agar gel immunodiffusion tests, are simple and economic, yet can be labour intensive and 
time consuming (Jenson 2014; Pedersen 2014). Faster, simpler methods with high throughput 
options are much preferred, such as real-time PCR-based methods (Dovas et al. 2010; Gall et 
al. 2008) for detection of active infection,  and enzyme-linked immunosorbent assays 
(ELISA) targeting anti-AIV protein antibodies for detection of prior exposure. 
 
Two of the most commonly available ELISA-based systems are the indirect ELISA (iELISA) 
and the competitive ELISA (cELISA).  An advantage of cELISA is that, unlike iELISA, 
species-specific secondary antibodies are not required. A cELISA tests the ability of the test 
antibodies to inhibit the competitor antibodies from binding to a particular antigen. Thus, it is 
important that the competitor antibody identifies the same epitope as the test species 
antibodies. A cELISA based on AIV nucleoprotein (NP) (Shafer, Katz & Eernisse 1998; 
Starick et al. 2006; Zhou et al. 1998) was proven to be reliable as a species-independent assay 
with comparable or better sensitivity and specificity to the HI assay (Song et al. 2009). This 
established cELISA as an ideal primary screening tool for AIV infection surveillance (Marche 
& Van den Berg 2010; Yang et al. 2011). 
 
However, none of the available tests is suitable for detection of AIV infection in AIV (H5N1) 
vaccinated animals. This is because the tests do not differentiate  antibodies raised in response 
to exposure to  live virus infection from those raised in response to  killed virus vaccination 
(reviewed in Pantin-Jackwood and Suarez (2013)). Although cELISA is ideal as an AIV 




of H5N1 enzootic countries because inactivated virus vaccination is practised in most of these 
countries (Chen 2009; Marangon, Cecchinato & Capua 2008). Vaccination usually targets 
HPAIV, while other low pathogenic avian influenza virus circulation within the population is 
still possible. Hence, a detection system using anti-NP antibodies as a discriminating system 
has a serious limitation and vaccination complicates result interpretation when testing for 
infection (James et al. 2008).   
 
Given the simpler and easier approach of cELISA-based tools in comparison to other 
available diagnostic tools, the current study was conducted to determine the potential value of 
a cELISA test based on the AIV external domain of matrix 2 (M2e) protein for H5N1 
infection serosurveillance. Advantages in targeting this protein are its sensitivity and 
specificity in differentiating H5N1 virus infected chickens from vaccinated ones (Hadifar et 
al. 2014; Hemmatzadeh et al. 2013; Kim et al. 2010; Lambrecht et al. 2007; Tarigan et al. 
2015). AIV is known to infect various hosts such as swine, horses, dogs, cats and marine 
mammals, as well as various avian species (Chambers, Dubovi & Donis 2013). The challenge 
in setting up a cELISA-based test with a broad-hosted pathogen is in ensuring that the 
competitor antibodies recognized the same antigenic determinants of the target protein across 
host species, as this has proven to be not always the case (Darnule et al. 1980; Finlay & 
Almagro 2012; Hasan et al. 2016; Rotter et al. 1983).Our recent investigation indicated that 
anti-M2e mouse monoclonal antibodies and chicken polyclonal antibodies recognise the same 
epitope on the M2e antigen (Hasan et al. 2016). Hence, this study aims to identify and 
validate the potential development of an M2e-based cELISA as a large-scale serosurveillance 





 Material and Methods 
 M2e peptide as antigen for indirect and competitive ELISA 
M2e peptide (M2e2-18, 
2SLLTEVETPTRNEWECKC18) (Abmart, Shanghai, China) based on 
HPAIV H5N1 M2e protein was used in all ELISAs. Optimum concentration of 10 µg/ml was 
used for microtitre plate coating as described previously (Hadifar et al. 2014; Hemmatzadeh 
et al. 2013).  
 
 Monoclonal antibody (mAb) 
Mouse monoclonal antibodies 1N5, 2D16 and 3H4 were from hybridoma cell lines derived  
from mice immunised against HPAIV H5N1 M2e protein peptide (aa 2-19) (Abmart, 
Shanghai, China)  (Hemmatzadeh et al. 2013) (Table 4.1). Briefly, six female BALB/c mice 
were immunized on six (6) occasions by injections at multiple subcutaneous sites. The first 
five injections were done using 0.05 mg KLH-M2e peptide with complete Freund’s adjuvant, 
14 days apart.The final immunization was done with 0.05 mg KLH-M2e peptide in 
incomplete Freund’s adjuvant. Serum was collected on day 7 after the fourth immunization to 
test for its reactivity in an M2e-based ELISA. Hybridoma clones strongly positive for anti-
M2e antibody production  were selected using indirect M2e ELISA as previously described  
(Hadifar et al. 2014; Hemmatzadeh et al. 2013). Clones 1N5, 2D16 and 3H4 were further 
grown in Dulbecco’s modified Eagles medium (DMEM) high glucose (Hyclone, GE 
Healthcare) supplied with 15% foetal bovine serum (Hyclone, GE Healthcare) and 1% (v/v) 
penicillin streptomycin (Gibco, Thermofisher Scientific). Using sterile techniques, protein 
precipitated from cell culture supernatants with ammonium sulphate (1:2) and resuspended in 
1X phosphate buffered saline (1:2) was used without further purification  (Hadifar et al. 2014; 
Hemmatzadeh et al. 2013).  The M2e-ELISA titer was determined for each mAb in 10-steps 
two-fold dilutions (from 1:10). Protein concentration of mAb solution was quantified by 
measuring light absorbance at 280 nm on a NanoDrop 1000 Spectrophotometer 






Chicken anti-influenza virus antibodies (cAbs) were produced as described previously 
(Hadifar et al. 2014; Tarigan et al. 2015). Positive sera (H5N1 vaccinated and challenged 
chickens, n=6) were produced by vaccination with inactivated H5N1 AI vaccine (Medivac-
AI, PT Medion, Bandung, Indonesia), followed by live H5N1 virus challenge with strain 
A/Ck/West Java/PWT-WIJ/2006 or A/Ck/West Java/Sbg-29/2007 (Table 4.1).  Commercial 
layer chicks were vaccinated once (16 weeks of age), twice (12 and 16 weeks of age) or three 
times (8, 12 and 16 weeks of age) and then challenged with live H5N1 two weeks after the 
last vaccination. Challenge experiments were conducted in the Biosecurity level 3 (BSL3) 
facilities at the Indonesian Research Centre for Veterinary Science, Bogor, Indonesia. Sera 
obtained from the challenged birds were tested for anti-M2e antibodies using indirect M2e-
ELISA (Table 4.1) (Hadifar et al. 2014; Hemmatzadeh et al. 2013). The M2e-ELISA titer of 
the known positive sera was determined in 10-steps two-fold dilutions (from 1:40). Control 
sera were obtained from chicks which were vaccinated with H5N1 AI vaccine (Medivac-AI, 
PT Medion, Bandung, Indonesia), but not challenged with live H5N1 virus (chicken 
vaccinated only,  n=145), and field sera from chicks which were H5N1 vaccinated using 
unknown sources and untreated (non-H5N1-challenged) (chicken field sera, presumably 
H5N1 negative, n=194). Vaccinated only chicken sera were included to ensure that the test is 
able to differentiate between H5N1 vaccinated and H5N1 infected sera. Sera from two 
unvaccinated specific pathogen free (SPF) chicken were also included as negative control 
(Table 4.1). Additional known positive chicken sera (n=6, Table 4.1) were obtained from 
Australian Animal Health Laboratory (AAHL), Geelong, as described previously 




Table 4.1 Anti-M2e positive antibodies generated in response to specific immunogens, either H5 virus challenge (chicken antibodies) or M2e peptide (aa 2-
24) immunization (mouse monoclonal antibodies). Negative sera were collected from vaccinated field sera and specific-pathogen free chickens (Indonesian 











Chicken Positivea, e 
PL64a, PL80a 2 A/Ck/West Java/PWT-WIJ/2006 H5N1 
2B10a, 2B2a, 2B47a, 2D10a 4 A/Ck/West Java/Sbg-29/2007 H5N1 
103e 1 A/Ck/West Java/Subang/29/2007 H5N1 
104e 1 A/Ck/Indonesia/CSLK-EB/2006 H5N1 
105e 1 A/Ck/Wates/1/2005 H5N1 
107e 1 A/Ck/Myanmar/295/2010 H5N1 
110e 1 A/Ck/Myanmar/1001/1/2006 H5N1 






H5N1 AI vaccine (Medivac-AI, PT 
Medion, Bandung, Indonesia) 
 
na 
Field serac 194 na na 
SPFd 1 SPF H5N1 
Mouse Positive 
1N5, 2D16, 3H4 3 M2e2-19 peptide:  
SLLTEVETPTRNEWECKC-KLH 
H5N1 
na – not available; a – positive chicken sera (experimentally challenged); b – vaccinated only chicken sera (negative sera); c – chicken field 








 Indirect M2e-ELISA  
96-well flat bottom microtiter plates (Maxisorp, NUNC) were coated overnight at 4°C with 
M2e peptide diluted in 0.1 M carbonate-bicarbonate buffer, pH 9.6 (0.1 M Na2CO3, 0.1 M 
NaHCO3) to a final concentration of 10 µg/ml (100 µl/well). Plates were washed five times 
with PBS containing 0.05% Tween 20 (PBS-T) and blocked using 1% BSA in PBS, 200 µl/ 
well, for 2 hrs at room temperature (RT). After five rounds of washing with PBS-T, test 
serum diluted to the desired concentration with PBS containing 1% BSA and 0.05% Tween 
20 (PBS-BSA-T) for mAbs, and high salt dilution buffer (HS-DB: 0.1 M Tris pH 7.4, 0.5 M 
NaCl, 1 mM Na2EDTA, 2% w/v BSA, 3% w/v Triton X-100, 3% w/v Tween 20) for the cAbs 
(Hadifar et al. 2014), was added into the designated wells (100 µl/well). After 1 hr of 
incubation at RT, the plates were washed five times with PBS-T. Anti-mouse HRP (Sigma), 
diluted with PBS-BSA-T (1:1000), was added to each well (100 µl/well), followed by a 1 hr 
incubation at RT. After a final washing step (five rounds), substrate solution (100 µg/ml of 
tetramethylbenzidine substrate (TMB) (Sigma, St Louis, MO, USA) in citrate buffer (pH 8) 
containing hydrogen peroxide (100 µl of 0.6% H2O2) was added to the plate (100 µl/ well) 
and incubated at RT for 5-20 minutes. Reaction development was stopped by adding stop 
buffer (1 M sulphuric acid) (50 µl/ well) and the optical densities (OD) of each well were 
determined at OD450 nm using an ELISA plate reader (xMark Microplate Absorbance 
Spectrophotometer, BioRad). Corrected OD was used for the final result and this was 
obtained by subtraction of blank well OD reading (well with antigen absent, antibody present) 
from the test well OD reading to remove non-specific background produced by the antibodies 






 Development and standardization of competitive ELISA 
Different positive and negative cAbs with known titers in indirect M2e-ELISA were used as 
standard test sera and three different monoclonal antibodies (1N5, 2D16, 3H4) were used as 
competitor antibodies to develop the cELISA.  
 
This protocol was based on the blocking ELISA manual developed for AIV nucleoprotein 
(Selleck 2010) with modification. 96-well flat bottom microtiter plates (Maxisorp, NUNC) 
were coated with the M2e peptide (final concentration of 10 µg/ml) and washed prior to 
addition of test sera as described in the section above. Each cAb was diluted 1:10 with HS-
DB, 50 µl/well with duplicate wells per dilution and incubated for 1 hr at RT. Without 
washing, mAb were added to a desired final concentration (two-fold dilutions, from 1:250 to 
1:4000) (50 µl/ well) and incubated at RT for another 1 hr. Wells were washed five times with 
PBS-T before the addition of anti-mouse HRP (Sigma) (1:1000) and incubation for 1 hr at 
RT. Wells were washed with PBS-T five times prior to development and OD reading as 
described above. Corrected OD for each well was done as described above, where blank OD 
were wells with cAb and mAb present, but lack of antigen to remove non-specific reactivity 
of mAb with cAb if present.   
 
Percentage inhibition (PI) of competitor mAb binding to the antigen in the presence of cAb 
was calculated according to the formula below (Song et al. 2009), where the OD of wells with 
a mixture of cAb and mAb (OD inhibited) was expressed as a percentage of the OD of wells 
with only mAb (OD noninhibited).  
𝐏𝐈% =  𝟏𝟎𝟎 − (








 Statistical analysis  
All data analyses were conducted using MedCalc version 16.8 (MedCalc Software, Ostend, 
Belgium), while figures were produced using GraphPad Prism® version 6.  
 
Efficiency of the current diagnostic assay was evaluated by calculation of its specificity, 
sensitivity and both positive and negative predictive value (PPV and NPV, respectively) 
(Florkowski 2008; Parikh et al. 2008; Stojanovic et al. 2014; Walker et al. 2000). Specificity 
and sensitivity of the current test were calculated as: specificity = (true positive * 100)/(true 
positive + false negative); sensitivity = (true negative*100)/(true negative + false positive) 
(Walker et al. 2000). Cut off titre was established using receiver operating characteristics 
(ROC) where specificity (x-axis) was plotted against sensitivity (y-axis) using MedCalc 
version 16.8 (Adhikari et al. 2015).  
 
 Results 
 Optimization of chicken polyclonal and mouse monoclonal antibodies anti-M2e 
titers for M2e-based competitive ELISA 
To determine the titer for anti-M2e cAbs and mAbs to be tested in cELISA, an indirect 
ELISA using M2e peptide was conducted. OD readings for cAbs showed that cAb PL80 and 
cAb 2B47 had the highest anti-M2e end titer (1:2560), with cAb PL64 having the lowest end 
titre (1:640) (Figure 4.1). OD readings for the mAbs revealed that mAb 1N5 had the highest 
titer (1:1600), followed by mAb 2D16 (1:400) and mAb 3H4 (1:200) (Figure 4.2).  To 
determine the optimum mAb dilution in setting up the cELISA test, cAb PL80 (strong 
positive) and cAb PL64 (weak positive) were used as samples in the preliminary testing. 
 
 Selection of mAb 3H4 as the competitor in M2e-based competitive ELISA 
To select the mAb which provided the optimum inhibition for both high and low positive anti-





and weak cAb representatives. Results for mAb selection showed that only mAb 3H4 
demonstrated comparable level of mAb binding inhibition (mAb dilution 1:500, 86.2% - 
87.6% inhibition) for both high and low positive cAbs (Figure 4.3), hence the selection of 
mAb 3H4 in cELISA.  
 
 cELISA using mAb 3H4 distinguished infected from vaccinated chicken sera 
To evaluate the ability of mAb 3H4 to identify H5N1 positive test sera, percentage of 
inhibition (PI) between mAb 3H4 and known positive sera was measured. cELISA with an 
expanded panel of sera from H5N1 positive cAbs (n=12) showed high PI values with an 
average of 81.5% (range of 62% - 98%, sd=7.88) (Table 4.2, Figure 4.4). This showed that 
the anti-M2e antibodies produced by the H5N1 challenged chicken sera successfully inhibit 
the binding of mAb to the M2e antigen. To verify the M2e-based cELISA is capable of 
DIVA, chicken sera which were H5N1 vaccinated only (H5N1 negative) sera (n=145) were 
tested. Results showed a mean of 36.3% (range 5.8% - 53.0%, sd=9.06) which indicated low 
competition for M2e antigen binding between the chicken sera and the mAb. Since 
experimentally controlled and field chicken sera may show variability in field condition, 
chicken field sera (H5N1 negative) (n=194) were included in the cELISA and showed an 
average of 5.8% (range 0.0% - 61.6%, sd=13.06) inhibition, while SPF chicken sera (H5N1 
negative) (n=2) as the negative control showed a mean of 27.6% (25.3% - 30.0%, sd=3.34). 
The negative chicken sera (vaccinated-non-challenged, n=145; non-vaccinated-non-
challenged, n=194; known negative, n=2) showed a mean optical density 18.9 (sd=19.0). 
Calculation of positive inhibition cut-off value for anti-M2e chicken antisera was 56.8 (mean 






Figure 4.1 OD450 nm of 2-fold dilutions of chicken sera (1:40 – 1:10240 dilutions) incubated 
with M2e peptide (10 µg/ml) and binding visualised as described in methods. 
 
Figure 4.2 Monoclonal antibodies (mAb) of 2-fold dilutions (1:100 – 1:51200 dilutions) anti-







Figure 4.3 Comparison of percentage of inhibition, PI (%) amongst monoclonal antibodies  
1N5, 2D16 and 3H4 (final dilution of 1:500) against known high titre anti-M2e sera 
(experimentally challenged), chicken antibody (cAb) PL80, and known low titre anti-M2e 
sera, cAb PL64 (both at 1:10 dilution). mAb 3H4 shows comparable competitive level against 
both chicken antibodies in comparison to the other two monoclonal antibodies.  
 
Figure 4.4 Mouse monoclonal antibody 3H4 (1:500) binding inhibition by H5N1 positive, 
vaccinated only (negativeb), field and SPF chicken sera (negativea) (1:10) in M2e-based 








Each cAb was tested in duplicate of 1:500 mAb dilutions, the optimal dilution based on three 
separate trial runs (results not shown). A cut-off value for positive inhibition was calculated 
by using mean OD values of negative sera (including H5N1 vaccinated only, field sera and 
SPF chicken sera) + 2-fold value the standard deviation (mean negative OD + 2SD) (Table 
4.2). Based on the mean OD and SD values, the cut-off value for H5N1 negative in chicken 
was 56.8%. Therefore, test sera with PI value exceeding these cut-off values were considered 
as anti-M2e positive, hence infected with H5N1.  
 
Table 4.2. Summary of the H5N1 treatment and infection for chicken sera used in this study, 
with the average percentage of inhibition (PI) value in the M2e-based cELISA, showing the 








sd Vaccinated Challenged 
Chicken 





√a - 145 
36.3% 
(5.8% - 53.0%) 
9.06 
√b - 194 
5.8% 
(0.0% - 61.6%) 
13.06 





a: vaccinated with H5N1 AI vaccine (Medivac-AI, PT Medion, Bandung, Indonesia) 







Table 4.3. Sensitivity, specificity, positive predictive value (PPV) and negative predictive 




78.2% to 100% 
Specificity 99.4 
98.9% to 100% 
PPV 88.2 
63.6% to 98.5% 
NPV 100 
98.9% to 100% 
 
 
 Sensitivity and specificity of M2e-based cELISA 
M2e-based cELISA demonstrated 100% sensitivity and 99.4% specificity when tested with 
cAb exposed to H5N1 (Table 4.3). Sera which tested positive showed 88.2% likelihood to be 
infected with H5N1, while sera that tested negative showed 100% likelihood to be non-H5N1 
infected. ROC curve analysis was significantly different from 0.5 (<0.5) for cAb sera group 
and this indicated that the M2e-cELISA does has an ability to distinguish between the 
infected and non-infected sera in chicken (Table 4.4, Figure 4.5).  
 
Table 4.4. Area under the ROC curve shows ability of test to distinguish between diseased 
and non-diseased sera in chicken. 
  
Area under the ROC curve (AUC) cAb 
Area under the ROC curve (AUC)  1.000 
Standard Error a 0.000 
95% Confidence interval b 1.000 to 1.000 
Significance level P (Area=0.5) <0.0001 








Figure 4.5 Interactive dot diagram on ROC curve evaluation of sensitivity and specificity of 
M2e-based cELISA using chicken sera from infected (challenged), non-vaccinated and 
vaccinated chickens.  
 
 Discussion 
This study demonstrates the ability of M2e-based cELISA to be used as a sero-surveillance 
and DIVA tool in H5N1 infection detection in chicken. This test successfully identified 
vaccinated-then-challenged chicken sera as positive, and vaccinated only chicken sera as 
negative. These are important criteria for H5N1 enzootic countries which practise vaccination 
using H5N1 killed virus. H5N1 tests using cELISA based on the AIV-NP  had similar or 
better sensitivity and specificity in comparison with  agar gel immunodiffusion (AGID) and 
HI tests in domestic birds (Shafer, Katz & Eernisse 1998; Song et al. 2009; Starick et al. 
2006; Zhou et al. 1998). For H5N1 enzootic countries, where vaccination using inactivated 
virus is practised however, NP-based cELISA is rendered inapplicable for surveillance of 
AIV infection as it does not distinguish vaccinated from infected birds. Development of an 
M2e-based cELISA is highly anticipated based on its demonstrated sensitivity and specificity 
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as a DIVA marker (Hadifar et al. 2014; Hemmatzadeh et al. 2013; Kim et al. 2010; 
Lambrecht et al. 2007; Tarigan et al. 2015).   
 
Maximising the dynamic range of the M2e-based cELISA for detection of infection required a 
screening step titrating mAb concentrations to positive chicken sera with low (PL64) and high 
(PL80) anti-M2e antibody titers. Although mAb 1N5 possessed the highest anti-M2e antibody 
titer among the three mAbs, it showed no inhibition with the low M2e-antibody titer cAb. 
Instead, mAb 3H4 with the lowest anti-M2e antibody titer among the mAbs demonstrated the 
optimum competition with both high and low anti-M2e antibody titer cAbs. Difference in 
competition ability between mAbs may be related to the high 1N5 titer, which may has 
hindered or displaced the binding of low M2e titer cAbs to the antigen, resulting in the 
observed lack of competition between mAb 1N5 and cAb PL64, despite positive inhibition 
between mAb 1N5 and cAb PL80 (high anti-M2e cAb titer). On the other hand, positive 
inhibition between mAb 3H4 and cAb PL64 may be explained by the lower anti-M2e 
antibodies titer of mAb 3H4 in comparison to mAb 1N5. Such condition may has lowered the 
difference in concentration between the antibodies, thus reduced the binding interference as 
observed previously.   
 
It is not known if different subtypes of the immunoglobulin may have affected the 
competition of antibodies in an ELISA setting. Previous studies have shown that chicken sera 
are generally composed of three immunoglobulin classes, namely IgY (5 to 15 mg/ml), IgM 
(1 to 3 mg/ml) and IgA (0.3 to 0.5 mg/ml) (Kowalczyk et al. 1985; Rose, Orlans & Buttress 
1974), in the order of the highest concentration to the lowest. Meanwhile, the mAb used in 
this study were of IgG2 subtypes (Hasan et al. 2016). Structurally, both IgY and IgG are 
relatively similar, with differences in the number of their heavy chain constant regions (four 





between the constant variable (Cv) region 1 and Cv2 in IgY, which made it less flexible than 
IgG, among others (reviewed in Michael et al. (2010)). Nevertheless, all of these antibodies 
have demonstrated similar ability to identify the M2e peptide based on our previous epitope 
mapping experiment (Hasan et al. 2016). It was observed that cAbs PL64 and PL80 mapped 
to the same epitopes as each other on the M2e peptide used in the cELISA. Similarly, the 
three mAbs (1N5, 2D16 and 3H4) showed no differences in the epitope to which they bound 
on the same peptide. Therefore, it was unlikely that differences in the immunoglobulin 
subtypes may have influenced the different observation made between both mAbs with cAb 
PL64.  
 
The range of inhibition percentages observed in this study for the negative cAb sera is 
relatively high in comparison with previously reported AIV-based cELISA, the majority of 
which reported cut off values <30% (Dlugolenski et al. 2010; Shafer, Katz & Eernisse 1998; 
Starick et al. 2006; Zhou et al. 1998). It is unlikely that such non-specific readings are caused 
by non-specific reaction between the sera and the M2e antigen, since the test format was 
proven to be highly specific and sensitive in an M2e-based indirect ELISA in previous studies 
(Hadifar et al. 2014; Hemmatzadeh et al. 2013; Tarigan et al. 2015).  A caveat for this is the 
prior observation that non-specific reactions in an M2e-based indirect ELISA format were 
associated with the use of lipemic or haemolysed sera (Hemmatzadeh et al. 2013). Further 
investigation is needed to further clarify this observation. Nevertheless, all cAbs were 
correctly identified for both H5N1 negative (including vaccinated not challenged) and 
positive sera.  
 
In wild birds serologic surveillance, diverse populations and complicated nature of AIV 
present difficulties for diagnostic tool development. Serological manifestations observed in 





wild birds, as these are affected by the bird species, locality and virus adaptation to the host 
(Curran et al. 2014; Swayne 2007). Although NP-based cELISA is demonstrated as highly 
sensitive and specific tool for serologic surveys in several wild bird species (Brown et al. 
2009; Curran et al. 2014; Perez-Ramirez et al. 2010), this is not always the case in some 
others (Claes et al. 2012). Our preliminary works with AIV positive mallard and pheasant sera 
showed M2e-based cELISA is capable of detecting AIV infection in these wild bird’s species. 
However, duck sera demonstrated a mixed reactivity, where only duck sera which have been 
vaccinated-and-challenged were identified as AIV positive. Non-vaccinated-and-challenged 
duck sera demonstrated negative inhibition. Low inhibition value observed for the non-
vaccinated and challenged duck sera despite being H5N1 positive is assumed to be due to the 
low level of anti-M2e antibodies produced from the challenge. Due to the low density of the 
M2e protein on the surface of the virus particle, and domination of HA and NA proteins on 
the surface of the infected cells, the duck immune response is likely to be incapable of 
producing a significant level of M2e-specific antibodies in relation to HA- and NA-specific 
antibodies for the H5N1 positive duck (Feng et al. 2006; Neirynck et al. 1999). Nevertheless, 
further investigation is required to be done while considering the challenge virus, duck 
species use, vaccination protocols, role of maternally derived antibodies as well as the 
synergies between co-infecting pathogens (Pantin-Jackwood & Suarez 2013).  
 
Although the currently presented M2e-based cELISA possess a limited panel of test sera for 
known positive H5N1, our findings indicates that M2e-based cELISA is capable of 
discriminating between H5N1 positive and negative sera in chickens. Further testing with a 
larger number and variety of animal sera is necessary to aid the capability validation of the 
M2e-based cELISA system. In conclusion, development of M2e-cELISA based on mAb 3H4 
still potentially results in a broad range and species-independent immunodiagnostic assay 
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Avian influenza virus (AIV) H5N1 has continuously evolved and caused outbreaks in its 
enzootic countries. Due to economically impractical option of poultry culling, vaccination has 
been practiced to cushion the danger of an epizootic which pose concerns to public health. 
Well-developed diagnostic tools to detect AIV infection are available. However, most are not 
capable of differentiating infected from vaccinated animals (DIVA), making silent spread of 
AIV in a vaccinated animal population a major threat. Hence, a rapid and cost-effective 
diagnostic tool capable of DIVA is critical in AIV enzootic countries. The highly conserved 
extracellular matrix 2 (M2e) protein, an AIV surface protein has shown high potential for 
such application, but its small size and naturally low immunogenicity to the host immune 
system make its detectability an issue when employed as a target for DIVA tools. In this 
study, we have successfully isolated highly reactive and sensitive single chain variable 
fragment (scFv) anti-M2e antibodies from AIV-immunized and -challenged chicken using 
phage display technology to compensate for its low immunogenicity. mRNA isolation was 
done from spleen lymphocytes of chickens with high anti-M2e ELISA titer, where the 
immunoglobulin fragments (heavy chain, VH and light chain, VL) were then amplified and 
assembled into a phagemid before being displayed as recombinant bacteriophage to allow 
reactive antibodies selection. Findings showed that the isolated scFv antibodies possessed 
high reactivity with M2e antigen, both in soluble and phage-displayed form. Sequence 
analysis of six selected scFvs from pooled recombinant phages showed that the heavy chain 
of complementarity determining region 3 (CDRH3) is responsible for 55.6% of the overall 
variation of the positive scFv antibodies. Although refinement of the scFv anti-M2e 
antibodies is still required for a viable commercial assay, these antibodies hold potential use 










Developments in biotechnology have introduced methods to obtain genetically engineered 
antibodies, specifically the single-chain variable fragment antibody (scFv), a minimal form of 
a functional synthetic antibody that contains the variable heavy (VH) and variable light (VL) 
chains connected by a flexible polypeptide linker (Bird et al. 1988; Bird & Walker 1991; 
Wang et al. 2013). It is used as a tool for therapeutic and diagnostic purposes such as 
detection of antibodies against a wide variety of infectious pathogens (Chen et al. 2014; 
Nimmagadda et al. 2012), and to investigate the antigen-antibody binding interaction and 
isolation of the reactive antibodies to an antigen of interest (Guo et al. 2003; Winter et al. 
1994). scFv antibodies have accessible coding sequence for further analysis and modification 
(Hoogenboom et al. 1991; Yajima et al. 2008), can be expressed in high yield bacterial 
expression systems (Holliger & Hudson 2005), and are also isolatable from the bacterial 
periplasm space (Nossal & Heppel 1966). In vitro directed molecular evolution can be used to 
improve the antibody affinity for specific antigens (Fukuda et al. 2006; Liu et al. 2012).  
 
ScFv is usually obtained using phage display technology which uses the bacteriophage ability 
to express a foreign protein on its surface. Bacteriophages are viruses that feed on bacteria.  
Bacteriophage used for phage display purposes are modified to support the optimal conditions 
for the specific protein expression. Advantage of this technology lies in the power to select 
the most reactive antibodies through a process of affinity selection known as biopanning. This 
involves repetitive immobilisation of reactive phage using synthetic antigen, thus allows 
effective selection of antibodies with high affinity and specificity and their rapid generation 





and cost effective way to obtain targeted antibodies, circumventing the needs for animals or 
cell culture experiments and facilities (van Wyngaardt et al. 2004).  
 
Established enzootic of avian influenza virus (AIV) H5N1 in several countries has made 
vaccination the primary tool to mitigate the risk of avian influenza virus (AIV) infection and 
outbreaks (Domenech et al. 2009; Suarez 2012; Swayne et al. 2011). Differentiation of 
antibodies generated from AIV infection versus those from vaccination (DIVA) is still a 
challenge in monitoring the condition and spread of this virus especially in domestic animals 
such as the poultry industry. Importance of DIVA tools has been noted as it is critical in 
ensuring the animals are disease-free. Serosurveillance is important for early detection of 
potential outbreaks, and diagnostic tools based on AIV proteins such as hemagglutinin (HA), 
neuraminidase (NA) and non-structural protein 1 (NS1) have been developed to tackle this 
problem.  Although these diagnostic tools are effective in detecting AIV infection in animals, 
they lack the ability to distinguish the animals which are infected from the vaccinated ones 
since both conditions produce similar types of antibodies (Hadifar et al. 2014; Hemmatzadeh 
et al. 2013). 
 
Previous studies on the extracellular domain of the matrix 2 protein (M2e) of AIV have 
demonstrated its potential use for sero-surveillance in sensitive and specific diagnostic tools 
with DIVA capabilities (Hadifar et al. 2014; Hasan, Ignjatovic, et al. 2016; Hemmatzadeh et 
al. 2013; Tarigan et al. 2015). Briefly, the M2e protein is a 24 amino acid (aa) membrane 
protein on the surface of the AIV particle. It is the N-terminal of M2, a type III 
homotetrameric, integral membrane protein which further consists of a transmembrane 
domain and a cytoplasmic tail domain (Rossman & Lamb 2011; Schnell & Chou 2008). Apart 
from channelling ion exchange during the release of virus genetic material into the host cell 





the trans-Golgi network (Ciampor et al. 1992). M2 protein is known to inhibit autophagy 
which may affect the infected cell’s survival (Gannage et al. 2009), as well as assisting in 
virion release (Rossman & Lamb 2011).  
 
Factors driving researchers to take interest of M2e protein are its stable sequence across AIV 
subtypes and its differential epitope density on infected (high) and non-infected (low) cells 
(Lamb, Zabedee & Richardson 1985; Zabedee & Lamb 1988). M2e is relatively invariant 
across AIV subtypes due to its minimal exposure to the host immune response. Its small size 
and low density on the virus particle in comparison to the other surface proteins i.e 
hemagglutinin and neuraminidase proteins have partly contributed to this feature. It also 
tolerates minimal amino acid changes due to its overlapping gene segments with the highly 
conserved M1 protein.  
 
M2e protein also demonstrated differential epitope density between the surface of the virus 
particle and on an infected cell, where the latter is significantly higher from the former (Lamb, 
Zabedee & Richardson 1985; Zabedee, Richardson & Lamb 1985). This characteristic makes 
M2e protein an attractive target as a marker in DIVA strategies, as this enable the 
differentiation between an AIV-vaccinated-only animal, from an AIV-vaccinated-then 
infected animal. Vaccination is usually done using inactivated AIV particle – a whole virus 
which lacks the ability to replicate. Although M2e protein is present on the inactivated AIV 
particle, its low density will not elicit any significant antibody response. However, M2e 
protein is displayed in a large amount on the surface of an infected cells as a part of the AIV 
progeny assembly and budding strategy (reviewed in Rossman and Lamb (2011)). Therefore, 
high amount of M2e protein will elicit high level of anti-M2e antibodies, which is indicative 
of AIV infection. Several studies demonstrated the capability of M2e for chicken and duck 





sensitivity and specificity of the M2e-based DIVA was demonstrated more recently (Hadifar 
et al. 2014; Tarigan et al. 2015).  
 
However, the main limitation of strategies based on M2e protein is its low detectability, as 
this may cost the test’s sensitivity as well as specificity (Feng et al. 2006). Therefore, using 
phage display technology to acquire highly specific and reactive anti-M2e antibodies may 
alleviate this shortcoming, as scFv antibodies are known to be stable and highly reactive 
(Chen et al. 2014; Min et al. 2011). Following interests on the AIV M2e protein as a target for 
diagnostic tools development capable of DIVA in AIV sero-surveillance, this study has been 
developed to isolate the most reactive antibodies against the M2e protein to be potentially 
used in a competitive ELISA setting. Recombinant Phage Antibody Systems (RPAS) has 
been showed to efficiently produce scFv through the use of phagemid vector such as 
pCANTAB5E (Guo et al. 2003; Sapats et al. 2003; Winter et al. 1994). Therefore, an immune 
scFv library was constructed using RNA isolated from chicken (ck) lymphocytes of an 
immunized donor vaccinated with H5N1. Specific ck scFv fragments were affinity selected 
from this library using plate-based biopanning. The selected scFv was expressed in E. coli, 
characterized and used in the development of an ELISA for quantification of reactive M2e 
antibodies.  
 
 Materials & methods 
 Plasmids, strains and cells  
Phagemid pCANTAB5E (Amersham Biosciences Inc., UK) was kindly donated by Dr 
Motohiro Ohshima, the University of Shizuaka, Japan. Escherichia coli strains TG1, SOLR, 
XL-Blue MRF, HB2151 were purchased from Agilent Technologies (Santa Clara, California, 
USA), while helper phage M13KO7 was purchased from New England Biolabs (MA, USA). 





Anti-E tag monoclonal antibodies for affinity purification, E tag peptide 
(GAPVPYPDPLEPR) (Abmart, Shanghai, China), and the M2e peptide (aa 2-18: 
SLLTEVETPTRNEWECK) were purchased from Abmart (Shanghai, China). 
 
 Chicken serum samples 
Anti-M2e positive chicken sera (n=35) were produced as described previously (Hadifar et al. 
2014).  Three-weeks-old specific pathogen free (SPF) chickens were immunized one to three 
times with commercial inactivated AI vaccine (Medivac-AI, PT Medion, Bandung, Indonesia) 
before challenged with live H5N1 strains (A/chicken/West Java/Sbg-29/2007 or 
A/chicken/West Java/PWT-WIJ/2006) two weeks after the last vaccination. Challenge 
experiments were done in the Biosecurity level 3 (BSL3) facilities at the Indonesian Research 
Centre for Veterinary Science, Bogor, Indonesia. Serum from SPF chicken was used as the 
negative control and all sera were tested in three duplicates for anti-M2e antibodies using 
tM2e-ELISA (Hadifar et al. 2014; Hemmatzadeh et al. 2013). The chickens with the higher 
anti-M2e titre in ELISA were selected for mRNA isolation from spleen lymphocytes. Briefly, 
chickens were euthanized four weeks after last immunization and immediately, the chicken’s 
spleens were removed for lymphocytes purification.   
 
 cDNA synthesis and VH-linker-VL assembly 
Total RNA was isolated from the chicken spleen lymphocytes using GenElute™ Direct 
mRNA Miniprep Kit (Sigma, St. Louis, Missouri, USA), and cDNA was synthesised using 
both random hexamers and oligoDT primers using the SuperScript III Reverse Transcriptase 
(Invitrogen, Carlsbad, CA). VH and VL fragments were amplified with cloned Pfu Turbo DNA 
Polymerase AD (Agilent Technologies), using the primers indicated (Table 5.1; primers a – 
d) (GeneWorks, SA, Australia). Linker sequences (Gly4Ser)3 were incorporated into each of 





primer a and f for VH, and primer d and g for VL. A complete insert fragment of VH-linker-VL 
was produced through splicing by overlap extension (SOE) PCR using primers a and d 
(Horton et al. 1989; Huston et al. 1988; Sapats et al. 2003; Singh et al. 2010) (Table 5.1). To 
obtain enough scFv products, five products of VH-linker-VL were pooled, precipitated with 
ethanol and washed. All amplified products were visualized using 1.5% agarose gel 
electrophoresis run at 100V for 1 hr with 100 bp DNA marker (Axygen, CA, USA) for 
product size estimation. The approximate size for each primer pair amplification is shown in 
Table 5.1. PCR product purifications were done using either QIAquick PCR Purification kit 
(QIAGEN) or QIAGEN Gel Extraction Purification kit (QIAGEN).  
 
 Recombinant phagemid construction 
Generally, recombinant phagemid construction was done according to the expression 
module/recombinant phage antibody system (RPAS) (Amersham Biosciences Inc., UK) with 
modifications. Briefly, vector phagemid pCANTAB5E was cultured overnight in 2YT broth 
(16 g/L bacto-tryptone, 10 g/L Bacto-yeast extract, 10 g/L NaCl) containing ampicillin 20 
µg/ml (Sigma) at 37°C with vigorous shaking at 250 rpm. Phagemid was then isolated using 
QIAprep Spin Miniprep kit (QIAGEN). Both the vector phagemid pCANTAB5E and the 
amplified insert fragment, VH-linker-VL were digested with SfiI at 50°C, and NotI enzymes at 
37°C, for three hours each. Digested products were visualized using 1.5% agarose gel 
electrophoresis and purified using QIAquick PCR Purification kit (QIAGEN) for the insert, 
and QIAGEN Gel Extraction Purification kit (QIAGEN) for the phagemid. Purified products 
were quantitated using the NanoDrop 1000 Spectrophotometer (Thermoscientific) with 
product’s purity was checked using sample absorbance ratio at 260 and 280 nm. Both purified 
products (the insert and the vector) must be at least 30 ng/µl at optical density (OD) 260 nm to 






The insert fragment were ligated into phagemid pCANTAB5E using Quick-Stick Ligase 
(Bioline, London, UK), transformed into competent E. coli TG1 cells and grown for 1 hr in 1 
ml 2YT broth at 37°C with shaking at 250 rpm. An aliquot of 250 µl of the culture 
(recombinant phagemid) was plated out on each 2YT plates (four 2YT plates in total) and left 
overnight at 37°C. Cell lawn contained recombinant phagemid on each 2YT plates were then 
scraped off and pooled into a new 5 ml 2YT broth containing 2% (w/v) glucose and 100 
µg/ml ampicillin (2YTG-A) and cultured overnight at 37°C with shaking at 250 rpm. Before 
these recombinant phagemid were stored at -20°C for further use, a loop-full of these culture 
were re-grown in a new 5 ml 2YTG-A for overnight at 37°C and 250 rpm. Recombinant 
phagemid were then isolated using QIAprep Spin Miniprep kit (QIAGEN) and all 
recombinant phagemid were confirmed for positive ligation using gene-specific primers 





Table 5.1. List of primers, the targeted region and the approximate product size in basepair (bp) used for the amplification of chicken VH and VL regions, as 
well as the primer used for linker (Gly4Ser)3 incorporation between the amplified genes to produce the scFv (insert). Positive phagemid and insert ligation 
was screened using vector specific primers (g and h) and gene-specific primers (a and d), while positive recombinant phages with insert was screened using 
the gene-specific primers.  
 
Primer Nucleotide sequence (5′ to 3′) Targeted region 
Approximate product 
size (bp) 
  Antibody library construction primers:   
a. HF-SfiI ATG TCT ATG GCC CAG CCG GCC GTG ACG TTG GAC G 
 VH   ~390 
b. HR-XbaI GAA CCG CCT CCA CCA TCT AGA GAG GAG ACG ATG ACT TCG G 
c. LF-SalI GGC GGT GGC GGG TCG ACA GCG CTG ACT CAG CCG TCC TCG 
VL ~350  
d. LR-NotI AGT TAC TGG AGC GGC CGC ACC TAG GAC GGT CAG GG 
e. Link1 GGT GGA GGC GGT TCA GGC GGA GGT GGC TCT 
Linker 
~400 (with primer d) 
f. Link2 CGA TCC GCC ACC GCC AGA GCC ACC TCC GCC TGA ~450 (with primer a) 
  Vector specific primers:   
g. S1F CAA CGT GAA AAA ATT ATT ATT CGC  
Insert-flanking region on 
vector 
 
h. S6R GGA GTA TGT CTT TTA AGT AAA TG 
~800 (with the presence of 
VH -linker-VL) 
 Gene specific primers:   
a. HF-SfiI ATG TCT ATG GCC CAG CCG GCC GTG ACG TTG GAC G Insert-flanking region ~750 (VH -linker-VL 












  Infection of VH-VL library with helper phage 
The positive recombinant phagemid cultures were further expanded into a 200 ml volume of 
2YTG-A by adding 2 ml of the overnight culture an incubated at 37°C with shaking at 250 
rpm until OD600 reached 0.6-0.7. A total of 2 ml of 1x10
12 pfu/ml helper phage M13KO7 
(NEB) were added to the exponentially grown recombinant phagemid and incubated at 37°C 
for at least 30 minutes before centrifuged at 4500 rpm (3200 g), 4°C for 30 minutes. Pellets 
were resuspended in 200 ml of 2YTG-A with 50 µg/ml kanamycin (Sigma) (2YTG-AK) and 
grown 16-20 hrs at 30°C and 250 rpm. These culture of recombinant bacteriophages (phages) 
were centrifuged at 4500 rpm (3200 g), 4°C for 30 minutes before its supernatant were 
filtered using 0.45 µM filter (Millipore) to remove cellular debris. The recombinant phages 
were precipitated using 1/5 vol of polyethyl glycol (PEG)/NaCl (20% PEG in 2.5 M NaCl) 
and incubated at 4°C for at least 2 hrs. Recombinant phages pellet were resuspended in 1x 
phosphate saline buffer (PBS, 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, 
pH 7.4) and precipitation were repeated for another two times before the final recombinant 
phage pellet were resuspended in 1xPBS and filtered using 0.45 µM filter (Millipore). All 
produced recombinant phages library were checked for their titre using the plaque formation 
assay. Only recombinant bacteriophages library of at least 1 x 1012 pfu/ml were proceed for 
biopanning.    
 
 Selection of reactive recombinant phages displaying scFv antibodies and phage 
rescue 
Biopanning of the recombinant phage displayed scFv library was done based on previous 
reports (Haque & Tonks 2012; Nimmagadda et al. 2012), with modifications. Briefly, M2e 
peptide (aa 2-17) (Abmart, Shanghai, China) (final concentration 10 µg/ml) was immobilized 
in a 25 cm2 cell culture flask using carbonate-bicarbonate buffer (pH 9) as the plate coating 
buffer and left at 4°C overnight. Flask was emptied and washed for three times using washing 





µl/mL of 10% NaN3) with 0.01% sodium azide at room temperature (RT) for 1 hr. Flask was 
emptied and washed for another three times using washing buffer before incubated with the 
recombinant phage library and blocking buffer (8:7 ratio) mixture for 2 hr at 37°C. After the 
flask was emptied, it was washed 10 times with PBS, and another 10 times washing with 
PBS-0.1% Tween20. Finally, the bound recombinant phages were eluted with 0.2 M HCl-
glycine pH 2.2 which were incubated at 37°C for 10 minutes. Eluted recombinant phages 
were added to an equal amount of neutralization buffer (1M Tris pH 9.1) and mixed well. The 
retrieved recombinant phages titre were checked and expanded through phage rescue.  
 
Preparation for phage rescue was done using an overnight culture of E. coli TG1 cells in 
2YTG medium at 37°C with shaking at 250 rpm. The TG1 cells culture were renewed by 
adding 1/100 vol of overnight culture into a new 2YT media with 100 µg/ml ampicillin and 
1% glucose which incubated at 37°C and 250 rpm, until OD600 reached 0.6-0.7. The 
retrieved recombinant phages were added to the exponentially grown TG1 cells and further 
incubated at 37°C with shaking at 250 rpm for 1 hr. This culture was centrifuged at 4500 rpm 
(3200 g) for 30 minutes before the pellet were resuspended in an equal volume of pre-warmed 
2YT media with 100 µg/ml ampicillin and 50 µg/ml kanamycin, and incubate overnight at 
30°C with shaking at 250 rpm. The rescued recombinant phages were precipitated using 
PEG/NaCl as described above and followed by a second and third biopanning and phage 
rescue. In the second and third biopanning, the number of washes were increased from 10 
times washing with PBS and 10 times washing with PBS-0.1% Tween20, to 20 times each 
washing buffer in the second biopanning round, and 30 times each washing buffer in the third 






 Screening for recombinant phages and confirmation of its binding specificity 
using M2e-ELISA 
Post-panning recombinant phages were screened for the correct insert size by first infecting an 
aliquot of the phages with TG1 cells as described above, where the phagemid were retrieved 
using miniprep kit before amplified using gene-specific primers (Table 5.1, primer a and d) 
and vector-specific primers (Table 5.1, primer g and h). Recombinant phagemid from the 
post-panning phages were then sent for sequencing to the Australian Genome Research 
Facility (AGRF) sequencing services (VIC, Australia, with Sanger sequencing using Applied 
Biosystems 3730 capillary sequencers using Big Dye Terminator (BDT) chemistry version 
3.1 (Applied Biosystems) and analysed for their encoded protein.  
 
Binding specificity of the post-panning recombinant phages were tested in duplicates using an 
indirect M2e-ELISA as described previously (Hasan, Ebrahimie, et al. 2016), utilising 
horseradish peroxidase (HRP) mouse anti-M13 antibodies (GE Healthcare, Sweden) as the 
secondary antibodies. Briefly, M2e peptides were diluted to a final concentration of 50 µg/ml 
with 0.1 M carbonate-bicarbonate buffer, pH 9.6 (0.1 Na2CO3, 0.1 M NaHCO3) to each well 
of 96-well flat bottom microtiter plates (Maxisorp, NUNC) and incubated overnight at 4°C. 
The coated plates were washed five times with PBS containing 0.05% Tween 20 (PBS-T) and 
blocked with PBS containing 2% w/v bovine serum albumin (BSA) at RT for 2 hrs. 
Recombinant phages were diluted in PBS containing 1% BSA and 0.05% Tween 20 (PBS-
BT) in a 4:5 ratio (phage:buffer) and blocked wells were washed for another five times with 
PBS-T. Diluted phages were added into the wells in three duplicates and incubated for 1 hr at 
RT before washed another five times with PBS-T. Anti-M13 HRP were diluted to 1:500 with 
PBS-BT and added to the wells, followed by incubation for 1 hr at RT. After washing, 
substrate solution [100 µg/ml of tetramethylbenzidine substrate (TMB), (Sigma, MO, USA) 
in citrate buffer pH 8 containing hydrogen peroxide (100 µl of 0.6% H2O2)] was added and 





M sulphuric acid). The optical density (OD) of each well was read at OD450 nm using the 
BioRad Benchmark Plus Microplate Reader (BioRad, Hercules, USA). Graph of the M2e-
ELISA readings was produced using GraphPad Prism® version 7.02.  
 
 Expression and purification of soluble scFv 
Soluble scFv was produced by transforming the recombinant phages pCANTAB5E-scFv into 
the non-suppressor E. coli strain HB2151 with 1 mM IPTG induction for overnight in 2YT 
medium. To obtain enough soluble scFv, four preparations of recombinant phages were 
pooled, expanded and precipitated as described above. Soluble scFv was isolated using 
osmotic shock (Liu et al. 2012; Nossal & Heppel 1966) and later purified using affinity 
column with Protein G HP SpinTrap (GE Healthcare, Sweden). Briefly, recombinant phages 
were infected into the exponentially grown HB2151 cells in 2YT with 2% glucose (2YTG) 
and incubated at 37°C for 1 hr. This culture were then centrifuged at 4500 rpm (3200 g) for 
30 minutes and resuspended in an equal amount of pre-warmed 2YT medium. A total of 500 
µl of this suspension was set aside to be used as control (non-induced scFv expression 
sample), while the rest of the samples were added with 1 mM isopropylthiogalactosidase 
(IPTG) for the induction of scFv expression. Culture was incubated at 30°C for overnight 
with shaking at 250 rpm. Culture was centrifuged at 4500 rpm (3200 g) for 30 minutes at 4°C 
and the pellet was resuspended in 50 ml ice cold 1X TES (0.2 M Tris/HCl, 0.5 M EDTA, 0.5 
M sucrose, pH 8.0) and mixed well. Immediately after, 75 ml ice cold 1/5 TES buffer was 
added to the mixture to induce a mild osmotic shock and incubated on ice for 30 minutes. 
This mixture was centrifuged as above and the supernatant was retrieved and incubated in ice 
for 20 minutes with gentle agitation before being centrifuged again. The supernatant 
containing the soluble scFv was collected and filtered through 0.45 µM filter (Milipore). The 
soluble scFv was desalted and concentrated using size exclusion columns Vivaspin 20 






Affinity purification was employed by cross-linking E tag monoclonal antibodies (E tag mAb) 
(Abmart, Shanghai) to the binding protein used in the column according to the manufacturer’s 
instructions (Protein G HP SpinTrap, GE Healthcare, Sweden). E tag mAb was prepared from 
hybridoma cells (Abmart, Shanghai) and checked for positive reactivity in duplicates using 
indirect ELISA with the E tag peptide and a protocol similar to M2e-ELISA as described 
previously (Hasan, Ebrahimie, et al. 2016). To ensure compatibility of protein binding used 
with the E tag antibodies, isotyping of the E tag antibodies was done using Pierce Rapid 
Isotyping Kits – Mouse (Thermo Scientific, USA).  
 
Briefly, protein purification using Protein G HP SpinTrap was done as the following. The 
SpinTrap column was equilibrated with 400 µl TBS (50 mM Tris, 150 mM NaCl, pH 7.5) to 
the column for three times. A total of 200 µl of capture protein (E tag mAb, 1.86 mg/ml), pH 
7 was added to the column (0.5 to 1.0 mg/ml in TBS) and fully suspended by manual 
inversion and incubation of slow, end-over-end mixing for 1 hr on the rotary tube mixer 
(Ratek, VIC, Australia). The column was centrifuged for 1 min at 150 x g to remove unbound 
antibody and washed by the addition of 400 µl TBS before another step of centrifugation. A 
total of 400 µl 200 mM triethanolamine, pH 8.9 (Sigma) was added to the column and 
centrifuged. Cross-linking was done by the addition of 400 µl of 500 mM dimethyl 
pimelimidate dihydrochloride (DMP) (Sigma) in 200 mM triethanolamine, pH 8.9 to the 
column and fully suspended by manual inversion, followed by incubation with slow, end-
over-end mixing for 1 hr on the rotary tube mixer. The mixture was centrifuged and washed 
with 400 µl TBS before another step of centrifugation. This cross-linked mixture was blocked 
by the addition of 400 µl ethanolamine (100 mM, pH 8.9) (Sigma) and manually mixed and 
incubated end-over-end on the rotary tube mixer for 30 minutes and centrifuged. Unbound 





and centrifugation at 150 x g for 1 minute. The column was washed for three times with the 
addition of 400 µl TBS and centrifugation. The targeted protein (soluble scFv), pH 7 was 
bound by the addition of 200 µl of soluble scFv in TBS to the column and mixed by manual 
inversion, followed by an end-over-end incubation on the rotary tube mixer for 1 hr. This 
mixture was washed for five times with wash buffer (TBS with 2M urea, pH 7.5) and 
centrifuged at 150 x g for 1 min. Finally, elution of bound antibodies was done by the 
addition of 200 µl of 0.1 M glycine-HCl, pH 2.7, mixed by inversion and centrifugation at 
1000 x g for 1 min. Purified soluble scFv was desalted and further concentrated to at least 10 
mg/ml of protein using size exclusion columns Vivaspin 20 (Sartorius, Germany).  
 
 Soluble scFv binding specificity in M2e-ELISA 
Binding specificity of the soluble scFv was tested in duplicates using an indirect M2e-ELISA 
as described previously (Hasan, Ebrahimie, et al. 2016), utilising anti-E tag mouse antibodies 
(Abmart, Shanghai, China) as the secondary antibodies. Briefly, M2e-ELISA for soluble scFv 
was done similar with the post-panning recombinant bacteriophages with differences in the 
following: M2e peptide was diluted to two final concentrations of 50 µg/ml and 100 µg/ml 
with 0.1 M carbonate-bicarbonate buffer, pH 9.6 (0.1 Na2CO3, 0.1 M NaHCO3). Soluble scFv 
was diluted in 1:20 v/v in PBS containing 1% BSA and 0.05% Tween 20 (PBS-BT), while 
anti-E tag antibodies was diluted in 1:10 v/v, also in PBS-BT. The optical density of each well 
was read at OD450 nm using the BioRad Benchmark Plus Microplate Reader (BioRad, 
Hercules, USA). Graph of the M2e-ELISA readings was also produced using GraphPad 
Prism® version 7.02. 
 
 Antibody visualization and Western blotting 
To visualise soluble scFv and phage displayed scFV anti-M2e antibodies, at least 100 µg/ml 





PAGE at 100V. These protein molecular weight were estimated by using the Novel® Sharp 
Pre-stained Protein Standard (Life Technologies), and the SDS-PAGE were stained using 
Coomassie Brilliant Blue stain. For Western blotting, soluble scFV anti-M2e antibodies was 
separated using 12% SDS-PAGE followed by transfer to a nitrocellulose membrane using 1X 
transfer buffer (0.2 M glycine, 0.025 M tris base, 0.2 L methanol (v/v) in 1L) at 100V. The 
membrane was firstly washed with PBS-BSA 2%-Tween 0.05% for three times before 
blocked using PBS-BSA 10% solution for 2 hrs. The blocked membrane was washed with 
PBS-BSA 2%-Tween 0.05% for another three times and incubated with the primary antibody 
(anti-E tag mouse antibodies) for 1 hr at RT. Again, the membrane was washed with PBS-
BSA 2%-Tween 0.05% for three times before the enzyme-conjugated secondary antibody 
(anti-mouse HRP antibodies) was added to the membrane and incubated for 1 hr at RT. 
Membrane was washed with PBS-BSA 2%-Tween 0.05% for another three times and 
developed using the 3,3′-Diaminobenzidine (DAB) tablet (Sigma) suspended in TBS buffer 
(0.05 M Tris, 0.15 M NaCl, pH 7.5) with hydrogen peroxide. Development of substrate was 
stopped after 10 minutes by washing the membrane in PBS and followed by washing in 
distilled water for three times. The membrane was dabbed dry with blotting paper and left to 
air dry. Western blotting for phage displayed scFV anti-M2e antibodies was also done as 
described above, with difference in its primary antibody (anti-M13 mouse antibodies). 
 
 Results 
 Selection of chicken sera PL80 for mRNA isolation 
Following a high M2e-end titer shown in an indirect M2e-based ELISA in a previous study 
(Hasan, Ebrahimie, et al. 2016), the spleen lymphocytes from PL80 was selected as the 






 Chicken phage display scFv library 
Amplification of VH and VL products showed an approximate size of 400 bp and 350 bp, 
respectively (Figure 5.1a). Incorporation of linker to obtain the full insert (VH-linker-VL) 
showed amplified products with the approximate sizes of 800 bp for product amplified with 
vector specific primers (S1F and S6R, Table 5.1) and 750 bp for product amplified using gene 
specific primers (HSfiI and LNotI, Table 1) (Figure 5.1b). This was again checked for selected 
individual clones after cloning of insert to the phagemid vector using the gene specific 
primers (a and d, Table 5.1), where positive inserts were observed from phagemid, with full 
and partial insert (the latter resulted from mixed colonies), as well as unsuccessful ligation 
product (Figure 5.1c). Screening for the insert size was again done from the phagemid of the 
post-panning (rescued) recombinant phages, where slight variation in the insert sizes was 
observable (Figure 5.1d).  
 
 Biopanning against M2e peptide and selection of M2e-specific chicken 
recombinant antibodies  
Recombinant phagemid clones which are positive (contain the VH-linker-VL) were then 
infected with the helper bacteriophages to enable the production of bacteriophages displaying 
anti-M2e scFv antibodies. Selection of these bacteriophages was done by repeated binding, 
washing and elution of the bound (reactive) bacteriophages to the immobilised M2e peptides 
on the surface of a culture flask. Rescued bacteriophages (post-panning bacteriophages) were 
then screened to ensure the isolation of specific anti-M2e antibodies. A total of 5 µl of the 
recombinant phages from each biopanning were PCR-screened for positive inserts containing 
linked VH and VL using primers a and d (Table 5.1, Figure 5.1d). Visualization of post-
panning positive bacteriophages using 12% SDS-PAGE and Coomassie Brilliant Blue stain 
stained revealed the expected protein bands of ~43 kDa, which was the expressed full-length 
scFv in comparison to the negative control bacteriophage without insert, pCANTAB5E 





antibodies was checked by indirect M2e ELISA using anti-M13 as the secondary antibodies. 
Eight selected recombinant phages pools with positive scFv anti-M2e antibodies gave 







Figure 5.1 DNA products from (a) amplified products of 1: VH (~400 bp) and 2: VL (~350 bp), (M: 100 bp marker), (b) amplified products of 3: VH-Linker-
VL combination after SOE PCR using vector specific primers (S1F and S6R primers, ~800 bp), and 4: VH-Linker-VL combination after SOE PCR using gene 
specific primers (HSfi and LNotI primers, ~750 bp (c) screening for VH-Linker-VL from bacterial colonies using gene specific primers, HF-SfiI and LR-NotI 
after ligation and cloning shows partial insert suspected of mixed colonies (5 and 7), the full insert (6 and 8), and unsuccessful ligate and clone product (9), 
(d) screening for VH-Linker-VL from individual rescued (post-panning) recombinant phages phagemid (~600-700 bp) (10). Slight differences in insert sizes 










Figure 5.2 (a) Selected post-panning recombinant phages displaying anti-M2e scFv antibodies stained with Coomassie Brilliant Blue (lane 1, 3 to 8) in 12% 
SDS-PAGE shows protein bands at ~43 kDa, in comparison with negative control pCANTAB5E without any insert (lane 2).  (b)  Comparison of native 








 Soluble antibodies showed positive reactivity with indirect M2e-ELISA 
Specificity of the soluble scFv anti-M2e antibodies was again checked using M2e-ELISA and 
findings showed OD450 nm reading of 0.2 for both soluble scFv with 100 µg/ml final 
concentration of the M2e peptide (Figure 5.4).  
 
 
Figure 5.3 Selected post-panning recombinant phages displaying M2e-reactive scFv (1x1012 
pfu/ml) reading at OD450 nm done in duplicates detected using M2e-based ELISA (50 µg/ml 
peptide) using anti-M13 HRP (1:500).  
 
 
Figure 5.4 Two separate pools of soluble scFv (S1 and S5) reactivity at OD450 nm detected 
using M2e-based ELISA (100 µg/ml and 50 µg/ml of M2e peptide), with anti-E tag antibodies 





 Anti-M2e scFv antibodies visualization and specificity in Western blotting 
To further evaluate the specificity of the M2e soluble scFv anti-M2e antibodies, SDS-PAGE 
and western blotting were conducted. All soluble scFv anti-M2e antibodies were subjected to 
12% SDS-PAGE and stained with the Coomassie Brilliant Blue stain for visualization of 
protein in SDS-PAGE. IPTG-induced soluble scFv anti-M2e antibodies expression 
comparison with the non-induced soluble scFv anti-M2e antibodies showed expressed 
proteins at ~43 kDa (Figure 5.5a), which were then desalted and concentrated using the size-
exclusion column (Figure 5.5b).  
 
All positive soluble scFV anti-M2e antibodies from four pools of recombinant bacteriophages 
were pooled together to increase scFv concentration and subjected to protein purification 
using Protein G HP SpinTrap (GE Healthcare) which targeted the affinity protein tag, E tag. 
Anti-E tag subclass was showed to be IgG3 (Figure 5.6), which known to have a relatively 
strong binding to the trapping protein G column. ELISA titer showed that the anti-E tag mAb 
at 1:20 dilution gave OD450 nm reading of more than 1.5 which suggested good reactivity 









Figure 5.5 Soluble scFv-1 and soluble scFv-5 culture supernatants were run on a SDS-PAGE following induction with IPTG and osmotic shock isolation. 
Protein marker (M) were located at both end sides of the gel. 1: Negative control – non-IPTG-induced, 2: Negative control – IPTG-induced, 3: scFv sAb-1 – 
non-IPTG-induced, 4: scFv sAb-1 – IPTG-induced, 5: scFv sAb-5 – non-IPTG-induced, 6: scFv sAb-5-IPTG-induced. The expected product of soluble scFv 
anti-M2e antibodies is observed at ~43 kDa. (b) Soluble scFv anti-M2e antibodies expression after desalted and concentrated using size exclusion columns to 









Figure 5.6 Anti-E tag isotyping test shows that it is IgG3 
which showed relatively strong binding to the binding 
protein G. Left panel: C – positive control; G1, G2a, G2b -  
mouse isotypes. Right panel: C – positive control; G3, A, 
M – mouse isotypes. Red line indicates positive reaction.  
 
 
Figure 5.7 Anti-E tag monoclonal antibodies reactivity at OD450 nm against E tag peptide (10 
µg/ml) in an indirect ELISA.  
 
Comparison of flow-through, washed and eluted solutions containing antibodies showed 
recovery of the targeted scFv of ~43 kDa in the washed solution instead of the eluted solution 
(Figure 5.8a). Further attempt to confirm the specificity of the isolated scFV anti-M2e 
antibodies was done through Western blotting of the phage displayed form of the scFV anti-
M2e antibodies. The targeted M2e scFv antibodies protein band was visible at ~43 kDa. 
Similar protein band was observed for the scFV anti-M2e antibodies tested with anti-M13 
HRP (Figure 5.8b). However, no visible protein band was observed for the soluble anti-M2e 







Figure 5.8 (a) Comparison of the flow through (FT) solution, wash (W) and eluted (E) soluble scFV anti-M2e antibodies during protein column purification 
shows recovery of the targeted protein (~43 kDa) in the washed solution; (b) Phage displayed scFV anti-M2e antibodies shows the targeted protein bands at 
~43 kDa in response to anti-M13 HRP (M1, M2, M3), while no visible protein bands are observable for soluble anti-M2e scFv development with anti-E tag 









 Analysis of the isolated chicken recombinant antibodies sequence (crAb) 
To identify the resulted antibodies composition for anti-M2e protein, the post-panning 
recombinant phages were screened for positive insert using PCR with the insert primers (SfiI 
and NotI). The amplified insert sequences which encoded the anti-M2e scFv from the pooled 
positive recombinant phages (crAb-19, -51, -64, -73, -80, -152) (Figure 5.3) were then 
purified and sent for sequencing, and produced an average of 249 amino acid (Figure 5.9). 
These crAbs sequences were then aligned and the complementarity determining region (CDR) 
of the VH and VL regions were identified to analyse the variation contributed by each crAb 
(Figure 5.9). Most amino acid variations can be observed at the CDR regions, especially at the 
heavy chain CDR (CDRH). It is noted that CDRH is responsible for 55.6% of the overall 
variation in the crAbs, in comparison to the light chain CDR (CDRL) region, with 42.9% 
(Table 5.2). Meanwhile, within the VH region, CDRH3 contributed the highest variation 
overall with 34.3% (CDRH3 variation (12)/total variation aa H and L (35)), and within the VL 
region, CDRL3 contributed 22.8% (CDRL3 variation (8)/total variation aa H and L (35)). It 
was noted that two types of modifications were observed for the linker sequence in 
comparison to the original linker sequence. One being the deleted linker repeat (one of three 
linker repeats), while another was the substitution of glycine (G) to cysteine (C) in one of the 







Table 5.2. Variation percentage calculation per complementarity determining region (CDR), 
per chain (heavy and light) and overall variation observed in percentage. Calculations were 
done as follows: variation aa = (variation aa/total aa)*100; variation per chain = (total 
variation aa for H OR L /overall total aa for H OR L)*100, accordingly; overall variation = 
(total variation for each chain/total aa for H AND L)*100. 
 




per chain (H/L) Overall 
H CDRH2 18 8 (44.4) 40.0 55.6 
CDRH3 18 12 (70.6) 60.0  
Subtotal 36 20 100.0  
L CDRL1 6 4 (66.7) 26.7 42.9 
CDRL2 9 3 (33.3) 20.0  
CDRL3 10 8 (80.0) 53.3  
Subtotal 25 15 100.0  








Figure 5.9 Amino acid sequence alignment of the anti-M2e scFv antibodies representatives. Sequences identical to the top-most sequences are indicated by 
dotted lines (.), while amino acid gaps are indicated by dash (-). Variable heavy (VH), linker, and variable light (VL) regions are indicated. Complementarity 
determining regions 1-3 (CDR1-CDR3) are indicated for both VH and VL chains (CDRH, CDRL). Flexible (Gly4Ser)3 is indicated with the blue shades, 
while the E tag is in green.  
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crAb19 1 CGGCCTCCAGACGCCCGGAGGACGCTCAGCCTCGTCTGTAAGGCCTCCGGGTTCACCTTCAGTGACCGTGGCATGGGCTGGGTGCGACAGGCGCCCGGCAAGGGGCTGGAGTGGATCGCTGGTATTGATGATGATGGTGGTAGCACATAC 150 crAb19
 M  G  W  V  R  Q  A  P  G  K  G  L  E  W  I  A  G  I  D  D  D  G  G  S  T  Y 
crAb51 1 ......................................C......................ACAGTTACTC....TT..............................C..A...G....AA....CTG.AG....A..A.---AG..... 147 crAb51
 M  F  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  S  I  C  S  D  S  R  A  Y 
crAb64 1 ......................................C....GT.................CAG.TTCAA....TT...................................TCG....A.T....A...C.......A...C....... 150 crAb64
 M  F  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  V  I  N  A  D  G  S  T  T  Y 
crAb73 1 ......................................C....G..................CAG.TTC.A....TT...................................TCG....A.T....A...C.......A...C....... 150 crAb73
 M  F  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  V  I  N  A  D  G  S  T  T  Y 
crAb80 1 ......................................C.......................CAGTTAC.......TG..................................TCG..................G....A..TA....GG. 150 crAb80
 M  V  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  G  I  D  D  G  G  S  Y  T  G 
crAb152 1 ......................................C.......................CAGTTACAA......T....................................G......C.GC..G.AG..G.A..A.---....GGA 147 crAb152
 M  G  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  A  A  G  S  G  S  S  T  G 
160 170 180 190 200 210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 151 TACGCGCCGGCGGTGAAGGGCCGTGCCATCATCTCGAGGGACAACGGGCAGAGCACAGTGAGGCTGCAGCTGAACAACCTCAGGGCTGAGGACACCGCCACCTACTACTGCGCCAAGGGTGCTTACAATTGTGGTAATTGTGGT------ 294 crAb19
 Y  A  P  A  V  K  G  R  A  I  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  Y  C  A  K  G  A  Y  N  C  G  N  C  G 
crAb51 148 ..T.G.T..A............A.....C.............G...............C......................................G........T.........A......AGTGG..A....TG.G..AACTCCTGT 297 crAb51
 Y  G  S  T  V  K  G  H  A  T  I  S  R  D  D  G  Q  S  T  A  R  L  Q  L  N  N  L  R  A  E  D  T  G  T  Y  F  C  A  K  G  A  S  G  Y  G  C  G  N  S  C 
crAb64 151 ....G.T.....................C.............................................................................T.............AA.GGT.G.CC.T...G.GC.TC.GCTT-- 298 crAb64
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  F  C  A  K  G  N  G  S  P  C  S  A  S  A 
crAb73 151 ....G.T.....................C.............................................................................T.............AA.GGT.G.CC.T.G.G.GC.TC.GCTT-- 298 crAb73
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  F  C  A  K  G  N  G  S  P  W  S  A  S  A 
crAb80 151 ....G.T.....................C....................................................................G..................AA.......TCT.G..TACTG.GC....TGGTGT 300 crAb80
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  G  T  Y  Y  C  A  K  S  A  Y  L  G  Y  C  A  G  W  C 
crAb152 148 ............................C.......................................................................................AA.....G.TGG.AT.T.G.G.GC.A-------- 289 crAb152
 Y  A  P  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  Y  C  A  K  S  A  D  G  I  W  S  A 
310 320 330 340 350 360 370 380 390 400 410 420 430 440 450
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 294 ------GCTGAGATCGACGCATGGGGCCACGGGACCGAAGTCATCGTCTCCTCTGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGCGCTGACTCAGCCGTCCTCAGTGTCAGCGAACCCGGGAGAAACCGTTGAG 438 crAb19
 A  E  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  E 
crAb51 298 GGTT---....T.........................................C...........................------------.....................G....G........A.....A...........CA.. 432 crAb51
 G  S  D  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  P  G  E  T  V  K 
crAb64 298 -------AC.GT........................A................C...............T...........------------....................A.....G........A.....A...........CA.. 429 crAb64
 Y  G  I  D  A  W  G  H  G  T  K  V  I  V  S  S  G  G  G  G  S  C  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  K 
crAb73 298 -------AC.GT.........................................C...........................------------....................A.....G........A.....A...........CA.. 429 crAb73
 Y  G  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  K 
crAb80 301 GGTTGT.A.ACC.........................................C............................................................G....G........A....T.....G......CA.. 450 crAb80
 G  C  D  T  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  L  G  G  T  V  K 
crAb152 289 -------A.A.A.........................................C............................................................G....G........A.................CA.. 432 crAb152
 N  K  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  P  G  E  T  V  K 
460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 439 ATCACCTGCTCCGGGGGTTACAGCG---------------AC---TATGGCTGGTTCCAGCAGAAGTCACCTGGCAGTGCCCCTGTCACTGTGATCTATTACAACGACAAGAGACCCTCGGACATCCCTTCACGATTCTCCGGTTCCAAA 570 crAb19
 I  T  C  S  G  G  Y  S  D  Y  G  W  F  Q  Q  K  S  P  G  S  A  P  V  T  V  I  Y  Y  N  D  K  R  P  S  D  I  P  S  R  F  S  G  S  K 
crAb51 433 ..................AGTG..AGGTTTGCTGGAAGTT..TAT..........A..........G................................A.....A....C.........A..........G............G..CTG 582 crAb51
 I  T  C  S  G  G  S  G  R  F  A  G  S  Y  Y  Y  G  W  Y  Q  Q  K  A  P  G  S  A  P  V  T  V  I  Y  N  N  N  N  R  P  S  N  I  P  S  R  F  S  G  A  L 
crAb64 430 ..................AGTG..A---------------G.---..........AT.................................C.............................A...........................C. 561 crAb64
 I T  C  S  G G  S  G  S  Y  G  W  Y  Q  Q  K  S  P  G  S  A  P  V  T  L  I  Y  Y  N  D  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
crAb73 430 ..................AGTG..A---------------G.---..........AT.................................C.............................A...........................C. 561 crAb73
 I  T  C  S  G  G  S  G  S  Y  G  W  Y  Q  Q  K  S  P  G  S  A  P  V  T  L  I  Y  Y  N  D  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
crAb80 451 ...............A..AGTG..A---------------..AAC..........AT.....T........................................................A.............................. 585 crAb80
 I  T  C  S  G  S  S  G  N  N  Y  G  W  Y  Q  H  K  S  P  G  S  A  P  V  T  V  I  Y  Y  N  D  K  R  P  S  D  I  P  S  R  F  S  G  S  K 
crAb152 433 ...............A..AGTG..A---------------G.---.......................T.............T............G.C.G.-...--.............A...........................C. 561 crAb152
 I  T  C  S  G  S  S  G  S  Y  G  W  F  Q  Q  K  S  P  G  S  A  L  V  T  V  M  S  E  T  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
610 620 630 640 650 660 670 680 690 700 710 720 730 740 750
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 571 TCCGGCTCCACAGCCACATTAACCATCACTGGGGTCCAAGCCGAGGACGAGGCTGTCTATTACTGTGGGAGTGCAGACAGCAACTATGCTGGTATTTTTGGGACCGGGACTACCCTGACCGTCCTAGGTGCGGCCGCAGGTGCGCCGGTG 720 crAb19
 S  G  S  T  A  T  L  T  I  T  G  V  Q  A  E  D  E  A  V  Y  Y  C  G  S  A  D  S  N  Y  A  G  I  F  G  T  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb51 583 ............AA.......................G.......................T.........CTGG.......G---.........A......G.......A....................................... 729 crAb51
 S  G  S  T  N  T  L  T  I  T  G  V  R  A  E  D  E  A  V  Y  F  C  G  S  W  D  S  S  A  G  I  F  G  A  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb64 562 ............AG..............................C................T.......G.CTAC..AG...C.AC.AG......A......G..A....A....................................... 711 crAb64
 S  G  S  T  S  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  G  Y  E  G  T  T  S  G  I  F  G  A  R  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb73 562 ............AG..............................C................T.......G.CTAC..AG...C.AC.AG......A......G..A....A....................................... 711 crAb73
 S  G  S  T  S  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  G  Y  E  G  T  T  S  G  I  F  G  A  R  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb80 586 ...........G.G..............................C................T.........CA.........G.....T......A......G.......A....................TA................. 735 crAb80
 S  G  S  T  G  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  S  T  D  S  S  Y  V  G  I  F  G  A  G  T  T  L  T  V  L  G  A  T  A  G  A  P  V 
crAb152 562 ..T.....................................T....................T......TG.CTTC.G.....CTG..A...C...A......G.......A....................................... 711 crAb152
 S  G  S  T  A  T  L  T  I  T  G  V  Q  V  E  D  E  A  V  Y  F  C  G  G  F  G  S  T  D  T  A  I  F  G  A  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
760 770
. . . . | . . . . | . . . . | . . . . | . . . . | . .
crAb19 721 CCGTATCCGGATCCGCTGGAACCGCGT 747                                                                                                                            crAb19
 P  Y  P  D  P  L  E  P  R 
crAb51 730 ........................... 756                                                                                                                            crAb51
 P  Y  P  D  P  L  E  P  R 
crAb64 712 ........................... 738                                                                                                                            crAb64
 P  Y  P  D  P  L  E  P  R 
crAb73 712 ........................... 738                                                                                                                            crAb73
 P  Y  P  D  P  L  E  P  R 
crAb80 736 ........................... 762                                                                                                                            crAb80
 P  Y  P  D  P  L  E  P  R 
crAb152 712 ........................... 738                                                                                                                            crAb152













Figure 5.9. Continued.   
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crAb19 1 CGGCCTCCAGACGCCCGGAGGACGCTCAGCCTCGTCTGTAAGGCCTCCGGGTTCACCTTCAGTGACCGTGGCATGGGCTGGGTGCGACAGGCGCCCGGCAAGGGGCTGGAGTGGATCGCTGGTATTGATGATGATGGTGGTAGCACATAC 150 crAb19
 M  G  W  V  R  Q  A  P  G  K  G  L  E  W  I  A  G  I  D  D  D  G  G  S  T  Y 
crAb51 1 ......................................C......................ACAGTTACTC....TT..............................C..A...G....AA....CTG.AG....A..A.---AG..... 147 crAb51
 M  F  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  S  I  C  S  D  S  R  A  Y 
crAb64 1 ......................................C....GT.................CAG.TTCAA....TT...................................TCG....A.T....A...C.......A...C....... 150 crAb64
 M  F  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  V  I  N  A  D  G  S  T  T  Y 
crAb73 1 ......................................C....G..................CAG.TTC.A....TT...................................TCG....A.T....A...C.......A...C....... 150 crAb73
 M  F  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  V  I  N  A  D  G  S  T  T  Y 
crAb80 1 ......................................C.......................CAGTTAC.......TG..................................TCG..................G....A..TA....GG. 150 crAb80
 M  V  W  V  R  Q  A  P  G  K  G  L  E  F  V  A  G  I  D  D  G  G  S  Y  T  G 
crAb152 1 ......................................C.......................CAGTTACAA......T....................................G......C.GC..G.AG..G.A..A.---....GGA 147 crAb152
 M  G  W  V  R  Q  A  P  G  K  G  L  E  W  V  A  A  A  G  S  G  S  S  T  G 
160 170 180 190 200 210 220 230 240 250 260 270 280 290 300
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 151 TACGCGCCGGCGGTGAAGGGCCGTGCCATCATCTCGAGGGACAACGGGCAGAGCACAGTGAGGCTGCAGCTGAACAACCTCAGGGCTGAGGACACCGCCACCTACTACTGCGCCAAGGGTGCTTACAATTGTGGTAATTGTGGT------ 294 crAb19
 Y  A  P  A  V  K  G  R  A  I  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  Y  C  A  K  G  A  Y  N  C  G  N  C  G 
crAb51 148 ..T.G.T..A............A.....C.............G...............C......................................G........T.........A......AGTGG..A....TG.G..AACTCCTGT 297 crAb51
 Y  G  S  T  V  K  G  H  A  T  I  S  R  D  D  G  Q  S  T  A  R  L  Q  L  N  N  L  R  A  E  D  T  G  T  Y  F  C  A  K  G  A  S  G  Y  G  C  G  N  S  C 
crAb64 151 ....G.T.....................C.............................................................................T.............AA.GGT.G.CC.T...G.GC.TC.GCTT-- 298 crAb64
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  F  C  A  K  G  N  G  S  P  C  S  A  S  A 
crAb73 151 ....G.T.....................C.............................................................................T.............AA.GGT.G.CC.T.G.G.GC.TC.GCTT-- 298 crAb73
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  F  C  A  K  G  N  G  S  P  W  S  A  S  A 
crAb80 151 ....G.T.....................C....................................................................G..................AA.......TCT.G..TACTG.GC....TGGTGT 300 crAb80
 Y  G  S  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  G  T  Y  Y  C  A  K  S  A  Y  L  G  Y  C  A  G  W  C 
crAb152 148 ............................C.......................................................................................AA.....G.TGG.AT.T.G.G.GC.A-------- 289 crAb152
 Y  A  P  A  V  K  G  R  A  T  I  S  R  D  N  G  Q  S  T  V  R  L  Q  L  N  N  L  R  A  E  D  T  A  T  Y  Y  C  A  K  S  A  D  G  I  W  S  A 
310 320 330 340 350 360 370 380 390 400 410 420 430 440 450
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 294 ------GCTGAGATCGACGCATGGGGCCACGGGACCGAAGTCATCGTCTCCTCTGGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGCGCTGACTCAGCCGTCCTCAGTGTCAGCGAACCCGGGAGAAACCGTTGAG 438 crAb19
 A  E  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  E 
crAb51 298 GGTT---....T.........................................C...........................------------.....................G....G........A.....A...........CA.. 432 crAb51
 G  S  D  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  P  G  E  T  V  K 
crAb64 298 -------AC.GT........................A................C...............T...........------------....................A.....G........A.....A...........CA.. 429 crAb64
 Y  G  I  D  A  W  G  H  G  T  K  V  I  V  S  S  G  G  G  G  S  C  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  K 
crAb73 298 -------AC.GT.........................................C...........................------------....................A.....G........A.....A...........CA.. 429 crAb73
 Y  G  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  G  S  A  L  T  Q  P  S  S  V  S  A  N  P  G  E  T  V  K 
crAb80 301 GGTTGT.A.ACC.........................................C............................................................G....G........A....T.....G......CA.. 450 crAb80
 G  C  D  T  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  L  G  G  T  V  K 
crAb152 289 -------A.A.A.........................................C............................................................G....G........A.................CA.. 432 crAb152
 N  K  I  D  A  W  G  H  G  T  E  V  I  V  S  S  G  G  G  G  S  G  G  G  G  S  G  G  G  G  S  A  L  T  Q  P  A  S  V  S  A  N  P  G  E  T  V  K 
460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 439 ATCACCTGCTCCGGGGGTTACAGCG---------------AC---TATGGCTGGTTCCAGCAGAAGTCACCTGGCAGTGCCCCTGTCACTGTGATCTATTACAACGACAAGAGACCCTCGGACATCCCTTCACGATTCTCCGGTTCCAAA 570 crAb19
 I  T  C  S  G  G  Y  S  D  Y  G  W  F  Q  Q  K  S  P  G  S  A  P  V  T  V  I  Y  Y  N  D  K  R  P  S  D  I  P  S  R  F  S  G  S  K 
crAb51 433 ..................AGTG..AGGTTTGCTGGAAGTT..TAT..........A..........G................................A.....A....C.........A..........G............G..CTG 582 crAb51
 I  T  C  S  G  G  S  G  R  F  A  G  S  Y  Y  Y  G  W  Y  Q  Q  K  A  P  G  S  A  P  V  T  V  I  Y  N  N  N  N  R  P  S  N  I  P  S  R  F  S  G  A  L 
crAb64 430 ..................AGTG..A---------------G.---..........AT.................................C.............................A...........................C. 561 crAb64
 I  T  C  S  G  G  S  G  S  Y  G  W  Y  Q  Q  K  S  P  G  S  A  P  V  T  L  I  Y  Y  N  D  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
crAb73 430 ..................AGTG..A---------------G.---..........AT.................................C.............................A...........................C. 561 crAb73
 I  T  C  S  G  G  S  G  S  Y  G  W  Y  Q  Q  K  S  P  G  S  A  P  V  T  L  I  Y  Y  N  D  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
crAb80 451 ...............A..AGTG..A---------------..AAC..........AT.....T........................................................A.............................. 585 crAb80
 I  T  C  S  G  S  S  G  N  N  Y  G  W  Y  Q  H  K  S  P  G  S  A  P  V  T  V  I  Y  Y  N  D  K  R  P  S  D  I  P  S  R  F  S  G  S  K 
crAb152 433 ...............A..AGTG..A---------------G.---.......................T.............T............G.C.G.-...--.............A...........................C. 561 crAb152
 I  T  C  S  G  S  S  G  S  Y  G  W  F  Q  Q  K  S  P  G  S  A  L  V  T  V  M  S  E  T  K  R  P  S  N  I  P  S  R  F  S  G  S  T 
610 620 630 640 650 660 670 680 690 700 710 720 730 740 750
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
crAb19 571 TCCGGCTCCACAGCCACATTAACCATCACTGGGGTCCAAGCCGAGGACGAGGCTGTCTATTACTGTGGGAGTGCAGACAGCAACTATGCTGGTATTTTTGGGACCGGGACTACCCTGACCGTCCTAGGTGCGGCCGCAGGTGCGCCGGTG 720 crAb19
 S  G  S  T  A  T  L  T  I  T  G  V  Q  A  E  D  E  A  V  Y  Y  C  G  S  A  D  S  N  Y  A  G  I  F  G  T  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb51 583 ............AA.......................G.......................T.........CTGG.......G---.........A......G.......A....................................... 729 crAb51
 S  G  S  T  N  T  L  T  I  T  G  V  R  A  E  D  E  A  V  Y  F  C  G  S  W  D  S  S  A  G  I  F  G  A  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb64 562 ............AG..............................C................T.......G.CTAC..AG...C.AC.AG......A......G..A....A....................................... 711 crAb64
 S  G  S  T  S  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  G  Y  E  G  T  T  S  G  I  F  G  A  R  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb73 562 ............AG..............................C................T.......G.CTAC..AG...C.AC.AG......A......G..A....A....................................... 711 crAb73
 S  G  S  T  S  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  G  Y  E  G  T  T  S  G  I  F  G  A  R  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
crAb80 586 ...........G.G..............................C................T.........CA.........G.....T......A......G.......A....................TA................. 735 crAb80
 S  G  S  T  G  T  L  T  I  T  G  V  Q  A  D  D  E  A  V  Y  F  C  G  S  T  D  S  S  Y  V  G  I  F  G  A  G  T  T  L  T  V  L  G  A  T  A  G  A  P  V 
crAb152 562 ..T.....................................T....................T......TG.CTTC.G.....CTG..A...C...A......G.......A....................................... 711 crAb152
 S  G  S  T  A  T  L  T  I  T  G  V  Q  V  E  D  E  A  V  Y  F  C  G  G  F  G  S  T  D  T  A  I  F  G  A  G  T  T  L  T  V  L  G  A  A  A  G  A  P  V 
760 770
. . . . | . . . . | . . . . | . . . . | . . . . | . .
crAb19 721 CCGTATCCGGATCCGCTGGAACCGCGT 747                                                                                                                            crAb19
 P  Y  P  D  P  L  E  P  R 
crAb51 730 ........................... 756                                                                                                                            crAb51
 P  Y  P  D  P  L  E  P  R 
crAb64 712 ........................... 738                                                                                                                            crAb64
 P  Y  P  D  P  L  E  P  R 
crAb73 712 ........................... 738                                                                                                                            crAb73
 P  Y  P  D  P  L  E  P  R 
crAb80 736 ........................... 762                                                                                                                            crAb80
 P  Y  P  D  P  L  E  P  R 
crAb152 712 ........................... 738                                                                                                                            crAb152
 P  Y  P  D  P  L  E  P  R 
CDRL1 CDRL2 







We described here the construction, expression, purification and immunological 
characterization of reactive scFV anti-M2e antibodies (scFv) in investigation of its use as the 
basis for diagnostic tool in AIV sero-surveillance study in H5N1 enzootic countries. To our 
knowledge, this study is the first attempt in isolating avian origin, recombinant anti-M2e 
antibodies in scFv form.  
 
The M2e-indirect ELISA results showed that the isolated scFV anti-M2e antibodies bind 
M2e, following purification of the soluble form of the antibodies. M2e protein itself has a low 
antigenicity due to its small size (Johansson, Moran & Kilbourne 1987) and relatively low 
density on the surface of the virus particle in comparison to the other surface proteins, namely 
hemagglutinin and neuraminidase (Feng et al. 2006).  A potential advantage of the phage 
display system is that four or five copies of the protein product of an introduced gene can be 
displayed on the pIII part of the bacteriophage (Bazan, Calkosinski & Gamian 2012; Huang et 
al. 2005; Smith 1993). In the case of scFv anti-M2e, this might lead to enhanced antigen 
binding ability.  Indeed, others have shown that a dimer form of scFv, e.g scFv anti-mycelia 
for pathogenic fungus Sclerotinia sclerotiorum had better antigen binding than the monomeric 
form (Yajima et al. 2008). Low quantity yield of the purified anti-M2e scFv from this study 
may have been related to the binding capacity of the tag protein used in the scFv purification 
in relation to the scFv linker. This was suggested as the targeted anti-M2e scFv was expressed 
in its soluble form but not detected in the Western blotting. 
 
 Minimal detectability of the tag protein and low yield in both Western blotting 
and protein purification 
Relatively low concentration of the scFV anti-M2e antibodies was retrieved after column 
purification (Figure 5.8a), despite the high intensity of the protein bands observed after 





observed in ELISA for both phage displayed and soluble forms of the anti-M2e scFV 
antibodies. It was observed that the anti-M2e scFv (~43 kDa) was retrieved in the washed 
solution (Figure 5.8a), which indirectly indicated the anti-E tag antibody poorly able to 
capture the E tag-tagged anti-M2e scFv antibodies during affinity column purification. 
Therefore, it is assumed that the low yield of the anti-M2e scFv may be related to either 
biological or physical factors, or possibly both. For example, impaired binding of anti-E tag 
antibodies to the targeted crAbs, or the non-optimal condition during purification may led to 
such outcome. Generally, according to the manufacturer, antibodies with isotype IgG3 (anti-E 
tag antibodies) are known to have high binding compatibility with the protein G, the binding 
protein used for purification. Hence, compatibility between the tag protein antibodies and the 
binding protein is presumably not a problem.    
  
Next, the ability of the anti-E tag antibodies to capture the expressed E tag protein at the C-
terminal of the scFV anti-M2e antibodies is in question. Ability of anti-E tag antibodies to 
bind to E tag peptides has been demonstrated prior to its application (Figure 5.7). This 
verified reactivity of the anti-E tag antibodies employed to capture the expressed E tag in the 
affinity column. An alternative explanation for this problem might be the poor accessibility of 
the E tag on the scFv anti-M2e antibody. This assumption is further suggested with the 
absence of the targeted protein bands in the Western blotting for the phage displayed scFV 
anti-M2e antibodies (Figure 5.8b). 
 
Tag proteins can play a significant role in the isolation of the purified protein. In this study, E 
tag tag protein has been employed as it has shown to be an effectively functional tag protein 
in previous studies (Abdelkader & Rifaat 2007; Bjerketorp et al. 2004; Wall et al. 2003). 
Small size of the E tag is desirable since theoretically it will not interfere with the targeted 





isolated scFv or low intrinsic affinity when the scFv is not in its phage displayed form 
contributed to the low protein yield in current  study (van Wyngaardt et al. 2004). This relates 
to the cooperative effect of the copies of scFv expressed on the surface of the bacteriophage, 
which explains the higher intensity detection in ELISA (Sapats et al. 2003).  
  
Gly-Ser linker plays an important role in holding the scFv conformation, imitating a natural 
antibody. Sequence analysis on the isolated scFv anti-M2e antibodies showed a shortened 
linker sequence in three of the six representatives obtained for the anti-M2e scFv antibodies 
(Figure 5.9). Changes in its amino acid was also observed in one of the scFv, where it include 
a shift of glycine (G) to cysteine (C) (Figure 5.9). It was observed in previous study that a 
shift from G to serine (S) and vice versa was noted, and this did not significantly affected the  
stability and flexibility of the linker since the scFv anti-M2e antibodies were still detectable in 
the ELISA (Finlay et al. 2006). Changes from G to C was relatively unusual, with no known 
effects. Although the changes in the linker sequences does not affect the reactivity of the scFv 
itself, position of the E tag protein at the C-terminal of the anti-M2e scFv antibodies may 
have been partially concealed and poorly accessible to anti-E tag antibodies at the scFv final 
conformation. This was later showed in the purified protein yield, where only a low amount 
of the tagged scFv anti-M2e antibodies were isolated. Further study is needed to confirm this 
assumption.  
 
 M2e-cRABs reactivity and the initial diversity of antibody library  
In our study, the antibodies were derived from immunized birds which showed high reactivity 
for anti-M2e antibodies. Thus, it is a reasonable assumption that antibody libraries generated 
from immunized bird would be highly specific and possess a high quality pool of the targeted 
antibodies. Previous studies had well documented that the VH region, especially the 





interaction (Boder, Midelfort & Wittrup 2000; Fermer et al. 2004; Kabat & Wu 1991). This 
was evidenced by the higher mutation rate in this region in comparison to the others (Boder, 
Midelfort & Wittrup 2000; Chowdhury & Pastan 1999; Finlay et al. 2006). More than a 1000-
fold increase rate of association in monovalent ligand-binding affinity showed to accompany 
higher mutation rates in the VH CDR3 region (Boder, Midelfort & Wittrup 2000), while better 
affinity was observed with increased amino acid length in both VH and VL CDR3 regions 
(Finlay et al. 2006). Also, improvement in anti-mesothelin scFv binding ability of 15- to 55- 
fold observed to be contributed by random mutations in the VL CDR3 region (Chowdhury & 
Pastan 1999). Other findings suggested that the VL region is also important in determining the 
specificity and affinity of the isolated antibodies (Hoet et al. 1999; Jang & Sanford 2001; 
Sapats et al. 2003), where one study isolated a clone which lack entire  VH  region but still 
capable of binding to the antigen (van Wyngaardt et al. 2004). These are in agreement with 
our isolated anti-M2e scFv antibodies, where high variability of amino acid observed in both 
VH and VL CDR3 regions of the reactive clones. Isolation of six reactive anti-M2e scFv 
representative clones which resulted from a pooled library of recombinant phages may not be 
able to represent the actual diversity of the anti-M2e scFv library constructed in this study. It 
is likely that these representatives were the most dominant clones within the pooled reactive 
clones to the M2e antigen. Nevertheless, these anti-M2e scFv clones have provided an insight 
on the diversity demonstrated by the dominant reactive clones isolated from the high quality 
pool of the targeted antibodies.  
 
 Conclusion and Recommendations 
This work can be further improved by employing different types of tag protein such as His-
tag or FLAG (Kirsch et al. 2005; McCafferty et al. 1994). Compatibility of the tag protein and 
the vector used in this study may also need to be considered. It is noted that scFv expression 





Soltes et al. 2007). For example, expression of scFv may be increased by subcloning it into a 
highly efficient expression system such as pBV220 (Yang et al. 2011). Selection of the helper 
phage used in complement with a vector of optimal compatibility may contributed to the 
isolation of better quality antibodies (Baek et al. 2002; Soltes et al. 2007). For instance, 
KM13 is suggested to perform better than M13K07 as the former showed high discriminatory 
power manifested by the lower number of eluted phage from the first selection round (Goletz 
et al. 2002).  
 
Phage display technology is an effective way to isolate pure protein with carefully optimized 
methods and experience. However, it is rather a long and tedious approach as it is time and 
energy consuming. As a conclusion, this study has successfully isolated phage displayed and 
soluble scFV anti-M2e antibodies with high reactivity against the AIV-M2e antigen. Based on 
these, an H5N1 serosurveillance test based on the anti-M2e scFv antibodies seems promising. 
Further enrichment and purification of the isolated scFv anti-M2e antibodies is recommended 
for development of a diagnostic tool which is capable of rapid AIV serosurveillance and 
DIVA application to prevent further outbreak, especially in H5N1 enzootic countries.  
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 General discussions 
Overall, this study has demonstrated the promising potential of the AIV M2e protein as the 
target for diagnostic tool application for AIV infection surveillance. In H5N1 enzootic 
countries where vaccination using the inactivated AIV virus are practiced, a diagnostic tool 
with DIVA capability is highly of interest. Indirect M2e-ELISA is proven to be economical 
with high-throughput capacity, apart from sensitive and specific for AIV infection 
surveillance. As AIV is a multispecies agent (Chambers, Dubovi & Donis 2013), availability 
of a more universal test format such as competitive ELISA is ideal. However, the key factor 
for such universality lies on the ability of the competitor antibody to demonstrate cross-
reactivity in multiple species, as previous findings do observed slight variations of antibodies 
to the same antigen in different species (Almagro 2004; Darnule et al. 1980; Rotter et al. 
1983). Identification of the best anti-M2e antibodies source which can be used as the 
competitor antibodies has brought the success on characterization of the dominant epitope of 
AIV M2e protein from mouse, rabbit and chicken anti-M2e antibodies.  
 
Overlapping of recognised M2e epitopes has been observed across literatures on M2e protein 
studies, which is in agreement with findings from this study (De Filette et al. 2011; Fu et al. 
2009; Grandea III et al. 2010; Liu, W, Li & Chen 2003; Liu, W, Zou & Chen 2004; Pejoski et 
al. 2010; Wang et al. 2009; Zabedee & Lamb 1988; Zhang et al. 2006; Zharikova et al. 2005; 
Zou, Liu & Chen 2005). Generally, we agrees that epitope 6EVETPTRN13 is the dominant 
epitope for the M2e protein. However, this study suggested that rabbit and chicken anti-M2e 
antibodies showed a slightly different preferences in its epitope. This indicated that different 
animal species may produce similar antibodies to the same antigen, but with fine difference in 
epitope recognitions, as observed previously (Hjelm et al. 2012). This knowledge is important 
especially for diagnostic test development and vaccine development where caution should be 





the possibility of using rabbit anti-M2e antibodies as the candidate for an M2e-based 
competitive ELISA development.  
 
Findings from the M2e protein antigenic mapping has brought the attempt on the 
development of a competitive ELISA based on M2e protein for AIV infection screening. As 
noted earlier, competitive ELISA-based diagnostic tool is highly attractive due to its potential 
on multispecies applicability (Starick et al. 2006; Zhou et al. 1998). This is especially for a 
multiple host pathogen, as a competitive ELISA-based tool will remove the needs for species-
specific secondary antibodies. Our findings demonstrated the ability of a mouse monoclonal 
anti-M2e antibodies to be used as the competitor antibodies in the M2e-based competitive 
ELISA. It also showed the M2e protein ability in differentiating between infected and 
vaccinated-only animal sera, as noted in previous works using M2e protein in an indirect 
ELISA-based approach (Hadifar et al. 2014; Hemmatzadeh et al. 2013; Kim et al. 2010; 
Lambrecht et al. 2007; Tarigan et al. 2015). This finding is significant as the presented 
competitive M2e-ELISA showed high specificity and sensitivity to AIV infection which can 
be developed to a full in the field diagnostic tools.  
 
Studies showed that antibodies in a scFv format also possess high sensitivity and specificity 
for pathogen antigen detection (Chen et al. 2014; Nimmagadda et al. 2012). Therefore, this 
study has successfully isolated the scFv form of the anti-M2e antibodies from H5N1 
immunised chicken. The isolated anti-M2e scFv antibodies are highly reactive and specific in 
both of its recombinant phage form and soluble antibodies form. This is a critical achievement 
as this was the first attempt on the isolation of the anti-M2e scFv antibodies, considering the 
protein’s low immunogenicity. High affinity antibodies are highly desirable in its selection for 
further immunological based application. However, equally important are factors such as the 





proportionate to the diversity of the V-gene repertoire from the sample pool (Pansri et al. 
2009). Hence, enrichment of the targeted antibodies through the use of immunised donor as 
the source of immunoglobulin gene isolation coupled with the use of phage display 
technology is a significant approach to ensure such outcomes. 
 
It is acknowledged that this study is limited in terms of the individual species tested for the 
anti-M2e antibodies. Future studies which includes antibodies sourced from more animal 
species may provide additional clues on the intrinsic or extrinsic factors which may have 
influenced such differences between the epitope recognised by the antibodies from different 
animal species. Although such differences may have been related to the nature of the 
immunogen itself, it may have been also dependant on the level of host animal exposure to 
the immunogen (Hjelm et al. 2012). As mouse has been used in most of the studies which 
discovered the M2e epitopes, the recognised epitopes must have been biased towards mouse 
antibodies, while it is not the natural host for AIV, as such is also the case for rabbit. 
Therefore, epitope recognised by chicken antibodies, the natural host for AIV shows more 
defined recognition for the M2e epitope. Nevertheless, further research is required to verify 
this assumptions.  
 
In this study, only chicken sera are available to be tested as its development is meant to be 
applied for the AIV infections surveillance in the vaccinated poultry industry. Nevertheless, it 
is noted that the question whether it is applicable for use in other species apart from chicken 
still remains. Previous study on duck challenge experiment using H5N1 indicated that the 
detectability of the M2e antibody level varies, and is likely dependent on the specificity of the 
antigen used in an indirect ELISA (Lambrecht et al. 2007). It is important to keep in mind that 
for optimum vaccination system in duck, factors that needs serious consideration includes the 





as well as the synergies between co-infecting pathogens (Pantin-Jackwood & Suarez 2013). 
Further study which includes four types of sera (non-vaccinated and non-challenged sera, 
vaccinated only sera, infected-only sera, and vaccinated-then-challenged sera) from a larger 
range of animal species will be able to provide answers. It will be interesting to see if the 
observed findings in this study for chicken, which is a domestic poultry, will be resonated 
when the same test is to be tested using wild bird’s sera.   
 
Although indisputably reactive to the M2e antigen, these anti-M2e scFv antibodies shows 
minimal detectability in the Western blotting. This may be related with the final conformation 
of the anti-M2e scFv antibodies in different conditions, such as in an ELISA system, and 
immobilised on a nitrocellulose membrane during Western blotting. It is noted that different 
expression detection system may results different behaviour of the antibody as noted in 
previous studies (Sapats et al. 2003; Van Wyngaardt & Du Plessis 1998), although this was 
not always true (Muller et al. 1997; Tikunova et al. 2001). Therefore, it would be interesting 
to explore if there are variations in the protein conformations through the prediction of the 3D 
structure of the isolated antibodies using x-ray crystallography or nuclear magnetic resonance 
approaches (Liu, G et al. 2005; Newby et al. 2009).  
 
ELISA are sometimes accompanied by lower analytical sensitivity and are limited to certain 
types of sample (Hoffmann et al. 2009). Therefore, alternatives technology such as real time 
PCR (RT-PCR) is one of the highly sorted option and the recommended technology in routine 
diagnostic work for microorganism infection detection in animal due to its convenience, 
sensitivity and rapidity (Vidanovic et al. 2016). RT-PCR approach is known to be capable of 
enabling epidemiological investigation of microorganism apart from its use for the 
microorganism identification and genotyping (Gwida et al. 2016). It has been highly used for 





fever, bluetongue disease, avian influenza and Newcastle disease (reviewed in Hoffmann et 
al. (2009).  
 
In consideration of DIVA application, RT-PCR is suitable for application in disease detection 
which the targeted gene or combination of gene is credible for differentiating wild-type and 
vaccine-type virus. Such observation was noted for the canine distemper virus (CDV) in dogs 
(Dong et al. 2014). Duplex RT-PCR employed primers specific to the highly conserved 
region of the CDV, and primers which are specific to the wild-type strain CDV. Different size 
of the amplified products was the indicator for the wild-type virus or vaccine strain genome 
(Dong et al. 2014). Another example was the targeted group-specific-antigen (gag gene) for 
the feline immunodeficiency virus (FIV) which has been demonstrated to be useful in 
differentiating between FIV-vaccinated and FIV-infected cats (Wang et al. 2010). Differently 
labelled probe for different FIV subtypes made the vaccine subtypes to be easily identified. 
Such application is doable for AIV infection detection, as AIV strain used as vaccine can be 
easily tagged and differentiated from the circulating AIV strain infecting the host.  
 
Another interesting approach is the multiple microsphere-based assay. It enables the detection 
of multiple analytes simultaneously through detection by antibodies coupled to different 
microsphere types (Powell et al. 2013; Wood, O'Halloran & VandeWoude 2011). This was 
done by internally dyeing the polystyrene microsphere with two or three distinct 
fluorochromes spectral, so that only unique fluorescence signature are emitted for each 
microsphere type (Dunbar & Hoffmeyer 2013). This technology also requires a reduced 
volume of sample to evaluate multiple antibodies, apart from being superior in detecting low 
level analyte in comparison with ELISA (Powell et al. 2013). Its ability to be multiplexed 
means that it can be used to detect multiple types of common virus infection in poultry at 





apart from influenza virus (Boodhoo et al. 2016; Bulbule et al. 2015; Coppo et al. 2013). A 
recent development of a microsphere-based assay for detection of antibody to influenza A and 
Newcastle disease viruses had shown high sensitivity (9.7% and 95.4%, respectively) and 
specificity (97.3% and 98.5%, respectively).  However, such improvement in sensitivity is 
also accompanied with reduced level of specificity, which means that false positive increased 
in comparison to ELISA (Powell et al. 2013), especially in detection of analytes at lower 
concentrations (Dossus et al. 2009; Elshal & McCoy 2006; Nifli et al. 2006).  
 
Nevertheless, these technologies are still costly to support surveillance works in a developing 
country, which made recombinant technology-based ELISA is still the best option at the 
moment. It is undeniable that emergence of new technologies will likely bring better options 
for DIVA purposes, and made the cost for RT-PCR and microsphere-based assay negligible. 
The RT-PCR would be one of the next best option in consideration of its sensitivity and 
rapidity for results. Meanwhile, multiple microsphere-based assay would be best in condition 
where multiple detection of different analytes in one individual is necessary or highly 
recommended for detection of multiple infections. In the end, what matter is which 
technology is sensitive and specific enough to detect virus infection during surveillance, with 
the ability to differentiate between antibodies due to virus infection and vaccination (DIVA), 
and at the same time is easily accessible and economic for a big scale recurring applications. 
 
 Conclusions 
In conclusion, this study has successfully accomplished three tasks, namely (i) identified the 
most reactive epitope for the M2e protein by mapping the M2e antigen, while (ii) developed a 
competitive ELISA (cELISA) as a diagnostic tool based on the AIV-M2e protein using a 
monoclonal antibody as a competing antibody for chicken sera, and (iii) constructed and 





(scFv) format. All these tasks are completed through the usage of M2e-based indirect ELISA 
for the M2e antigenic mapping, M2e-based cELISA assay development and using phage 
display technology for the anti-M2e scFv isolation, respectively. These are done in response 
to the suggestions that an M2e-based diagnostic tool will be an ideal target protein for a rapid, 
specific and sensitive DIVA tools for AIV infection surveillance, especially in H5N1 enzootic 
countries. This includes an M2e-based cELISA format which envisioned a rapid and 
universal, species independent diagnostic tool for AIV infection surveillance. Previous 
attempt on the development of an M2e-based cELISA using rabbit polyclonal antibodies as 
the competitor was unsuccessful. Hence, antigenic mapping of antibodies against M2e protein 
originated from various animal hosts are carried out to finely map the AIV M2e protein 
dominant epitope. Although an M2e-based indirect ELISA using recombinant M2e protein as 
antigen shows to be highly sensitive and specific, it is suggested that antibodies in scFv form 
constructed from a H5N1 immunised chicken will produce anti-M2e library which are highly 
specific and reactive to M2e protein. Therefore, this study has managed to found the 
following: (i) epitopes 6EVETPTRN13 and 10PTRNEWECK18 are identified as the dominant 
epitope for anti-M2e antibodies in rabbit, and mouse and chicken, respectively, (ii) anti-M2e 
monoclonal antibodies originated from mouse demonstrates its ability to be used as the 
universal competitor antibody in a M2e-based cELISA format diagnostic tool for AIV 
infection surveillance which is capable of DIVA, and (iii) anti-M2e scFv antibodies which are 
highly reactive to the M2e antigen have been successfully isolated.  
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Principal Component Analysis: 1, 2, 3, 4, 5, 6, 7, 8, A, B, C, Full  
 
Eigenanalysis of the Correlation Matrix 
 
Eigenvalue  4.3760  3.3972  2.2004  0.8835  0.5474  0.3408  0.1058  0.0839  0.0620  0.0025 
Proportion   0.365   0.283   0.183   0.074   0.046   0.028   0.009   0.007   0.005   0.000 
Cumulative   0.365   0.648   0.831   0.905   0.950   0.979   0.988   0.995   1.000   1.000 
 
Eigenvalue  0.0005  0.0000 
Proportion   0.000   0.000 
Cumulative   1.000   1.000 
 
 
Variable     PC1     PC2     PC3     PC4     PC5     PC6     PC7     PC8     PC9    PC10 
1          0.345   0.021  -0.381  -0.283  -0.111   0.327   0.279  -0.644   0.187   0.022 
2         -0.211  -0.107  -0.568   0.222  -0.021   0.019   0.251   0.112  -0.282   0.377 
3         -0.218  -0.146  -0.559   0.167  -0.048  -0.067   0.027   0.179  -0.073  -0.293 
4          0.063  -0.509   0.193   0.019   0.075   0.075   0.330  -0.065  -0.256  -0.099 
5          0.273  -0.405   0.010   0.235   0.261   0.239   0.145   0.208   0.226  -0.484 
6          0.457  -0.043  -0.091   0.023   0.048  -0.103  -0.441  -0.170  -0.712  -0.139 
7          0.424   0.032  -0.216  -0.087  -0.118   0.403  -0.333   0.522   0.205   0.237 
8          0.403  -0.035  -0.013  -0.370  -0.226  -0.555   0.443   0.344  -0.025   0.048 
A         -0.062  -0.475  -0.169  -0.029  -0.332  -0.416  -0.448  -0.215   0.376  -0.063 
B          0.046  -0.503   0.228   0.106   0.025   0.097  -0.030  -0.052  -0.018   0.635 
C          0.324   0.175  -0.136   0.421   0.571  -0.401   0.017  -0.140   0.268   0.201 
Full       0.220   0.173   0.167   0.673  -0.638   0.030   0.158  -0.074   0.006  -0.038 
 
Variable    PC11    PC12 
1          0.072  -0.063 
2         -0.123   0.509 
3          0.230  -0.638 
4         -0.661  -0.251 
5          0.298   0.376 
6          0.113   0.066 
7         -0.301  -0.128 
8          0.148   0.009 
A         -0.182   0.180 
B          0.462  -0.224 
C         -0.169  -0.145 



















































































































































   
